id	sid	tid	token	lemma	pos
aji-132	1	1	_	_	PUNCT
aji-132	2	1	_	_	PUNCT
aji-132	3	1	_	_	PUNCT
aji-132	4	1	_	_	PUNCT
aji-132	5	1	_	_	PUNCT
aji-132	6	1	_	_	PUNCT
aji-132	7	1	_	_	PUNCT
aji-132	8	1	_	_	PUNCT
aji-132	9	1	_	_	PUNCT
aji-132	10	1	_	_	PUNCT
aji-132	11	1	_	_	PUNCT
aji-132	12	1	_	_	PUNCT
aji-132	13	1	_	_	PUNCT
aji-132	14	1	_	_	PUNCT
aji-132	15	1	_	_	PUNCT
aji-132	16	1	_	_	PUNCT
aji-132	17	1	_	_	PUNCT
aji-132	18	1	_	_	PUNCT
aji-132	19	1	_	_	PUNCT
aji-132	20	1	_	_	PUNCT
aji-132	21	1	_	_	PUNCT
aji-132	22	1	_	_	PUNCT
aji-132	23	1	_	_	PUNCT
aji-132	24	1	_	_	PUNCT
aji-132	25	1	_	_	PUNCT
aji-132	26	1	_	_	PUNCT
aji-132	27	1	_	_	PUNCT
aji-132	28	1	_	_	PUNCT
aji-132	29	1	_	_	PUNCT
aji-132	30	1	_	_	PUNCT
aji-132	31	1	_	_	PUNCT
aji-132	32	1	_	_	PUNCT
aji-132	33	1	_	_	PUNCT
aji-132	34	1	_	_	PUNCT
aji-132	35	1	_	_	PUNCT
aji-132	36	1	_	_	PUNCT
aji-132	37	1	_	_	PUNCT
aji-132	38	1	_	_	PUNCT
aji-132	39	1	_	_	PUNCT
aji-132	40	1	_	_	PUNCT
aji-132	41	1	_	_	PUNCT
aji-132	42	1	_	_	PUNCT
aji-132	43	1	_	_	PUNCT
aji-132	44	1	_	_	PUNCT
aji-132	45	1	_	_	PUNCT
aji-132	46	1	_	_	PUNCT
aji-132	47	1	_	_	PUNCT
aji-132	48	1	_	_	PUNCT
aji-132	49	1	_	_	PUNCT
aji-132	50	1	_	_	PUNCT
aji-132	51	1	_	_	PUNCT
aji-132	52	1	_	_	PUNCT
aji-132	53	1	_	_	PUNCT
aji-132	54	1	_	_	PUNCT
aji-132	55	1	_	_	PUNCT
aji-132	56	1	_	_	PUNCT
aji-132	57	1	_	_	PUNCT
aji-132	58	1	_	_	PUNCT
aji-132	59	1	_	_	PUNCT
aji-132	60	1	_	_	PUNCT
aji-132	61	1	_	_	PUNCT
aji-132	62	1	_	_	PUNCT
aji-132	63	1	_	_	PUNCT
aji-132	64	1	_	_	PUNCT
aji-132	65	1	_	_	PUNCT
aji-132	66	1	_	_	PUNCT
aji-132	67	1	_	_	PUNCT
aji-132	68	1	_	_	PUNCT
aji-132	69	1	_	_	PUNCT
aji-132	70	1	_	_	PUNCT
aji-132	71	1	_	_	PUNCT
aji-132	72	1	_	_	PUNCT
aji-132	73	1	_	_	PUNCT
aji-132	74	1	_	_	PUNCT
aji-132	75	1	_	_	PUNCT
aji-132	76	1	_	_	PUNCT
aji-132	77	1	_	_	PUNCT
aji-132	78	1	_	_	PUNCT
aji-132	79	1	_	_	PUNCT
aji-132	80	1	_	_	PUNCT
aji-132	81	1	_	_	PUNCT
aji-132	82	1	_	_	PUNCT
aji-132	83	1	_	_	PUNCT
aji-132	84	1	_	_	PUNCT
aji-132	85	1	_	_	PUNCT
aji-132	86	1	_	_	PUNCT
aji-132	87	1	_	_	PUNCT
aji-132	88	1	_	_	PUNCT
aji-132	89	1	_	_	PUNCT
aji-132	90	1	_	_	PUNCT
aji-132	91	1	_	_	PUNCT
aji-132	92	1	_	_	PUNCT
aji-132	93	1	_	_	PUNCT
aji-132	94	1	_	_	PUNCT
aji-132	95	1	_	_	PUNCT
aji-132	96	1	_	_	PUNCT
aji-132	97	1	_	_	PUNCT
aji-132	98	1	_	_	PUNCT
aji-132	99	1	_	_	PUNCT
aji-132	100	1	_	_	PUNCT
aji-132	101	1	_	_	PUNCT
aji-132	102	1	+	+	ADJ
aji-132	102	2	+	+	NUM
aji-132	102	3	assistant	assistant	ADJ
aji-132	102	4	professor	professor	NOUN
aji-132	102	5	;	;	PUNCT
aji-132	102	6	*	*	PUNCT
aji-132	102	7	corresponding	correspond	VERB
aji-132	102	8	author	author	NOUN
aji-132	102	9	:	:	PUNCT
aji-132	102	10	e	e	NOUN
aji-132	102	11	-	-	NOUN
aji-132	102	12	mail	mail	NOUN
aji-132	102	13	:	:	PUNCT
aji-132	102	14	pranithaavunoori1310@gmail.com	pranithaavunoori1310@gmail.com	NUM
aji-132	102	15	;	;	PUNCT
aji-132	102	16	cite	cite	VERB
aji-132	102	17	as	as	ADP
aji-132	102	18	:	:	PUNCT
aji-132	102	19	gupta	gupta	PROPN
aji-132	102	20	,	,	PUNCT
aji-132	102	21	n.	n.	NOUN
aji-132	102	22	,	,	PUNCT
aji-132	102	23	begum	begum	PROPN
aji-132	102	24	,	,	PUNCT
aji-132	102	25	s.	s.	PROPN
aji-132	102	26	,	,	PUNCT
aji-132	102	27	farooqui	farooqui	NOUN
aji-132	102	28	,	,	PUNCT
aji-132	102	29	v.	v.	PROPN
aji-132	102	30	,	,	PUNCT
aji-132	102	31	afreen	afreen	PROPN
aji-132	102	32	,	,	PUNCT
aji-132	102	33	s.	s.	PROPN
aji-132	102	34	,	,	PUNCT
aji-132	102	35	&	&	CCONJ
aji-132	102	36	avunoori	avunoori	PROPN
aji-132	102	37	,	,	PUNCT
aji-132	102	38	p.	p.	NOUN
aji-132	102	39	(	(	PUNCT
aji-132	102	40	2024	2024	NUM
aji-132	102	41	)	)	PUNCT
aji-132	102	42	.	.	PUNCT
aji-132	103	1	a	a	DET
aji-132	103	2	review	review	NOUN
aji-132	103	3	on	on	ADP
aji-132	103	4	iguratimod	iguratimod	PROPN
aji-132	103	5	:	:	PUNCT
aji-132	103	6	bridging	bridging	NOUN
aji-132	103	7	hope	hope	NOUN
aji-132	103	8	for	for	ADP
aji-132	103	9	arthritis	arthritis	NOUN
aji-132	103	10	patients	patient	NOUN
aji-132	103	11	through	through	ADP
aji-132	103	12	the	the	DET
aji-132	103	13	dual	dual	ADJ
aji-132	103	14	power	power	NOUN
aji-132	103	15	of	of	ADP
aji-132	103	16	immunomodulation	immunomodulation	NOUN
aji-132	103	17	and	and	CCONJ
aji-132	103	18	anti	anti	ADJ
aji-132	103	19	-	-	ADJ
aji-132	103	20	inflammation	inflammation	ADJ
aji-132	103	21	.	.	PUNCT
aji-132	104	1	asian	asian	ADJ
aji-132	104	2	journal	journal	NOUN
aji-132	104	3	of	of	ADP
aji-132	104	4	immunology	immunology	NOUN
aji-132	104	5	,	,	PUNCT
aji-132	104	6	7(1	7(1	NUM
aji-132	104	7	)	)	PUNCT
aji-132	104	8	,	,	PUNCT
aji-132	104	9	79	79	NUM
aji-132	104	10	–	–	SYM
aji-132	104	11	89	89	NUM
aji-132	104	12	.	.	PUNCT
aji-132	104	13	retrieved	retrieve	VERB
aji-132	104	14	from	from	ADP
aji-132	104	15	https://journalaji.com/index.php/aji/article/view/132	https://journalaji.com/index.php/aji/article/view/132	NOUN
aji-132	104	16	asian	asian	ADJ
aji-132	104	17	journal	journal	NOUN
aji-132	104	18	of	of	ADP
aji-132	104	19	immunology	immunology	NOUN
aji-132	104	20	volume	volume	NOUN
aji-132	104	21	7	7	NUM
aji-132	104	22	,	,	PUNCT
aji-132	104	23	issue	issue	NOUN
aji-132	104	24	1	1	NUM
aji-132	104	25	,	,	PUNCT
aji-132	104	26	page	page	NOUN
aji-132	104	27	79	79	NUM
aji-132	104	28	-	-	SYM
aji-132	104	29	89	89	NUM
aji-132	104	30	,	,	PUNCT
aji-132	104	31	2024	2024	NUM
aji-132	104	32	;	;	PUNCT
aji-132	104	33	article	article	NOUN
aji-132	104	34	no.aji.115805	no.aji.115805	VERB
aji-132	104	35	a	a	DET
aji-132	104	36	review	review	NOUN
aji-132	104	37	on	on	ADP
aji-132	104	38	iguratimod	iguratimod	PROPN
aji-132	104	39	:	:	PUNCT
aji-132	104	40	bridging	bridging	NOUN
aji-132	104	41	hope	hope	NOUN
aji-132	104	42	for	for	ADP
aji-132	104	43	arthritis	arthritis	NOUN
aji-132	104	44	patients	patient	NOUN
aji-132	104	45	through	through	ADP
aji-132	104	46	the	the	DET
aji-132	104	47	dual	dual	ADJ
aji-132	104	48	power	power	NOUN
aji-132	104	49	of	of	ADP
aji-132	104	50	immunomodulation	immunomodulation	NOUN
aji-132	104	51	and	and	CCONJ
aji-132	104	52	anti	anti	ADJ
aji-132	104	53	-	-	ADJ
aji-132	104	54	inflammation	inflammation	ADJ
aji-132	104	55	nikita	nikita	PROPN
aji-132	104	56	gupta	gupta	PROPN
aji-132	104	57	a++	a++	NOUN
aji-132	104	58	,	,	PUNCT
aji-132	104	59	sana	sana	PROPN
aji-132	104	60	begum	begum	VERB
aji-132	104	61	a++	a++	NOUN
aji-132	104	62	,	,	PUNCT
aji-132	104	63	varda	varda	NOUN
aji-132	104	64	farooqui	farooqui	NOUN
aji-132	104	65	a++	a++	NOUN
aji-132	104	66	,	,	PUNCT
aji-132	104	67	summaiya	summaiya	PROPN
aji-132	104	68	afreen	afreen	PROPN
aji-132	104	69	a++	a++	NOUN
aji-132	104	70	and	and	CCONJ
aji-132	104	71	pranitha	pranitha	ADV
aji-132	104	72	avunoori	avunoori	VERB
aji-132	104	73	a++	a++	NOUN
aji-132	104	74	*	*	PUNCT
aji-132	104	75	a	a	DET
aji-132	104	76	department	department	NOUN
aji-132	104	77	of	of	ADP
aji-132	104	78	pharmacy	pharmacy	NOUN
aji-132	104	79	practice	practice	NOUN
aji-132	104	80	,	,	PUNCT
aji-132	104	81	st	st	PROPN
aji-132	104	82	.	.	PROPN
aji-132	104	83	pauls	pauls	PROPN
aji-132	104	84	college	college	PROPN
aji-132	104	85	of	of	ADP
aji-132	104	86	pharmacy	pharmacy	NOUN
aji-132	104	87	,	,	PUNCT
aji-132	104	88	hyderabad	hyderabad	PROPN
aji-132	104	89	,	,	PUNCT
aji-132	104	90	telangana-510	telangana-510	ADJ
aji-132	104	91	.	.	PUNCT
aji-132	105	1	india	india	PROPN
aji-132	105	2	.	.	PUNCT
aji-132	106	1	authors	author	NOUN
aji-132	106	2	’	’	PART
aji-132	106	3	contributions	contribution	NOUN
aji-132	106	4	this	this	DET
aji-132	106	5	work	work	NOUN
aji-132	106	6	was	be	AUX
aji-132	106	7	carried	carry	VERB
aji-132	106	8	out	out	ADP
aji-132	106	9	in	in	ADP
aji-132	106	10	collaboration	collaboration	NOUN
aji-132	106	11	among	among	ADP
aji-132	106	12	all	all	DET
aji-132	106	13	authors	author	NOUN
aji-132	106	14	.	.	PUNCT
aji-132	107	1	all	all	DET
aji-132	107	2	authors	author	NOUN
aji-132	107	3	read	read	VERB
aji-132	107	4	and	and	CCONJ
aji-132	107	5	approved	approve	VERB
aji-132	107	6	the	the	DET
aji-132	107	7	final	final	ADJ
aji-132	107	8	manuscript	manuscript	NOUN
aji-132	107	9	.	.	PUNCT
aji-132	108	1	article	article	NOUN
aji-132	108	2	information	information	PROPN
aji-132	108	3	doi	doi	PROPN
aji-132	108	4	:	:	PUNCT
aji-132	108	5	https://doi.org/10.9734/aji/2024/v7i1132	https://doi.org/10.9734/aji/2024/v7i1132	PROPN
aji-132	108	6	open	open	ADJ
aji-132	108	7	peer	peer	NOUN
aji-132	108	8	review	review	NOUN
aji-132	108	9	history	history	NOUN
aji-132	108	10	:	:	PUNCT
aji-132	108	11	this	this	DET
aji-132	108	12	journal	journal	NOUN
aji-132	108	13	follows	follow	VERB
aji-132	108	14	the	the	DET
aji-132	108	15	advanced	advance	VERB
aji-132	108	16	open	open	ADJ
aji-132	108	17	peer	peer	NOUN
aji-132	108	18	review	review	NOUN
aji-132	108	19	policy	policy	NOUN
aji-132	108	20	.	.	PUNCT
aji-132	109	1	identity	identity	NOUN
aji-132	109	2	of	of	ADP
aji-132	109	3	the	the	DET
aji-132	109	4	reviewers	reviewer	NOUN
aji-132	109	5	,	,	PUNCT
aji-132	109	6	editor(s	editor(s	NOUN
aji-132	109	7	)	)	PUNCT
aji-132	109	8	and	and	CCONJ
aji-132	109	9	additional	additional	ADJ
aji-132	109	10	reviewers	reviewer	NOUN
aji-132	109	11	,	,	PUNCT
aji-132	109	12	peer	peer	NOUN
aji-132	109	13	review	review	NOUN
aji-132	109	14	comments	comment	NOUN
aji-132	109	15	,	,	PUNCT
aji-132	109	16	different	different	ADJ
aji-132	109	17	versions	version	NOUN
aji-132	109	18	of	of	ADP
aji-132	109	19	the	the	DET
aji-132	109	20	manuscript	manuscript	NOUN
aji-132	109	21	,	,	PUNCT
aji-132	109	22	comments	comment	NOUN
aji-132	109	23	of	of	ADP
aji-132	109	24	the	the	DET
aji-132	109	25	editors	editor	NOUN
aji-132	109	26	,	,	PUNCT
aji-132	109	27	etc	etc	X
aji-132	109	28	are	be	AUX
aji-132	109	29	available	available	ADJ
aji-132	109	30	here	here	ADV
aji-132	109	31	:	:	PUNCT
aji-132	109	32	https://www.sdiarticle5.com/review-history/115805	https://www.sdiarticle5.com/review-history/115805	PROPN
aji-132	109	33	received	receive	VERB
aji-132	109	34	:	:	PUNCT
aji-132	109	35	13/02/2024	13/02/2024	NUM
aji-132	109	36	accepted	accept	VERB
aji-132	109	37	:	:	PUNCT
aji-132	109	38	16/04/2024	16/04/2024	NUM
aji-132	109	39	published	publish	VERB
aji-132	109	40	:	:	PUNCT
aji-132	109	41	18/05/2024	18/05/2024	NUM
aji-132	109	42	abstract	abstract	ADJ
aji-132	109	43	iguratimod	iguratimod	NOUN
aji-132	109	44	is	be	AUX
aji-132	109	45	a	a	DET
aji-132	109	46	small	small	ADJ
aji-132	109	47	novel	novel	NOUN
aji-132	109	48	compound	compound	NOUN
aji-132	109	49	considered	consider	VERB
aji-132	109	50	as	as	ADP
aji-132	109	51	a	a	DET
aji-132	109	52	disease	disease	NOUN
aji-132	109	53	-	-	PUNCT
aji-132	109	54	modifying	modify	VERB
aji-132	109	55	anti	anti	ADJ
aji-132	109	56	-	-	ADJ
aji-132	109	57	rheumatic	rheumatic	ADJ
aji-132	109	58	drug	drug	NOUN
aji-132	109	59	(	(	PUNCT
aji-132	109	60	dmard	dmard	NOUN
aji-132	109	61	)	)	PUNCT
aji-132	109	62	,	,	PUNCT
aji-132	109	63	which	which	PRON
aji-132	109	64	exhibits	exhibit	VERB
aji-132	109	65	anti	anti	ADJ
aji-132	109	66	-	-	ADJ
aji-132	109	67	inflammatory	inflammatory	ADJ
aji-132	109	68	and	and	CCONJ
aji-132	109	69	immunomodulatory	immunomodulatory	ADJ
aji-132	109	70	effects	effect	NOUN
aji-132	109	71	.	.	PUNCT
aji-132	110	1	iguratimod	iguratimod	NOUN
aji-132	110	2	acts	act	NOUN
aji-132	110	3	directly	directly	ADV
aji-132	110	4	on	on	ADP
aji-132	110	5	b	b	NOUN
aji-132	110	6	cells	cell	NOUN
aji-132	110	7	by	by	ADP
aji-132	110	8	inhibiting	inhibit	VERB
aji-132	110	9	the	the	DET
aji-132	110	10	production	production	NOUN
aji-132	110	11	of	of	ADP
aji-132	110	12	inflammatory	inflammatory	ADJ
aji-132	110	13	cytokines	cytokine	NOUN
aji-132	110	14	(	(	PUNCT
aji-132	110	15	tumor	tumor	NOUN
aji-132	110	16	necrosis	necrosis	NOUN
aji-132	110	17	factor	factor	NOUN
aji-132	110	18	-	-	PUNCT
aji-132	110	19	α	α	NOUN
aji-132	110	20	,	,	PUNCT
aji-132	110	21	interleukin	interleukin	NOUN
aji-132	110	22	(	(	PUNCT
aji-132	110	23	il)-1β	il)-1β	PROPN
aji-132	110	24	,	,	PUNCT
aji-132	110	25	il-6	il-6	PRON
aji-132	110	26	,	,	PUNCT
aji-132	110	27	il-8	il-8	NOUN
aji-132	110	28	,	,	PUNCT
aji-132	110	29	il-17	il-17	NUM
aji-132	110	30	)	)	PUNCT
aji-132	110	31	,	,	PUNCT
aji-132	110	32	thereby	thereby	ADV
aji-132	110	33	suppressing	suppress	VERB
aji-132	110	34	the	the	DET
aji-132	110	35	production	production	NOUN
aji-132	110	36	of	of	ADP
aji-132	110	37	immunoglobulin	immunoglobulin	NOUN
aji-132	110	38	and	and	CCONJ
aji-132	110	39	inhibiting	inhibit	VERB
aji-132	110	40	the	the	DET
aji-132	110	41	activity	activity	NOUN
aji-132	110	42	of	of	ADP
aji-132	110	43	nuclear	nuclear	ADJ
aji-132	110	44	factor	factor	NOUN
aji-132	110	45	kappa	kappa	ADJ
aji-132	110	46	-	-	ADJ
aji-132	110	47	light	light	ADJ
aji-132	110	48	chain	chain	NOUN
aji-132	110	49	enhancer	enhancer	NOUN
aji-132	110	50	of	of	ADP
aji-132	110	51	activated	activate	VERB
aji-132	110	52	b	b	NOUN
aji-132	110	53	cells	cell	NOUN
aji-132	110	54	.	.	PUNCT
aji-132	111	1	preclinical	preclinical	ADJ
aji-132	111	2	studies	study	NOUN
aji-132	111	3	demonstrate	demonstrate	VERB
aji-132	111	4	its	its	PRON
aji-132	111	5	positive	positive	ADJ
aji-132	111	6	impact	impact	NOUN
aji-132	111	7	on	on	ADP
aji-132	111	8	arthritis	arthritis	NOUN
aji-132	111	9	models	model	NOUN
aji-132	111	10	in	in	ADP
aji-132	111	11	animals	animal	NOUN
aji-132	111	12	by	by	ADP
aji-132	111	13	reducing	reduce	VERB
aji-132	111	14	immunoglobulin	immunoglobulin	NOUN
aji-132	111	15	production	production	NOUN
aji-132	111	16	and	and	CCONJ
aji-132	111	17	various	various	ADJ
aji-132	111	18	inflammatory	inflammatory	ADJ
aji-132	111	19	cytokines	cytokine	NOUN
aji-132	111	20	.	.	PUNCT
aji-132	112	1	iguratimod	iguratimod	PROPN
aji-132	112	2	demonstrates	demonstrate	VERB
aji-132	112	3	its	its	PRON
aji-132	112	4	efficacy	efficacy	NOUN
aji-132	112	5	as	as	ADV
aji-132	112	6	well	well	ADV
aji-132	112	7	as	as	ADP
aji-132	112	8	tolerance	tolerance	NOUN
aji-132	112	9	when	when	SCONJ
aji-132	112	10	used	use	VERB
aji-132	112	11	as	as	ADP
aji-132	112	12	an	an	DET
aji-132	112	13	additional	additional	ADJ
aji-132	112	14	therapy	therapy	NOUN
aji-132	112	15	for	for	ADP
aji-132	112	16	rheumatoid	rheumatoid	NOUN
aji-132	112	17	arthritis	arthritis	NOUN
aji-132	112	18	patients	patient	NOUN
aji-132	112	19	who	who	PRON
aji-132	112	20	exhibit	exhibit	VERB
aji-132	112	21	an	an	DET
aji-132	112	22	insufficient	insufficient	ADJ
aji-132	112	23	response	response	NOUN
aji-132	112	24	to	to	ADP
aji-132	112	25	both	both	CCONJ
aji-132	112	26	methotrexate	methotrexate	VERB
aji-132	112	27	and	and	CCONJ
aji-132	112	28	biological	biological	ADJ
aji-132	112	29	disease	disease	NOUN
aji-132	112	30	-	-	PUNCT
aji-132	112	31	modifying	modify	VERB
aji-132	112	32	anti	anti	ADJ
aji-132	112	33	-	-	ADJ
aji-132	112	34	rheumatic	rheumatic	ADJ
aji-132	112	35	drugs	drug	NOUN
aji-132	112	36	.	.	PUNCT
aji-132	113	1	review	review	NOUN
aji-132	113	2	article	article	NOUN
aji-132	113	3	https://doi.org/10.9734/aji/2024/v7i1132	https://doi.org/10.9734/aji/2024/v7i1132	PROPN
aji-132	113	4	https://www.sdiarticle5.com/review-history/115805	https://www.sdiarticle5.com/review-history/115805	PROPN
aji-132	113	5	gupta	gupta	PROPN
aji-132	113	6	et	et	PROPN
aji-132	113	7	al	al	PROPN
aji-132	113	8	.	.	PROPN
aji-132	113	9	;	;	PUNCT
aji-132	113	10	asian	asian	PROPN
aji-132	113	11	j.	j.	PROPN
aji-132	113	12	immunol	immunol	PROPN
aji-132	113	13	.	.	PROPN
aji-132	113	14	,	,	PUNCT
aji-132	113	15	vol	vol	NOUN
aji-132	113	16	.	.	PROPN
aji-132	113	17	7	7	NUM
aji-132	113	18	,	,	PUNCT
aji-132	113	19	no	no	INTJ
aji-132	113	20	.	.	NOUN
aji-132	113	21	1	1	NUM
aji-132	113	22	,	,	PUNCT
aji-132	113	23	pp	pp	ADJ
aji-132	113	24	.	.	PUNCT
aji-132	114	1	79	79	NUM
aji-132	114	2	-	-	SYM
aji-132	114	3	89	89	NUM
aji-132	114	4	,	,	PUNCT
aji-132	114	5	2024	2024	NUM
aji-132	114	6	;	;	PUNCT
aji-132	114	7	article	article	NOUN
aji-132	114	8	no.aji.115805	no.aji.115805	VERB
aji-132	114	9	80	80	NUM
aji-132	114	10	additionally	additionally	ADV
aji-132	114	11	,	,	PUNCT
aji-132	114	12	iguratimod	iguratimod	PROPN
aji-132	114	13	was	be	AUX
aji-132	114	14	found	find	VERB
aji-132	114	15	to	to	PART
aji-132	114	16	possess	possess	VERB
aji-132	114	17	an	an	DET
aji-132	114	18	anabolic	anabolic	ADJ
aji-132	114	19	effect	effect	NOUN
aji-132	114	20	on	on	ADP
aji-132	114	21	bone	bone	NOUN
aji-132	114	22	metabolism	metabolism	NOUN
aji-132	114	23	,	,	PUNCT
aji-132	114	24	through	through	ADP
aji-132	114	25	both	both	DET
aji-132	114	26	stimulations	stimulation	NOUN
aji-132	114	27	of	of	ADP
aji-132	114	28	osteoblastic	osteoblastic	ADJ
aji-132	114	29	differentiation	differentiation	NOUN
aji-132	114	30	and	and	CCONJ
aji-132	114	31	inhibition	inhibition	NOUN
aji-132	114	32	of	of	ADP
aji-132	114	33	osteoclastogenesis	osteoclastogenesis	NOUN
aji-132	114	34	.	.	PUNCT
aji-132	115	1	further	far	ADV
aji-132	115	2	,	,	PUNCT
aji-132	115	3	the	the	DET
aji-132	115	4	mechanism	mechanism	NOUN
aji-132	115	5	also	also	ADV
aji-132	115	6	involves	involve	VERB
aji-132	115	7	suppressing	suppress	VERB
aji-132	115	8	nuclear	nuclear	ADJ
aji-132	115	9	factor	factor	NOUN
aji-132	115	10	kappa	kappa	PROPN
aji-132	115	11	b	b	PROPN
aji-132	115	12	(	(	PUNCT
aji-132	115	13	nf	nf	NOUN
aji-132	115	14	-	-	PUNCT
aji-132	115	15	κb	κb	NOUN
aji-132	115	16	)	)	PUNCT
aji-132	115	17	activation	activation	NOUN
aji-132	115	18	without	without	ADP
aji-132	115	19	blocking	block	VERB
aji-132	115	20	nf	nf	NOUN
aji-132	115	21	-	-	PUNCT
aji-132	115	22	κb	κb	NOUN
aji-132	115	23	inhibitor	inhibitor	NOUN
aji-132	115	24	α	α	NOUN
aji-132	115	25	(	(	PUNCT
aji-132	115	26	iκbα	iκbα	NOUN
aji-132	115	27	)	)	PUNCT
aji-132	115	28	degradation	degradation	NOUN
aji-132	115	29	.	.	PUNCT
aji-132	116	1	although	although	SCONJ
aji-132	116	2	the	the	DET
aji-132	116	3	true	true	ADJ
aji-132	116	4	target	target	NOUN
aji-132	116	5	molecules	molecule	NOUN
aji-132	116	6	of	of	ADP
aji-132	116	7	iguratimod	iguratimod	NOUN
aji-132	116	8	have	have	AUX
aji-132	116	9	been	be	AUX
aji-132	116	10	unclear	unclear	ADJ
aji-132	116	11	,	,	PUNCT
aji-132	116	12	it	it	PRON
aji-132	116	13	would	would	AUX
aji-132	116	14	be	be	AUX
aji-132	116	15	necessary	necessary	ADJ
aji-132	116	16	to	to	PART
aji-132	116	17	suppose	suppose	VERB
aji-132	116	18	the	the	DET
aji-132	116	19	multiple	multiple	ADJ
aji-132	116	20	mechanisms	mechanism	NOUN
aji-132	116	21	including	include	VERB
aji-132	116	22	suppression	suppression	NOUN
aji-132	116	23	of	of	ADP
aji-132	116	24	nf	nf	NOUN
aji-132	116	25	-	-	PUNCT
aji-132	116	26	κb	κb	NOUN
aji-132	116	27	.	.	PUNCT
aji-132	117	1	clinical	clinical	ADJ
aji-132	117	2	trials	trial	NOUN
aji-132	117	3	of	of	ADP
aji-132	117	4	rheumatoid	rheumatoid	NOUN
aji-132	117	5	arthritis	arthritis	NOUN
aji-132	117	6	patients	patient	NOUN
aji-132	117	7	have	have	AUX
aji-132	117	8	shown	show	VERB
aji-132	117	9	more	more	ADJ
aji-132	117	10	effectiveness	effectiveness	NOUN
aji-132	117	11	and	and	CCONJ
aji-132	117	12	tolerability	tolerability	NOUN
aji-132	117	13	when	when	SCONJ
aji-132	117	14	compared	compare	VERB
aji-132	117	15	to	to	ADP
aji-132	117	16	salazosulfapyridine	salazosulfapyridine	NOUN
aji-132	117	17	,	,	PUNCT
aji-132	117	18	making	make	VERB
aji-132	117	19	iguratimod	iguratimod	NOUN
aji-132	117	20	a	a	DET
aji-132	117	21	promising	promising	ADJ
aji-132	117	22	dmard	dmard	NOUN
aji-132	117	23	with	with	ADP
aji-132	117	24	unique	unique	ADJ
aji-132	117	25	novel	novel	ADJ
aji-132	117	26	properties	property	NOUN
aji-132	117	27	and	and	CCONJ
aji-132	117	28	positive	positive	ADJ
aji-132	117	29	clinical	clinical	ADJ
aji-132	117	30	outcomes	outcome	NOUN
aji-132	117	31	.	.	PUNCT
aji-132	118	1	further	further	ADJ
aji-132	118	2	research	research	NOUN
aji-132	118	3	will	will	AUX
aji-132	118	4	determine	determine	VERB
aji-132	118	5	its	its	PRON
aji-132	118	6	suitability	suitability	NOUN
aji-132	118	7	as	as	ADP
aji-132	118	8	an	an	DET
aji-132	118	9	alternative	alternative	NOUN
aji-132	118	10	for	for	ADP
aji-132	118	11	patients	patient	NOUN
aji-132	118	12	unable	unable	ADJ
aji-132	118	13	to	to	PART
aji-132	118	14	use	use	VERB
aji-132	118	15	biologics	biologic	NOUN
aji-132	118	16	.	.	PUNCT
aji-132	119	1	keywords	keyword	NOUN
aji-132	119	2	:	:	PUNCT
aji-132	119	3	anti	anti	ADJ
aji-132	119	4	-	-	ADJ
aji-132	119	5	inflammation	inflammation	ADJ
aji-132	119	6	;	;	PUNCT
aji-132	119	7	iguratimod	iguratimod	PROPN
aji-132	119	8	;	;	PUNCT
aji-132	119	9	arthritis	arthritis	NOUN
aji-132	119	10	;	;	PUNCT
aji-132	119	11	immunomodulation	immunomodulation	NOUN
aji-132	119	12	.	.	PUNCT
aji-132	120	1	1	1	X
aji-132	120	2	.	.	X
aji-132	120	3	introduction	introduction	NOUN
aji-132	120	4	1.1	1.1	NUM
aji-132	120	5	rheumatoid	rheumatoid	NOUN
aji-132	120	6	arthritis	arthritis	NOUN
aji-132	120	7	“	"	PUNCT
aji-132	120	8	rheumatoid	rheumatoid	VERB
aji-132	120	9	arthritis	arthritis	NOUN
aji-132	120	10	(	(	PUNCT
aji-132	120	11	ra	ra	NOUN
aji-132	120	12	)	)	PUNCT
aji-132	120	13	is	be	AUX
aji-132	120	14	a	a	DET
aji-132	120	15	persistent	persistent	ADJ
aji-132	120	16	autoimmune	autoimmune	ADJ
aji-132	120	17	disorder	disorder	NOUN
aji-132	120	18	with	with	ADP
aji-132	120	19	an	an	DET
aji-132	120	20	unknown	unknown	ADJ
aji-132	120	21	cause	cause	NOUN
aji-132	120	22	,	,	PUNCT
aji-132	120	23	marked	mark	VERB
aji-132	120	24	by	by	ADP
aji-132	120	25	synovial	synovial	ADJ
aji-132	120	26	inflammation	inflammation	NOUN
aji-132	120	27	in	in	ADP
aji-132	120	28	the	the	DET
aji-132	120	29	joints	joint	NOUN
aji-132	120	30	,	,	PUNCT
aji-132	120	31	gradual	gradual	ADJ
aji-132	120	32	bone	bone	NOUN
aji-132	120	33	damage	damage	NOUN
aji-132	120	34	,	,	PUNCT
aji-132	120	35	and	and	CCONJ
aji-132	120	36	a	a	DET
aji-132	120	37	decline	decline	NOUN
aji-132	120	38	in	in	ADP
aji-132	120	39	joint	joint	ADJ
aji-132	120	40	functionality	functionality	NOUN
aji-132	120	41	.	.	PUNCT
aji-132	121	1	in	in	ADP
aji-132	121	2	the	the	DET
aji-132	121	3	absence	absence	NOUN
aji-132	121	4	of	of	ADP
aji-132	121	5	treatment	treatment	NOUN
aji-132	121	6	,	,	PUNCT
aji-132	121	7	deteriorating	deteriorate	VERB
aji-132	121	8	joints	joint	NOUN
aji-132	121	9	can	can	AUX
aji-132	121	10	result	result	VERB
aji-132	121	11	in	in	ADP
aji-132	121	12	pain	pain	NOUN
aji-132	121	13	and	and	CCONJ
aji-132	121	14	stiffness	stiffness	NOUN
aji-132	121	15	,	,	PUNCT
aji-132	121	16	which	which	PRON
aji-132	121	17	limit	limit	VERB
aji-132	121	18	physical	physical	ADJ
aji-132	121	19	function	function	NOUN
aji-132	121	20	and	and	CCONJ
aji-132	121	21	lead	lead	VERB
aji-132	121	22	to	to	ADP
aji-132	121	23	long	long	ADJ
aji-132	121	24	-	-	PUNCT
aji-132	121	25	term	term	NOUN
aji-132	121	26	disability	disability	NOUN
aji-132	121	27	”	"	PUNCT
aji-132	122	1	[	[	X
aji-132	122	2	1	1	NUM
aji-132	122	3	]	]	PUNCT
aji-132	122	4	.	.	PUNCT
aji-132	123	1	“	"	PUNCT
aji-132	123	2	the	the	DET
aji-132	123	3	development	development	NOUN
aji-132	123	4	of	of	ADP
aji-132	123	5	ra	ra	PROPN
aji-132	123	6	is	be	AUX
aji-132	123	7	associated	associate	VERB
aji-132	123	8	with	with	ADP
aji-132	123	9	genetic	genetic	ADJ
aji-132	123	10	,	,	PUNCT
aji-132	123	11	environmental	environmental	ADJ
aji-132	123	12	,	,	PUNCT
aji-132	123	13	and	and	CCONJ
aji-132	123	14	immune	immune	ADJ
aji-132	123	15	factors	factor	NOUN
aji-132	123	16	.	.	PUNCT
aji-132	124	1	the	the	DET
aji-132	124	2	objective	objective	NOUN
aji-132	124	3	of	of	ADP
aji-132	124	4	treating	treat	VERB
aji-132	124	5	individuals	individual	NOUN
aji-132	124	6	with	with	ADP
aji-132	124	7	ra	ra	PROPN
aji-132	124	8	is	be	AUX
aji-132	124	9	to	to	PART
aji-132	124	10	achieve	achieve	VERB
aji-132	124	11	clinical	clinical	ADJ
aji-132	124	12	remission	remission	NOUN
aji-132	124	13	or	or	CCONJ
aji-132	124	14	maintain	maintain	VERB
aji-132	124	15	low	low	ADJ
aji-132	124	16	disease	disease	NOUN
aji-132	124	17	activity	activity	NOUN
aji-132	124	18	,	,	PUNCT
aji-132	124	19	ultimately	ultimately	ADV
aji-132	124	20	preventing	prevent	VERB
aji-132	124	21	damage	damage	NOUN
aji-132	124	22	to	to	ADP
aji-132	124	23	joint	joint	ADJ
aji-132	124	24	function	function	NOUN
aji-132	124	25	,	,	PUNCT
aji-132	124	26	current	current	ADJ
aji-132	124	27	treatments	treatment	NOUN
aji-132	124	28	for	for	ADP
aji-132	124	29	ra	ra	PROPN
aji-132	124	30	include	include	VERB
aji-132	124	31	non	non	ADJ
aji-132	124	32	-	-	ADJ
aji-132	124	33	steroidal	steroidal	ADJ
aji-132	124	34	anti	anti	ADJ
aji-132	124	35	-	-	ADJ
aji-132	124	36	inflammatory	inflammatory	ADJ
aji-132	124	37	drugs	drug	NOUN
aji-132	124	38	(	(	PUNCT
aji-132	124	39	nsaids	nsaid	NOUN
aji-132	124	40	)	)	PUNCT
aji-132	124	41	,	,	PUNCT
aji-132	124	42	conventional	conventional	ADJ
aji-132	124	43	synthetic	synthetic	ADJ
aji-132	124	44	disease	disease	NOUN
aji-132	124	45	-	-	PUNCT
aji-132	124	46	modifying	modify	VERB
aji-132	124	47	anti	anti	ADJ
aji-132	124	48	-	-	ADJ
aji-132	124	49	rheumatic	rheumatic	ADJ
aji-132	124	50	drugs	drug	NOUN
aji-132	124	51	(	(	PUNCT
aji-132	124	52	csdmards	csdmard	NOUN
aji-132	124	53	)	)	PUNCT
aji-132	124	54	,	,	PUNCT
aji-132	124	55	and	and	CCONJ
aji-132	124	56	biological	biological	ADJ
aji-132	124	57	disease	disease	NOUN
aji-132	124	58	-	-	PUNCT
aji-132	124	59	modifying	modify	VERB
aji-132	124	60	anti	anti	ADJ
aji-132	124	61	-	-	ADJ
aji-132	124	62	rheumatic	rheumatic	ADJ
aji-132	124	63	drugs	drug	NOUN
aji-132	124	64	(	(	PUNCT
aji-132	124	65	bdmards	bdmard	NOUN
aji-132	124	66	)	)	PUNCT
aji-132	124	67	.	.	PUNCT
aji-132	125	1	the	the	DET
aji-132	125	2	use	use	NOUN
aji-132	125	3	of	of	ADP
aji-132	125	4	biological	biological	ADJ
aji-132	125	5	dmards	dmard	NOUN
aji-132	125	6	to	to	PART
aji-132	125	7	treat	treat	VERB
aji-132	125	8	ra	ra	PROPN
aji-132	125	9	is	be	AUX
aji-132	125	10	not	not	PART
aji-132	125	11	suitable	suitable	ADJ
aji-132	125	12	for	for	ADP
aji-132	125	13	all	all	DET
aji-132	125	14	patients	patient	NOUN
aji-132	125	15	for	for	ADP
aji-132	125	16	various	various	ADJ
aji-132	125	17	reasons	reason	NOUN
aji-132	125	18	,	,	PUNCT
aji-132	125	19	including	include	VERB
aji-132	125	20	complications	complication	NOUN
aji-132	125	21	,	,	PUNCT
aji-132	125	22	side	side	NOUN
aji-132	125	23	effects	effect	NOUN
aji-132	125	24	,	,	PUNCT
aji-132	125	25	uncertain	uncertain	ADJ
aji-132	125	26	efficacy	efficacy	NOUN
aji-132	125	27	,	,	PUNCT
aji-132	125	28	and	and	CCONJ
aji-132	125	29	high	high	ADJ
aji-132	125	30	costs	cost	NOUN
aji-132	125	31	that	that	PRON
aji-132	125	32	prevent	prevent	VERB
aji-132	125	33	their	their	PRON
aji-132	125	34	use	use	NOUN
aji-132	125	35	”	"	PUNCT
aji-132	125	36	[	[	X
aji-132	125	37	2	2	NUM
aji-132	125	38	]	]	PUNCT
aji-132	125	39	.	.	PUNCT
aji-132	126	1	1.2	1.2	NUM
aji-132	126	2	iguratimod	iguratimod	NOUN
aji-132	126	3	“	"	PUNCT
aji-132	126	4	iguratimod	iguratimod	PROPN
aji-132	126	5	,	,	PUNCT
aji-132	126	6	is	be	AUX
aji-132	126	7	a	a	DET
aji-132	126	8	small	small	ADJ
aji-132	126	9	novel	novel	NOUN
aji-132	126	10	compound	compound	NOUN
aji-132	126	11	considered	consider	VERB
aji-132	126	12	as	as	ADP
aji-132	126	13	a	a	DET
aji-132	126	14	disease	disease	NOUN
aji-132	126	15	-	-	PUNCT
aji-132	126	16	modifying	modify	VERB
aji-132	126	17	antirheumatic	antirheumatic	ADJ
aji-132	126	18	drug	drug	NOUN
aji-132	126	19	(	(	PUNCT
aji-132	126	20	dmard	dmard	NOUN
aji-132	126	21	)	)	PUNCT
aji-132	126	22	,	,	PUNCT
aji-132	126	23	which	which	PRON
aji-132	126	24	exhibits	exhibit	VERB
aji-132	126	25	antiinflammatory	antiinflammatory	NOUN
aji-132	126	26	and	and	CCONJ
aji-132	126	27	immunomodulatory	immunomodulatory	NOUN
aji-132	126	28	effects.igu	effects.igu	X
aji-132	126	29	suppresses	suppress	VERB
aji-132	126	30	the	the	DET
aji-132	126	31	production	production	NOUN
aji-132	126	32	of	of	ADP
aji-132	126	33	inflammatory	inflammatory	ADJ
aji-132	126	34	cytokines	cytokine	NOUN
aji-132	126	35	in	in	ADP
aji-132	126	36	cultured	cultured	ADJ
aji-132	126	37	monocyte	monocyte	NOUN
aji-132	126	38	thp-1	thp-1	ADP
aji-132	126	39	cells	cell	NOUN
aji-132	126	40	and	and	CCONJ
aji-132	126	41	synovial	synovial	ADJ
aji-132	126	42	cells	cell	NOUN
aji-132	126	43	derived	derive	VERB
aji-132	126	44	from	from	ADP
aji-132	126	45	ra	ra	PROPN
aji-132	126	46	patients	patient	NOUN
aji-132	126	47	by	by	ADP
aji-132	126	48	inhibiting	inhibit	VERB
aji-132	126	49	the	the	DET
aji-132	126	50	activation	activation	NOUN
aji-132	126	51	of	of	ADP
aji-132	126	52	nuclear	nuclear	ADJ
aji-132	126	53	factor	factor	NOUN
aji-132	126	54	kappa	kappa	PROPN
aji-132	126	55	-	-	PROPN
aji-132	126	56	b	b	PROPN
aji-132	126	57	(	(	PUNCT
aji-132	126	58	nf	nf	NOUN
aji-132	126	59	-	-	PUNCT
aji-132	126	60	κb	κb	NOUN
aji-132	126	61	)	)	PUNCT
aji-132	126	62	”	"	PUNCT
aji-132	127	1	[	[	X
aji-132	127	2	3	3	NUM
aji-132	127	3	]	]	PUNCT
aji-132	127	4	.	.	PUNCT
aji-132	128	1	“	"	PUNCT
aji-132	128	2	additionally	additionally	ADV
aji-132	128	3	,	,	PUNCT
aji-132	128	4	it	it	PRON
aji-132	128	5	hinders	hinder	VERB
aji-132	128	6	immunoglobulin	immunoglobulin	NOUN
aji-132	128	7	production	production	NOUN
aji-132	128	8	through	through	ADP
aji-132	128	9	a	a	DET
aji-132	128	10	direct	direct	ADJ
aji-132	128	11	impact	impact	NOUN
aji-132	128	12	on	on	ADP
aji-132	128	13	b	b	NOUN
aji-132	128	14	cells	cell	NOUN
aji-132	128	15	without	without	ADP
aji-132	128	16	inducing	induce	VERB
aji-132	128	17	cytostatic	cytostatic	ADJ
aji-132	128	18	effects	effect	NOUN
aji-132	128	19	”	"	PUNCT
aji-132	129	1	[	[	X
aji-132	129	2	4	4	NUM
aji-132	129	3	]	]	PUNCT
aji-132	129	4	.	.	PUNCT
aji-132	130	1	“	"	PUNCT
aji-132	130	2	igu	igu	VERB
aji-132	130	3	exhibits	exhibit	VERB
aji-132	130	4	anti	anti	ADJ
aji-132	130	5	-	-	ADJ
aji-132	130	6	inflammatory	inflammatory	ADJ
aji-132	130	7	effects	effect	NOUN
aji-132	130	8	and	and	CCONJ
aji-132	130	9	improves	improve	VERB
aji-132	130	10	abnormal	abnormal	ADJ
aji-132	130	11	immunological	immunological	ADJ
aji-132	130	12	conditions	condition	NOUN
aji-132	130	13	in	in	ADP
aji-132	130	14	various	various	ADJ
aji-132	130	15	animal	animal	NOUN
aji-132	130	16	models	model	NOUN
aji-132	130	17	of	of	ADP
aji-132	130	18	inflammation	inflammation	NOUN
aji-132	130	19	and	and	CCONJ
aji-132	130	20	autoimmune	autoimmune	ADJ
aji-132	130	21	diseases	disease	NOUN
aji-132	130	22	,	,	PUNCT
aji-132	130	23	including	include	VERB
aji-132	130	24	ra	ra	NOUN
aji-132	130	25	”	"	PUNCT
aji-132	131	1	[	[	X
aji-132	131	2	5,6	5,6	NUM
aji-132	131	3	]	]	X
aji-132	131	4	.	.	PUNCT
aji-132	132	1	“	"	PUNCT
aji-132	132	2	recently	recently	ADV
aji-132	132	3	,	,	PUNCT
aji-132	132	4	it	it	PRON
aji-132	132	5	has	have	AUX
aji-132	132	6	been	be	AUX
aji-132	132	7	noted	note	VERB
aji-132	132	8	that	that	SCONJ
aji-132	132	9	igu	igu	PROPN
aji-132	132	10	inhibits	inhibit	VERB
aji-132	132	11	receptor	receptor	NOUN
aji-132	132	12	activator	activator	NOUN
aji-132	132	13	of	of	ADP
aji-132	132	14	nf	nf	ADJ
aji-132	132	15	-	-	PUNCT
aji-132	132	16	κb	κb	ADJ
aji-132	132	17	ligand	ligand	NOUN
aji-132	132	18	(	(	PUNCT
aji-132	132	19	rankl)-induced	rankl)-induced	ADJ
aji-132	132	20	osteoclast	osteoclast	ADJ
aji-132	132	21	differentiation	differentiation	NOUN
aji-132	132	22	and	and	CCONJ
aji-132	132	23	migration	migration	NOUN
aji-132	132	24	in	in	ADP
aji-132	132	25	raw264	raw264	PROPN
aji-132	132	26	cells	cell	NOUN
aji-132	132	27	by	by	ADP
aji-132	132	28	modulating	modulate	VERB
aji-132	132	29	the	the	DET
aji-132	132	30	nf	nf	NOUN
aji-132	132	31	-	-	PUNCT
aji-132	132	32	κb	κb	NOUN
aji-132	132	33	and	and	CCONJ
aji-132	132	34	mitogen	mitogen	NOUN
aji-132	132	35	-	-	PUNCT
aji-132	132	36	activated	activate	VERB
aji-132	132	37	protein	protein	NOUN
aji-132	132	38	kinase	kinase	NOUN
aji-132	132	39	(	(	PUNCT
aji-132	132	40	mapk	mapk	NOUN
aji-132	132	41	)	)	PUNCT
aji-132	132	42	pathways	pathway	NOUN
aji-132	132	43	.	.	PUNCT
aji-132	133	1	this	this	DET
aji-132	133	2	finding	finding	NOUN
aji-132	133	3	is	be	AUX
aji-132	133	4	especially	especially	ADV
aji-132	133	5	intriguing	intriguing	ADJ
aji-132	133	6	in	in	ADP
aji-132	133	7	relation	relation	NOUN
aji-132	133	8	to	to	ADP
aji-132	133	9	its	its	PRON
aji-132	133	10	stimulatory	stimulatory	ADJ
aji-132	133	11	effect	effect	NOUN
aji-132	133	12	on	on	ADP
aji-132	133	13	osteoblastic	osteoblastic	ADJ
aji-132	133	14	differentiation	differentiation	NOUN
aji-132	133	15	”	"	PUNCT
aji-132	134	1	[	[	X
aji-132	134	2	7	7	NUM
aji-132	134	3	]	]	PUNCT
aji-132	134	4	.	.	PUNCT
aji-132	135	1	2	2	X
aji-132	135	2	.	.	X
aji-132	135	3	mechanism	mechanism	NOUN
aji-132	135	4	of	of	ADP
aji-132	135	5	iguratimod	iguratimod	NOUN
aji-132	135	6	2.1	2.1	NUM
aji-132	135	7	anti	anti	ADJ
aji-132	135	8	-	-	ADJ
aji-132	135	9	inflammatory	inflammatory	ADJ
aji-132	135	10	“	"	PUNCT
aji-132	135	11	iguratimod	iguratimod	ADJ
aji-132	135	12	possesses	possesse	NOUN
aji-132	135	13	anti	anti	ADJ
aji-132	135	14	-	-	ADJ
aji-132	135	15	inflammatory	inflammatory	ADJ
aji-132	135	16	properties	property	NOUN
aji-132	135	17	,	,	PUNCT
aji-132	135	18	as	as	SCONJ
aji-132	135	19	demonstrated	demonstrate	VERB
aji-132	135	20	by	by	ADP
aji-132	135	21	its	its	PRON
aji-132	135	22	ability	ability	NOUN
aji-132	135	23	to	to	PART
aji-132	135	24	restrain	restrain	VERB
aji-132	135	25	the	the	DET
aji-132	135	26	release	release	NOUN
aji-132	135	27	of	of	ADP
aji-132	135	28	bradykinin	bradykinin	NOUN
aji-132	135	29	in	in	ADP
aji-132	135	30	a	a	DET
aji-132	135	31	mouse	mouse	NOUN
aji-132	135	32	model	model	NOUN
aji-132	135	33	of	of	ADP
aji-132	135	34	kaolin	kaolin	NOUN
aji-132	135	35	-	-	PUNCT
aji-132	135	36	induced	induce	VERB
aji-132	135	37	arthritis	arthritis	NOUN
aji-132	135	38	.	.	PUNCT
aji-132	136	1	initially	initially	ADV
aji-132	136	2	created	create	VERB
aji-132	136	3	as	as	ADP
aji-132	136	4	an	an	DET
aji-132	136	5	innovative	innovative	ADJ
aji-132	136	6	nonsteroidal	nonsteroidal	NOUN
aji-132	136	7	anti	anti	ADJ
aji-132	136	8	-	-	ADJ
aji-132	136	9	inflammatory	inflammatory	ADJ
aji-132	136	10	drug	drug	NOUN
aji-132	136	11	(	(	PUNCT
aji-132	136	12	nsaid	nsaid	PROPN
aji-132	136	13	)	)	PUNCT
aji-132	136	14	”	"	PUNCT
aji-132	137	1	[	[	X
aji-132	137	2	8	8	NUM
aji-132	137	3	]	]	PUNCT
aji-132	137	4	.	.	PUNCT
aji-132	138	1	research	research	NOUN
aji-132	138	2	has	have	AUX
aji-132	138	3	extensively	extensively	ADV
aji-132	138	4	documented	document	VERB
aji-132	138	5	the	the	DET
aji-132	138	6	anti	anti	ADJ
aji-132	138	7	-	-	ADJ
aji-132	138	8	inflammatory	inflammatory	ADJ
aji-132	138	9	,	,	PUNCT
aji-132	138	10	analgesic	analgesic	ADJ
aji-132	138	11	,	,	PUNCT
aji-132	138	12	and	and	CCONJ
aji-132	138	13	antipyretic	antipyretic	ADJ
aji-132	138	14	properties	property	NOUN
aji-132	138	15	of	of	ADP
aji-132	138	16	iguratimod	iguratimod	NOUN
aji-132	138	17	in	in	ADP
aji-132	138	18	diverse	diverse	ADJ
aji-132	138	19	animal	animal	NOUN
aji-132	138	20	models	model	NOUN
aji-132	138	21	.	.	PUNCT
aji-132	139	1	its	its	PRON
aji-132	139	2	mechanism	mechanism	NOUN
aji-132	139	3	involves	involve	VERB
aji-132	139	4	suppressing	suppress	VERB
aji-132	139	5	the	the	DET
aji-132	139	6	metabolism	metabolism	NOUN
aji-132	139	7	of	of	ADP
aji-132	139	8	arachidonic	arachidonic	ADJ
aji-132	139	9	acid	acid	NOUN
aji-132	139	10	metabolite	metabolite	NOUN
aji-132	139	11	prostaglandin	prostaglandin	PROPN
aji-132	139	12	e2	e2	NOUN
aji-132	140	1	[	[	X
aji-132	140	2	9	9	NUM
aji-132	140	3	]	]	PUNCT
aji-132	140	4	,	,	PUNCT
aji-132	140	5	inhibiting	inhibit	VERB
aji-132	140	6	the	the	DET
aji-132	140	7	release	release	NOUN
aji-132	140	8	of	of	ADP
aji-132	140	9	bradykinin	bradykinin	NOUN
aji-132	140	10	,	,	PUNCT
aji-132	140	11	decreasing	decrease	VERB
aji-132	140	12	the	the	DET
aji-132	140	13	production	production	NOUN
aji-132	140	14	of	of	ADP
aji-132	140	15	interleukin	interleukin	NOUN
aji-132	140	16	(	(	PUNCT
aji-132	140	17	il)-1	il)-1	NOUN
aji-132	140	18	and	and	CCONJ
aji-132	140	19	interleukin	interleukin	NOUN
aji-132	140	20	(	(	PUNCT
aji-132	140	21	il)-6	il)-6	NOUN
aji-132	140	22	[	[	X
aji-132	140	23	10,11	10,11	NOUN
aji-132	140	24	]	]	PUNCT
aji-132	140	25	,	,	PUNCT
aji-132	140	26	and	and	CCONJ
aji-132	140	27	selectively	selectively	ADV
aji-132	140	28	inhibiting	inhibit	VERB
aji-132	140	29	the	the	DET
aji-132	140	30	activity	activity	NOUN
aji-132	140	31	of	of	ADP
aji-132	140	32	cyclooxygenase-2	cyclooxygenase-2	NUM
aji-132	141	1	[	[	X
aji-132	141	2	12	12	NUM
aji-132	141	3	]	]	PUNCT
aji-132	141	4	.	.	PUNCT
aji-132	142	1	“	"	PUNCT
aji-132	142	2	in	in	ADP
aji-132	142	3	different	different	ADJ
aji-132	142	4	models	model	NOUN
aji-132	142	5	of	of	ADP
aji-132	142	6	autoimmune	autoimmune	ADJ
aji-132	142	7	disorders	disorder	NOUN
aji-132	142	8	,	,	PUNCT
aji-132	142	9	iguratimod	iguratimod	PROPN
aji-132	142	10	demonstrated	demonstrate	VERB
aji-132	142	11	notable	notable	ADJ
aji-132	142	12	inhibitory	inhibitory	ADJ
aji-132	142	13	effects	effect	NOUN
aji-132	142	14	.	.	PUNCT
aji-132	143	1	these	these	DET
aji-132	143	2	effects	effect	NOUN
aji-132	143	3	were	be	AUX
aji-132	143	4	observed	observe	VERB
aji-132	143	5	in	in	ADP
aji-132	143	6	experimental	experimental	ADJ
aji-132	143	7	autoimmune	autoimmune	ADJ
aji-132	143	8	encephalitis	encephalitis	NOUN
aji-132	143	9	,	,	PUNCT
aji-132	143	10	chronic	chronic	ADJ
aji-132	143	11	contractile	contractile	NOUN
aji-132	143	12	injury	injury	NOUN
aji-132	143	13	linked	link	VERB
aji-132	143	14	with	with	ADP
aji-132	143	15	neuropathic	neuropathic	ADJ
aji-132	143	16	pain	pain	NOUN
aji-132	143	17	,	,	PUNCT
aji-132	143	18	and	and	CCONJ
aji-132	143	19	dextran	dextran	VERB
aji-132	143	20	sodium	sodium	NOUN
aji-132	143	21	sulfateinduced	sulfateinduce	VERB
aji-132	143	22	colitis	colitis	NOUN
aji-132	143	23	”	"	PUNCT
aji-132	144	1	[	[	X
aji-132	144	2	4,12	4,12	NUM
aji-132	144	3	-	-	SYM
aji-132	144	4	20	20	NUM
aji-132	144	5	]	]	PUNCT
aji-132	144	6	.	.	PUNCT
aji-132	145	1	“	"	PUNCT
aji-132	145	2	significantly	significantly	ADV
aji-132	145	3	,	,	PUNCT
aji-132	145	4	iguratimod	iguratimod	PROPN
aji-132	145	5	's	's	PART
aji-132	145	6	ability	ability	NOUN
aji-132	145	7	to	to	PART
aji-132	145	8	selectively	selectively	ADV
aji-132	145	9	inhibit	inhibit	VERB
aji-132	145	10	cox-2	cox-2	ADV
aji-132	145	11	is	be	AUX
aji-132	145	12	crucial	crucial	ADJ
aji-132	145	13	,	,	PUNCT
aji-132	145	14	leading	lead	VERB
aji-132	145	15	to	to	ADP
aji-132	145	16	a	a	DET
aji-132	145	17	reduction	reduction	NOUN
aji-132	145	18	in	in	ADP
aji-132	145	19	prostaglandin	prostaglandin	NOUN
aji-132	145	20	levels	level	NOUN
aji-132	145	21	and	and	CCONJ
aji-132	145	22	accomplishing	accomplish	VERB
aji-132	145	23	its	its	PRON
aji-132	145	24	anti	anti	ADJ
aji-132	145	25	-	-	ADJ
aji-132	145	26	inflammatory	inflammatory	ADJ
aji-132	145	27	effects	effect	NOUN
aji-132	145	28	.	.	PUNCT
aji-132	146	1	importantly	importantly	ADV
aji-132	146	2	,	,	PUNCT
aji-132	146	3	iguratimod	iguratimod	PROPN
aji-132	146	4	is	be	AUX
aji-132	146	5	less	less	ADV
aji-132	146	6	prone	prone	ADJ
aji-132	146	7	to	to	ADP
aji-132	146	8	causing	cause	VERB
aji-132	146	9	gastrointestinal	gastrointestinal	ADJ
aji-132	146	10	ulcers	ulcer	NOUN
aji-132	146	11	because	because	SCONJ
aji-132	146	12	of	of	ADP
aji-132	146	13	its	its	PRON
aji-132	146	14	selective	selective	ADJ
aji-132	146	15	inhibition	inhibition	NOUN
aji-132	146	16	of	of	ADP
aji-132	146	17	cox-2	cox-2	NOUN
aji-132	146	18	,	,	PUNCT
aji-132	146	19	distinguishing	distinguish	VERB
aji-132	146	20	it	it	PRON
aji-132	146	21	from	from	ADP
aji-132	146	22	nonsteroidal	nonsteroidal	NOUN
aji-132	146	23	anti	anti	ADJ
aji-132	146	24	-	-	ADJ
aji-132	146	25	inflammatory	inflammatory	ADJ
aji-132	146	26	drugs	drug	NOUN
aji-132	146	27	(	(	PUNCT
aji-132	146	28	nsaids	nsaid	NOUN
aji-132	146	29	)	)	PUNCT
aji-132	146	30	that	that	PRON
aji-132	146	31	inhibit	inhibit	VERB
aji-132	146	32	both	both	PRON
aji-132	146	33	cox-1	cox-1	PUNCT
aji-132	146	34	and	and	CCONJ
aji-132	146	35	cox-2	cox-2	NOUN
aji-132	146	36	”	"	PUNCT
aji-132	146	37	gupta	gupta	PROPN
aji-132	146	38	et	et	PROPN
aji-132	146	39	al	al	PROPN
aji-132	146	40	.	.	PROPN
aji-132	146	41	;	;	PUNCT
aji-132	146	42	asian	asian	PROPN
aji-132	146	43	j.	j.	PROPN
aji-132	146	44	immunol	immunol	PROPN
aji-132	146	45	.	.	PROPN
aji-132	146	46	,	,	PUNCT
aji-132	146	47	vol	vol	NOUN
aji-132	146	48	.	.	PROPN
aji-132	147	1	7	7	NUM
aji-132	147	2	,	,	PUNCT
aji-132	147	3	no	no	INTJ
aji-132	147	4	.	.	NOUN
aji-132	147	5	1	1	NUM
aji-132	147	6	,	,	PUNCT
aji-132	147	7	pp	pp	ADJ
aji-132	147	8	.	.	PUNCT
aji-132	148	1	79	79	NUM
aji-132	148	2	-	-	SYM
aji-132	148	3	89	89	NUM
aji-132	148	4	,	,	PUNCT
aji-132	148	5	2024	2024	NUM
aji-132	148	6	;	;	PUNCT
aji-132	148	7	article	article	NOUN
aji-132	148	8	no.aji.115805	no.aji.115805	VERB
aji-132	148	9	81	81	NUM
aji-132	149	1	[	[	X
aji-132	149	2	12	12	NUM
aji-132	149	3	]	]	PUNCT
aji-132	149	4	.	.	PUNCT
aji-132	150	1	“	"	PUNCT
aji-132	150	2	iguratimod	iguratimod	NOUN
aji-132	150	3	also	also	ADV
aji-132	150	4	hampers	hamper	VERB
aji-132	150	5	the	the	DET
aji-132	150	6	secretion	secretion	NOUN
aji-132	150	7	of	of	ADP
aji-132	150	8	inflammatory	inflammatory	ADJ
aji-132	150	9	cytokines	cytokine	NOUN
aji-132	150	10	induced	induce	VERB
aji-132	150	11	by	by	ADP
aji-132	150	12	tnf	tnf	PROPN
aji-132	150	13	-	-	PUNCT
aji-132	150	14	α	α	PROPN
aji-132	150	15	and	and	CCONJ
aji-132	150	16	curtails	curtail	VERB
aji-132	150	17	nf	nf	ADJ
aji-132	150	18	-	-	PUNCT
aji-132	150	19	κb	κb	NOUN
aji-132	150	20	activation	activation	NOUN
aji-132	150	21	in	in	ADP
aji-132	150	22	human	human	ADJ
aji-132	150	23	synovial	synovial	ADJ
aji-132	150	24	cells	cell	NOUN
aji-132	150	25	.	.	PUNCT
aji-132	151	1	this	this	DET
aji-132	151	2	interference	interference	NOUN
aji-132	151	3	includes	include	VERB
aji-132	151	4	impeding	impede	VERB
aji-132	151	5	the	the	DET
aji-132	151	6	translocation	translocation	NOUN
aji-132	151	7	of	of	ADP
aji-132	151	8	nf	nf	ADJ
aji-132	151	9	-	-	PUNCT
aji-132	151	10	κb	κb	ADJ
aji-132	151	11	p65	p65	NOUN
aji-132	151	12	into	into	ADP
aji-132	151	13	the	the	DET
aji-132	151	14	nucleus	nucleus	NOUN
aji-132	151	15	.	.	PUNCT
aji-132	152	1	through	through	ADP
aji-132	152	2	the	the	DET
aji-132	152	3	inhibition	inhibition	NOUN
aji-132	152	4	of	of	ADP
aji-132	152	5	nf	nf	ADJ
aji-132	152	6	-	-	PUNCT
aji-132	152	7	κb	κb	NOUN
aji-132	152	8	activity	activity	NOUN
aji-132	152	9	,	,	PUNCT
aji-132	152	10	it	it	PRON
aji-132	152	11	modulates	modulate	VERB
aji-132	152	12	transcriptional	transcriptional	ADJ
aji-132	152	13	regulation	regulation	NOUN
aji-132	152	14	to	to	PART
aji-132	152	15	suppress	suppress	VERB
aji-132	152	16	the	the	DET
aji-132	152	17	production	production	NOUN
aji-132	152	18	of	of	ADP
aji-132	152	19	cytokines	cytokine	NOUN
aji-132	152	20	and	and	CCONJ
aji-132	152	21	chemokines	chemokine	NOUN
aji-132	152	22	,	,	PUNCT
aji-132	152	23	thereby	thereby	ADV
aji-132	152	24	exerting	exert	VERB
aji-132	152	25	anti	anti	ADJ
aji-132	152	26	-	-	ADJ
aji-132	152	27	inflammatory	inflammatory	ADJ
aji-132	152	28	effects	effect	NOUN
aji-132	152	29	”	"	PUNCT
aji-132	153	1	[	[	X
aji-132	153	2	16,17	16,17	NUM
aji-132	153	3	]	]	PUNCT
aji-132	153	4	.	.	PUNCT
aji-132	154	1	“	"	PUNCT
aji-132	154	2	iguratimod	iguratimod	PROPN
aji-132	154	3	has	have	AUX
aji-132	154	4	been	be	AUX
aji-132	154	5	observed	observe	VERB
aji-132	154	6	to	to	PART
aji-132	154	7	disrupt	disrupt	VERB
aji-132	154	8	the	the	DET
aji-132	154	9	tnf	tnf	PROPN
aji-132	154	10	-	-	PUNCT
aji-132	154	11	α	α	ADV
aji-132	154	12	-	-	PUNCT
aji-132	154	13	induced	induce	VERB
aji-132	154	14	translocation	translocation	NOUN
aji-132	154	15	of	of	ADP
aji-132	154	16	nf	nf	NOUN
aji-132	154	17	-	-	PUNCT
aji-132	154	18	κb	κb	NOUN
aji-132	154	19	from	from	ADP
aji-132	154	20	the	the	DET
aji-132	154	21	cytoplasm	cytoplasm	NOUN
aji-132	154	22	to	to	ADP
aji-132	154	23	the	the	DET
aji-132	154	24	nucleus	nucleus	NOUN
aji-132	154	25	.	.	PUNCT
aji-132	155	1	this	this	DET
aji-132	155	2	interference	interference	NOUN
aji-132	155	3	leads	lead	VERB
aji-132	155	4	to	to	ADP
aji-132	155	5	the	the	DET
aji-132	155	6	inhibition	inhibition	NOUN
aji-132	155	7	of	of	ADP
aji-132	155	8	tnf	tnf	PROPN
aji-132	155	9	-	-	PUNCT
aji-132	155	10	α	α	ADV
aji-132	155	11	-	-	PUNCT
aji-132	155	12	induced	induced	ADJ
aji-132	155	13	production	production	NOUN
aji-132	155	14	of	of	ADP
aji-132	155	15	il-6	il-6	NOUN
aji-132	155	16	,	,	PUNCT
aji-132	155	17	il-8	il-8	NOUN
aji-132	155	18	,	,	PUNCT
aji-132	155	19	and	and	CCONJ
aji-132	155	20	monocyte	monocyte	ADJ
aji-132	155	21	chemoattractant	chemoattractant	NOUN
aji-132	155	22	protein	protein	NOUN
aji-132	155	23	1	1	NUM
aji-132	155	24	.	.	PUNCT
aji-132	156	1	hence	hence	ADV
aji-132	156	2	,	,	PUNCT
aji-132	156	3	iguratiomud	iguratiomud	PROPN
aji-132	156	4	has	have	VERB
aji-132	156	5	the	the	DET
aji-132	156	6	potential	potential	NOUN
aji-132	156	7	to	to	PART
aji-132	156	8	modulate	modulate	VERB
aji-132	156	9	the	the	DET
aji-132	156	10	expression	expression	NOUN
aji-132	156	11	of	of	ADP
aji-132	156	12	inflammatory	inflammatory	ADJ
aji-132	156	13	factors	factor	NOUN
aji-132	156	14	by	by	ADP
aji-132	156	15	regulating	regulate	VERB
aji-132	156	16	the	the	DET
aji-132	156	17	nf	nf	ADJ
aji-132	156	18	-	-	PUNCT
aji-132	156	19	κb	κb	NOUN
aji-132	156	20	signaling	signal	VERB
aji-132	156	21	pathway	pathway	NOUN
aji-132	156	22	”	"	PUNCT
aji-132	157	1	[	[	X
aji-132	157	2	18	18	NUM
aji-132	157	3	]	]	PUNCT
aji-132	157	4	.	.	PUNCT
aji-132	158	1	“	"	PUNCT
aji-132	158	2	in	in	ADP
aji-132	158	3	the	the	DET
aji-132	158	4	regulation	regulation	NOUN
aji-132	158	5	of	of	ADP
aji-132	158	6	neutrophils	neutrophil	NOUN
aji-132	158	7	,	,	PUNCT
aji-132	158	8	it	it	PRON
aji-132	158	9	has	have	AUX
aji-132	158	10	been	be	AUX
aji-132	158	11	discovered	discover	VERB
aji-132	158	12	that	that	SCONJ
aji-132	158	13	iguratimod	iguratimod	PROPN
aji-132	158	14	suppressed	suppress	VERB
aji-132	158	15	the	the	DET
aji-132	158	16	expression	expression	NOUN
aji-132	158	17	of	of	ADP
aji-132	158	18	cps	cps	PROPN
aji-132	158	19	by	by	ADP
aji-132	158	20	downregulating	downregulate	VERB
aji-132	158	21	pad	pad	NOUN
aji-132	158	22	in	in	ADP
aji-132	158	23	neutrophils	neutrophil	NOUN
aji-132	158	24	from	from	ADP
aji-132	158	25	ra	ra	PROPN
aji-132	158	26	patients	patient	NOUN
aji-132	158	27	.	.	PUNCT
aji-132	159	1	notably	notably	ADV
aji-132	159	2	,	,	PUNCT
aji-132	159	3	this	this	DET
aji-132	159	4	effect	effect	NOUN
aji-132	159	5	was	be	AUX
aji-132	159	6	comparable	comparable	ADJ
aji-132	159	7	to	to	ADP
aji-132	159	8	the	the	DET
aji-132	159	9	impact	impact	NOUN
aji-132	159	10	of	of	ADP
aji-132	159	11	mtx	mtx	NOUN
aji-132	159	12	and	and	CCONJ
aji-132	159	13	dxm	dxm	NOUN
aji-132	159	14	at	at	ADP
aji-132	159	15	suitable	suitable	ADJ
aji-132	159	16	concentrations	concentration	NOUN
aji-132	159	17	.	.	PUNCT
aji-132	160	1	these	these	DET
aji-132	160	2	results	result	NOUN
aji-132	160	3	offer	offer	VERB
aji-132	160	4	valuable	valuable	ADJ
aji-132	160	5	insights	insight	NOUN
aji-132	160	6	for	for	ADP
aji-132	160	7	refining	refine	VERB
aji-132	160	8	the	the	DET
aji-132	160	9	treatment	treatment	NOUN
aji-132	160	10	of	of	ADP
aji-132	160	11	rheumatoid	rheumatoid	NOUN
aji-132	160	12	arthritis	arthritis	NOUN
aji-132	160	13	(	(	PUNCT
aji-132	160	14	ra	ra	NOUN
aji-132	160	15	)	)	PUNCT
aji-132	160	16	.	.	PUNCT
aji-132	161	1	iguratimod	iguratimod	PROPN
aji-132	161	2	,	,	PUNCT
aji-132	161	3	at	at	ADP
aji-132	161	4	an	an	DET
aji-132	161	5	optimal	optimal	ADJ
aji-132	161	6	concentration	concentration	NOUN
aji-132	161	7	comparable	comparable	ADJ
aji-132	161	8	to	to	ADP
aji-132	161	9	mtx	mtx	NOUN
aji-132	161	10	and	and	CCONJ
aji-132	161	11	dexamethasone	dexamethasone	NOUN
aji-132	161	12	,	,	PUNCT
aji-132	161	13	effectively	effectively	ADV
aji-132	161	14	hinders	hinder	VERB
aji-132	161	15	the	the	DET
aji-132	161	16	expression	expression	NOUN
aji-132	161	17	of	of	ADP
aji-132	161	18	citrulline	citrulline	ADJ
aji-132	161	19	proteins	protein	NOUN
aji-132	161	20	in	in	ADP
aji-132	161	21	neutrophils	neutrophil	NOUN
aji-132	161	22	from	from	ADP
aji-132	161	23	ra	ra	PROPN
aji-132	161	24	patients	patient	NOUN
aji-132	161	25	.	.	PUNCT
aji-132	162	1	this	this	DET
aji-132	162	2	inhibitory	inhibitory	ADJ
aji-132	162	3	effect	effect	NOUN
aji-132	162	4	is	be	AUX
aji-132	162	5	attributed	attribute	VERB
aji-132	162	6	to	to	ADP
aji-132	162	7	the	the	DET
aji-132	162	8	downregulation	downregulation	NOUN
aji-132	162	9	of	of	ADP
aji-132	162	10	peptidyl	peptidyl	NOUN
aji-132	162	11	arginine	arginine	NOUN
aji-132	162	12	deiminase	deiminase	VERB
aji-132	162	13	,	,	PUNCT
aji-132	162	14	shedding	shed	VERB
aji-132	162	15	light	light	NOUN
aji-132	162	16	on	on	ADP
aji-132	162	17	the	the	DET
aji-132	162	18	mechanism	mechanism	NOUN
aji-132	162	19	of	of	ADP
aji-132	162	20	iguratimod	iguratimod	NOUN
aji-132	162	21	in	in	ADP
aji-132	162	22	ra	ra	PROPN
aji-132	162	23	treatment	treatment	NOUN
aji-132	162	24	.	.	PUNCT
aji-132	163	1	the	the	DET
aji-132	163	2	findings	finding	NOUN
aji-132	163	3	from	from	ADP
aji-132	163	4	this	this	DET
aji-132	163	5	study	study	NOUN
aji-132	163	6	can	can	AUX
aji-132	163	7	provide	provide	VERB
aji-132	163	8	valuable	valuable	ADJ
aji-132	163	9	guidance	guidance	NOUN
aji-132	163	10	for	for	ADP
aji-132	163	11	the	the	DET
aji-132	163	12	treatment	treatment	NOUN
aji-132	163	13	of	of	ADP
aji-132	163	14	rheumatoid	rheumatoid	NOUN
aji-132	163	15	arthritis	arthritis	NOUN
aji-132	163	16	and	and	CCONJ
aji-132	163	17	facilitate	facilitate	VERB
aji-132	163	18	the	the	DET
aji-132	163	19	identification	identification	NOUN
aji-132	163	20	of	of	ADP
aji-132	163	21	additional	additional	ADJ
aji-132	163	22	therapeutic	therapeutic	ADJ
aji-132	163	23	targets	target	NOUN
aji-132	163	24	”	"	PUNCT
aji-132	164	1	[	[	X
aji-132	164	2	19	19	NUM
aji-132	164	3	]	]	PUNCT
aji-132	164	4	.	.	PUNCT
aji-132	165	1	2.2	2.2	NUM
aji-132	165	2	immune	immune	ADJ
aji-132	165	3	response	response	NOUN
aji-132	165	4	2.2.1	2.2.1	NUM
aji-132	165	5	regulating	regulate	VERB
aji-132	165	6	humoral	humoral	ADJ
aji-132	165	7	immunity	immunity	NOUN
aji-132	165	8	“	"	PUNCT
aji-132	165	9	in	in	ADP
aji-132	165	10	2003	2003	NUM
aji-132	165	11	,	,	PUNCT
aji-132	165	12	researchers	researcher	NOUN
aji-132	165	13	initially	initially	ADV
aji-132	165	14	observed	observe	VERB
aji-132	165	15	that	that	SCONJ
aji-132	165	16	igu	igu	PROPN
aji-132	165	17	had	have	VERB
aji-132	165	18	a	a	DET
aji-132	165	19	direct	direct	ADJ
aji-132	165	20	inhibitory	inhibitory	ADJ
aji-132	165	21	impact	impact	NOUN
aji-132	165	22	on	on	ADP
aji-132	165	23	b	b	NUM
aji-132	165	24	lymphocytes	lymphocyte	NOUN
aji-132	165	25	in	in	ADP
aji-132	165	26	both	both	PRON
aji-132	165	27	mouse	mouse	NOUN
aji-132	165	28	and	and	CCONJ
aji-132	165	29	human	human	ADJ
aji-132	165	30	subjects	subject	NOUN
aji-132	165	31	,	,	PUNCT
aji-132	165	32	leading	lead	VERB
aji-132	165	33	to	to	ADP
aji-132	165	34	a	a	DET
aji-132	165	35	decrease	decrease	NOUN
aji-132	165	36	in	in	ADP
aji-132	165	37	the	the	DET
aji-132	165	38	synthesis	synthesis	NOUN
aji-132	165	39	of	of	ADP
aji-132	165	40	immunoglobulins	immunoglobulin	NOUN
aji-132	165	41	.	.	PUNCT
aji-132	166	1	notably	notably	ADV
aji-132	166	2	,	,	PUNCT
aji-132	166	3	this	this	DET
aji-132	166	4	inhibition	inhibition	NOUN
aji-132	166	5	did	do	AUX
aji-132	166	6	not	not	PART
aji-132	166	7	influence	influence	VERB
aji-132	166	8	the	the	DET
aji-132	166	9	proliferation	proliferation	NOUN
aji-132	166	10	or	or	CCONJ
aji-132	166	11	apoptosis	apoptosis	NOUN
aji-132	166	12	of	of	ADP
aji-132	166	13	b	b	NOUN
aji-132	166	14	cells	cell	NOUN
aji-132	166	15	[	[	X
aji-132	166	16	4	4	NUM
aji-132	166	17	]	]	PUNCT
aji-132	166	18	.	.	PUNCT
aji-132	167	1	in	in	ADP
aji-132	167	2	mrl	mrl	PROPN
aji-132	167	3	/	/	SYM
aji-132	167	4	lpr	lpr	PROPN
aji-132	167	5	mice	mouse	NOUN
aji-132	167	6	,	,	PUNCT
aji-132	167	7	igu	igu	PROPN
aji-132	167	8	demonstrated	demonstrate	VERB
aji-132	167	9	the	the	DET
aji-132	167	10	ability	ability	NOUN
aji-132	167	11	to	to	PART
aji-132	167	12	decrease	decrease	VERB
aji-132	167	13	circulating	circulate	VERB
aji-132	167	14	plasma	plasma	NOUN
aji-132	167	15	cells	cell	NOUN
aji-132	167	16	through	through	ADP
aji-132	167	17	a	a	DET
aji-132	167	18	mechanism	mechanism	NOUN
aji-132	167	19	that	that	PRON
aji-132	167	20	does	do	AUX
aji-132	167	21	not	not	PART
aji-132	167	22	involve	involve	VERB
aji-132	167	23	antiproliferative	antiproliferative	ADJ
aji-132	167	24	effects	effect	NOUN
aji-132	167	25	”	"	PUNCT
aji-132	168	1	[	[	X
aji-132	168	2	21	21	NUM
aji-132	168	3	]	]	PUNCT
aji-132	168	4	.	.	PUNCT
aji-132	169	1	“	"	PUNCT
aji-132	169	2	in	in	ADP
aji-132	169	3	a	a	DET
aji-132	169	4	recent	recent	ADJ
aji-132	169	5	study	study	NOUN
aji-132	169	6	,	,	PUNCT
aji-132	169	7	it	it	PRON
aji-132	169	8	was	be	AUX
aji-132	169	9	shown	show	VERB
aji-132	169	10	that	that	SCONJ
aji-132	169	11	igu	igu	PROPN
aji-132	169	12	did	do	AUX
aji-132	169	13	not	not	PART
aji-132	169	14	influence	influence	VERB
aji-132	169	15	the	the	DET
aji-132	169	16	activation	activation	NOUN
aji-132	169	17	and	and	CCONJ
aji-132	169	18	proliferation	proliferation	NOUN
aji-132	169	19	of	of	ADP
aji-132	169	20	b	b	NOUN
aji-132	169	21	cells	cell	NOUN
aji-132	169	22	within	within	ADP
aji-132	169	23	the	the	DET
aji-132	169	24	established	establish	VERB
aji-132	169	25	in	in	ADP
aji-132	169	26	vitro	vitro	X
aji-132	169	27	human	human	ADJ
aji-132	169	28	antibody	antibody	NOUN
aji-132	169	29	-	-	PUNCT
aji-132	169	30	secreting	secrete	VERB
aji-132	169	31	cell	cell	NOUN
aji-132	169	32	differentiation	differentiation	NOUN
aji-132	169	33	system	system	NOUN
aji-132	169	34	.	.	PUNCT
aji-132	170	1	however	however	ADV
aji-132	170	2	,	,	PUNCT
aji-132	170	3	its	its	PRON
aji-132	170	4	inhibitory	inhibitory	ADJ
aji-132	170	5	effects	effect	NOUN
aji-132	170	6	were	be	AUX
aji-132	170	7	observed	observe	VERB
aji-132	170	8	in	in	ADP
aji-132	170	9	the	the	DET
aji-132	170	10	differentiation	differentiation	NOUN
aji-132	170	11	of	of	ADP
aji-132	170	12	human	human	ADJ
aji-132	170	13	antibody	antibody	NOUN
aji-132	170	14	-	-	PUNCT
aji-132	170	15	secreting	secrete	VERB
aji-132	170	16	cells	cell	NOUN
aji-132	170	17	,	,	PUNCT
aji-132	170	18	achieved	achieve	VERB
aji-132	170	19	by	by	ADP
aji-132	170	20	targeting	target	VERB
aji-132	170	21	the	the	DET
aji-132	170	22	protein	protein	NOUN
aji-132	170	23	kinase	kinase	NOUN
aji-132	170	24	c	c	PROPN
aji-132	170	25	(	(	PUNCT
aji-132	170	26	pkc	pkc	NOUN
aji-132	170	27	)	)	PUNCT
aji-132	170	28	and	and	CCONJ
aji-132	170	29	early	early	ADJ
aji-132	170	30	growth	growth	NOUN
aji-132	170	31	response	response	NOUN
aji-132	170	32	1	1	NUM
aji-132	170	33	(	(	PUNCT
aji-132	170	34	egr1	egr1	PROPN
aji-132	170	35	)	)	PUNCT
aji-132	170	36	axis	axis	NOUN
aji-132	170	37	”	"	PUNCT
aji-132	171	1	[	[	X
aji-132	171	2	22	22	NUM
aji-132	171	3	]	]	PUNCT
aji-132	171	4	.	.	PUNCT
aji-132	172	1	fig	fig	NOUN
aji-132	172	2	.	.	PUNCT
aji-132	173	1	1	1	NUM
aji-132	173	2	.	.	X
aji-132	173	3	depicts	depict	VERB
aji-132	173	4	the	the	DET
aji-132	173	5	anti	anti	ADJ
aji-132	173	6	-	-	ADJ
aji-132	173	7	inflammatory	inflammatory	ADJ
aji-132	173	8	mechanism	mechanism	NOUN
aji-132	173	9	of	of	ADP
aji-132	173	10	igu	igu	PROPN
aji-132	173	11	(	(	PUNCT
aji-132	173	12	iguratimod	iguratimod	PROPN
aji-132	173	13	)	)	PUNCT
aji-132	173	14	igu	igu	PROPN
aji-132	173	15	effectively	effectively	ADV
aji-132	173	16	suppresses	suppress	VERB
aji-132	173	17	inflammation	inflammation	NOUN
aji-132	173	18	through	through	ADP
aji-132	173	19	several	several	ADJ
aji-132	173	20	pathways	pathway	NOUN
aji-132	173	21	.	.	PUNCT
aji-132	174	1	firstly	firstly	ADV
aji-132	174	2	,	,	PUNCT
aji-132	174	3	it	it	PRON
aji-132	174	4	inhibits	inhibit	VERB
aji-132	174	5	the	the	DET
aji-132	174	6	activity	activity	NOUN
aji-132	174	7	of	of	ADP
aji-132	174	8	mif	mif	PROPN
aji-132	174	9	(	(	PUNCT
aji-132	174	10	macrophage	macrophage	ADJ
aji-132	174	11	migration	migration	NOUN
aji-132	174	12	inhibitory	inhibitory	ADJ
aji-132	174	13	factor	factor	NOUN
aji-132	174	14	)	)	PUNCT
aji-132	174	15	and	and	CCONJ
aji-132	174	16	counteracts	counteract	VERB
aji-132	174	17	mif	mif	PROPN
aji-132	174	18	-	-	PUNCT
aji-132	174	19	induced	induce	VERB
aji-132	174	20	proinflammatory	proinflammatory	ADJ
aji-132	174	21	effects	effect	NOUN
aji-132	174	22	.	.	PUNCT
aji-132	175	1	additionally	additionally	ADV
aji-132	175	2	,	,	PUNCT
aji-132	175	3	igu	igu	PROPN
aji-132	175	4	disrupts	disrupt	VERB
aji-132	175	5	il-17	il-17	ADV
aji-132	175	6	-	-	PUNCT
aji-132	175	7	mediated	mediate	VERB
aji-132	175	8	signaling	signal	VERB
aji-132	175	9	by	by	ADP
aji-132	175	10	interfering	interfere	VERB
aji-132	175	11	with	with	ADP
aji-132	175	12	the	the	DET
aji-132	175	13	interaction	interaction	NOUN
aji-132	175	14	between	between	ADP
aji-132	175	15	act1	act1	PROPN
aji-132	175	16	and	and	CCONJ
aji-132	175	17	traf5	traf5	PROPN
aji-132	175	18	,	,	PUNCT
aji-132	175	19	as	as	ADV
aji-132	175	20	well	well	ADV
aji-132	175	21	as	as	ADP
aji-132	175	22	ikki	ikki	NOUN
aji-132	175	23	,	,	PUNCT
aji-132	175	24	thereby	thereby	ADV
aji-132	175	25	reducing	reduce	VERB
aji-132	175	26	the	the	DET
aji-132	175	27	expression	expression	NOUN
aji-132	175	28	of	of	ADP
aji-132	175	29	various	various	ADJ
aji-132	175	30	inflammatory	inflammatory	ADJ
aji-132	175	31	factors	factor	NOUN
aji-132	175	32	induced	induce	VERB
aji-132	175	33	by	by	ADP
aji-132	175	34	il-17	il-17	NOUN
aji-132	175	35	.	.	PUNCT
aji-132	176	1	moreover	moreover	ADV
aji-132	176	2	,	,	PUNCT
aji-132	176	3	igu	igu	PROPN
aji-132	176	4	interferes	interfere	VERB
aji-132	176	5	with	with	ADP
aji-132	176	6	the	the	DET
aji-132	176	7	tnf	tnf	PROPN
aji-132	176	8	-	-	PUNCT
aji-132	176	9	α	α	ADV
aji-132	176	10	-	-	PUNCT
aji-132	176	11	induced	induce	VERB
aji-132	176	12	translocation	translocation	NOUN
aji-132	176	13	of	of	ADP
aji-132	176	14	nf	nf	NOUN
aji-132	176	15	-	-	PUNCT
aji-132	176	16	κb	κb	NOUN
aji-132	176	17	from	from	ADP
aji-132	176	18	the	the	DET
aji-132	176	19	cytoplasm	cytoplasm	NOUN
aji-132	176	20	to	to	ADP
aji-132	176	21	the	the	DET
aji-132	176	22	nucleus	nucleus	NOUN
aji-132	176	23	,	,	PUNCT
aji-132	176	24	consequently	consequently	ADV
aji-132	176	25	suppressing	suppress	VERB
aji-132	176	26	the	the	DET
aji-132	176	27	production	production	NOUN
aji-132	176	28	of	of	ADP
aji-132	176	29	il-6	il-6	NOUN
aji-132	176	30	and	and	CCONJ
aji-132	176	31	il-8	il-8	NOUN
aji-132	176	32	induced	induce	VERB
aji-132	176	33	by	by	ADP
aji-132	176	34	tnf	tnf	PROPN
aji-132	176	35	-	-	PUNCT
aji-132	176	36	α	α	PROPN
aji-132	176	37	gupta	gupta	PROPN
aji-132	176	38	et	et	PROPN
aji-132	176	39	al	al	PROPN
aji-132	176	40	.	.	PROPN
aji-132	176	41	;	;	PUNCT
aji-132	177	1	asian	asian	PROPN
aji-132	177	2	j.	j.	PROPN
aji-132	177	3	immunol	immunol	PROPN
aji-132	177	4	.	.	PROPN
aji-132	177	5	,	,	PUNCT
aji-132	177	6	vol	vol	NOUN
aji-132	177	7	.	.	PROPN
aji-132	177	8	7	7	NUM
aji-132	177	9	,	,	PUNCT
aji-132	177	10	no	no	INTJ
aji-132	177	11	.	.	NOUN
aji-132	177	12	1	1	NUM
aji-132	177	13	,	,	PUNCT
aji-132	177	14	pp	pp	ADJ
aji-132	177	15	.	.	PUNCT
aji-132	178	1	79	79	NUM
aji-132	178	2	-	-	SYM
aji-132	178	3	89	89	NUM
aji-132	178	4	,	,	PUNCT
aji-132	178	5	2024	2024	NUM
aji-132	178	6	;	;	PUNCT
aji-132	178	7	article	article	NOUN
aji-132	178	8	no.aji.115805	no.aji.115805	VERB
aji-132	178	9	82	82	NUM
aji-132	178	10	2.2.2	2.2.2	NUM
aji-132	178	11	suppression	suppression	NOUN
aji-132	178	12	of	of	ADP
aji-132	178	13	immunoglobulin	immunoglobulin	NOUN
aji-132	178	14	synthesis	synthesis	NOUN
aji-132	178	15	“	"	PUNCT
aji-132	178	16	in	in	ADP
aji-132	178	17	subsequent	subsequent	ADJ
aji-132	178	18	clinical	clinical	ADJ
aji-132	178	19	trials	trial	NOUN
aji-132	178	20	,	,	PUNCT
aji-132	178	21	it	it	PRON
aji-132	178	22	was	be	AUX
aji-132	178	23	noted	note	VERB
aji-132	178	24	that	that	SCONJ
aji-132	178	25	iguratimod	iguratimod	PROPN
aji-132	178	26	exhibited	exhibit	VERB
aji-132	178	27	favorable	favorable	ADJ
aji-132	178	28	therapeutic	therapeutic	ADJ
aji-132	178	29	outcomes	outcome	NOUN
aji-132	178	30	concerning	concern	VERB
aji-132	178	31	both	both	CCONJ
aji-132	178	32	clinical	clinical	ADJ
aji-132	178	33	symptoms	symptom	NOUN
aji-132	178	34	and	and	CCONJ
aji-132	178	35	biological	biological	ADJ
aji-132	178	36	markers	marker	NOUN
aji-132	178	37	,	,	PUNCT
aji-132	178	38	including	include	VERB
aji-132	178	39	rheumatoid	rheumatoid	NOUN
aji-132	178	40	factor	factor	NOUN
aji-132	178	41	(	(	PUNCT
aji-132	178	42	rf	rf	NOUN
aji-132	178	43	)	)	PUNCT
aji-132	178	44	levels	level	NOUN
aji-132	178	45	and	and	CCONJ
aji-132	178	46	immunoglobulin	immunoglobulin	NOUN
aji-132	178	47	concentrations	concentration	NOUN
aji-132	178	48	in	in	ADP
aji-132	178	49	plasma	plasma	NOUN
aji-132	178	50	.	.	PUNCT
aji-132	179	1	consequently	consequently	ADV
aji-132	179	2	,	,	PUNCT
aji-132	179	3	our	our	PRON
aji-132	179	4	investigations	investigation	NOUN
aji-132	179	5	were	be	AUX
aji-132	179	6	directed	direct	VERB
aji-132	179	7	toward	toward	ADP
aji-132	179	8	assessing	assess	VERB
aji-132	179	9	its	its	PRON
aji-132	179	10	impact	impact	NOUN
aji-132	179	11	on	on	ADP
aji-132	179	12	b	b	NOUN
aji-132	179	13	-	-	PUNCT
aji-132	179	14	cell	cell	NOUN
aji-132	179	15	functions	function	NOUN
aji-132	179	16	,	,	PUNCT
aji-132	179	17	particularly	particularly	ADV
aji-132	179	18	about	about	ADP
aji-132	179	19	immunoglobulin	immunoglobulin	NOUN
aji-132	179	20	production	production	NOUN
aji-132	179	21	and	and	CCONJ
aji-132	179	22	proliferation	proliferation	NOUN
aji-132	179	23	.	.	PUNCT
aji-132	180	1	in	in	ADP
aji-132	180	2	cultures	culture	NOUN
aji-132	180	3	of	of	ADP
aji-132	180	4	murine	murine	ADJ
aji-132	180	5	b	b	NOUN
aji-132	180	6	-	-	PUNCT
aji-132	180	7	cells	cell	NOUN
aji-132	180	8	,	,	PUNCT
aji-132	180	9	iguratimod	iguratimod	PROPN
aji-132	180	10	exhibited	exhibit	VERB
aji-132	180	11	a	a	DET
aji-132	180	12	notable	notable	ADJ
aji-132	180	13	reduction	reduction	NOUN
aji-132	180	14	in	in	ADP
aji-132	180	15	igm	igm	NOUN
aji-132	180	16	production	production	NOUN
aji-132	180	17	and	and	CCONJ
aji-132	180	18	the	the	DET
aji-132	180	19	isotype	isotype	NOUN
aji-132	180	20	-	-	PUNCT
aji-132	180	21	switch	switch	NOUN
aji-132	180	22	to	to	ADP
aji-132	180	23	igg1	igg1	NOUN
aji-132	180	24	class	class	NOUN
aji-132	180	25	induced	induce	VERB
aji-132	180	26	by	by	ADP
aji-132	180	27	lipopolysaccharide	lipopolysaccharide	ADJ
aji-132	180	28	(	(	PUNCT
aji-132	180	29	lps	lps	PROPN
aji-132	180	30	)	)	PUNCT
aji-132	180	31	and/or	and/or	CCONJ
aji-132	180	32	il-4	il-4	PROPN
aji-132	180	33	.	.	PUNCT
aji-132	181	1	additionally	additionally	ADV
aji-132	181	2	,	,	PUNCT
aji-132	181	3	it	it	PRON
aji-132	181	4	inhibits	inhibit	VERB
aji-132	181	5	spontaneous	spontaneous	ADJ
aji-132	181	6	igg	igg	NOUN
aji-132	181	7	production	production	NOUN
aji-132	181	8	without	without	ADP
aji-132	181	9	affecting	affect	VERB
aji-132	181	10	cell	cell	NOUN
aji-132	181	11	proliferation	proliferation	NOUN
aji-132	181	12	in	in	ADP
aji-132	181	13	a	a	DET
aji-132	181	14	human	human	ADJ
aji-132	181	15	plasmacytoma	plasmacytoma	NOUN
aji-132	181	16	cell	cell	NOUN
aji-132	181	17	line	line	NOUN
aji-132	181	18	(	(	PUNCT
aji-132	181	19	arh-77	arh-77	NUM
aji-132	181	20	)	)	PUNCT
aji-132	181	21	.	.	PUNCT
aji-132	182	1	moreover	moreover	ADV
aji-132	182	2	,	,	PUNCT
aji-132	182	3	when	when	SCONJ
aji-132	182	4	human	human	ADJ
aji-132	182	5	peripheral	peripheral	ADJ
aji-132	182	6	b	b	PROPN
aji-132	182	7	cells	cell	NOUN
aji-132	182	8	were	be	AUX
aji-132	182	9	stimulated	stimulate	VERB
aji-132	182	10	with	with	ADP
aji-132	182	11	autologous	autologous	ADJ
aji-132	182	12	t	t	NOUN
aji-132	182	13	cells	cell	NOUN
aji-132	182	14	and	and	CCONJ
aji-132	182	15	anti	anti	ADJ
aji-132	182	16	-	-	ADJ
aji-132	182	17	cd3	cd3	ADJ
aji-132	182	18	antibody	antibody	NOUN
aji-132	182	19	,	,	PUNCT
aji-132	182	20	iguratimod	iguratimod	PROPN
aji-132	182	21	demonstrated	demonstrate	VERB
aji-132	182	22	a	a	DET
aji-132	182	23	concentration	concentration	NOUN
aji-132	182	24	-	-	PUNCT
aji-132	182	25	dependent	dependent	ADJ
aji-132	182	26	inhibition	inhibition	NOUN
aji-132	182	27	of	of	ADP
aji-132	182	28	both	both	DET
aji-132	182	29	igm	igm	PROPN
aji-132	182	30	and	and	CCONJ
aji-132	182	31	igg	igg	PROPN
aji-132	182	32	production	production	NOUN
aji-132	182	33	”	"	PUNCT
aji-132	183	1	[	[	X
aji-132	183	2	4	4	NUM
aji-132	183	3	]	]	PUNCT
aji-132	183	4	.	.	PUNCT
aji-132	184	1	in	in	ADP
aji-132	184	2	contrast	contrast	NOUN
aji-132	184	3	,	,	PUNCT
aji-132	184	4	iguratimod	iguratimod	PROPN
aji-132	184	5	did	do	AUX
aji-132	184	6	not	not	PART
aji-132	184	7	exhibit	exhibit	VERB
aji-132	184	8	any	any	DET
aji-132	184	9	influence	influence	NOUN
aji-132	184	10	on	on	ADP
aji-132	184	11	the	the	DET
aji-132	184	12	mitogen	mitogen	NOUN
aji-132	184	13	-	-	PUNCT
aji-132	184	14	induced	induce	VERB
aji-132	184	15	proliferation	proliferation	NOUN
aji-132	184	16	response	response	NOUN
aji-132	185	1	[	[	X
aji-132	185	2	23,24	23,24	X
aji-132	185	3	]	]	PUNCT
aji-132	185	4	and	and	CCONJ
aji-132	185	5	thymus	thymus	VERB
aji-132	185	6	and	and	CCONJ
aji-132	185	7	activationregulated	activationregulate	VERB
aji-132	185	8	chemokine	chemokine	ADJ
aji-132	185	9	(	(	PUNCT
aji-132	185	10	tarc	tarc	PROPN
aji-132	185	11	)	)	PUNCT
aji-132	185	12	production	production	NOUN
aji-132	185	13	in	in	ADP
aji-132	185	14	human	human	PROPN
aji-132	185	15	b	b	PROPN
aji-132	185	16	cells	cell	NOUN
aji-132	185	17	stimulated	stimulate	VERB
aji-132	185	18	with	with	ADP
aji-132	185	19	anti	anti	ADJ
aji-132	185	20	-	-	ADJ
aji-132	185	21	cd40	cd40	ADJ
aji-132	185	22	antibody	antibody	NOUN
aji-132	185	23	and	and	CCONJ
aji-132	185	24	il-4	il-4	PRON
aji-132	185	25	[	[	X
aji-132	185	26	25	25	NUM
aji-132	185	27	]	]	PUNCT
aji-132	185	28	.	.	PUNCT
aji-132	186	1	hence	hence	ADV
aji-132	186	2	,	,	PUNCT
aji-132	186	3	it	it	PRON
aji-132	186	4	seems	seem	VERB
aji-132	186	5	that	that	SCONJ
aji-132	186	6	this	this	DET
aji-132	186	7	compound	compound	NOUN
aji-132	186	8	hinders	hinder	VERB
aji-132	186	9	the	the	DET
aji-132	186	10	production	production	NOUN
aji-132	186	11	of	of	ADP
aji-132	186	12	immunoglobulins	immunoglobulin	NOUN
aji-132	186	13	by	by	ADP
aji-132	186	14	b	b	PROPN
aji-132	186	15	cells	cell	NOUN
aji-132	186	16	without	without	ADP
aji-132	186	17	causing	cause	VERB
aji-132	186	18	a	a	DET
aji-132	186	19	cytostatic	cytostatic	NOUN
aji-132	186	20	effect.subsequently	effect.subsequently	ADV
aji-132	186	21	,	,	PUNCT
aji-132	186	22	to	to	PART
aji-132	186	23	elucidate	elucidate	VERB
aji-132	186	24	the	the	DET
aji-132	186	25	hyper	hyper	NOUN
aji-132	186	26	-	-	AUX
aji-132	186	27	immunoglobulinemia	immunoglobulinemia	NOUN
aji-132	186	28	observed	observe	VERB
aji-132	186	29	in	in	ADP
aji-132	186	30	rheumatoid	rheumatoid	NOUN
aji-132	186	31	arthritis	arthritis	NOUN
aji-132	186	32	(	(	PUNCT
aji-132	186	33	ra	ra	NOUN
aji-132	186	34	)	)	PUNCT
aji-132	186	35	patients	patient	NOUN
aji-132	186	36	and	and	CCONJ
aji-132	186	37	the	the	DET
aji-132	186	38	inhibitory	inhibitory	ADJ
aji-132	186	39	effects	effect	NOUN
aji-132	186	40	of	of	ADP
aji-132	186	41	iguratimod	iguratimod	NOUN
aji-132	186	42	,	,	PUNCT
aji-132	186	43	we	we	PRON
aji-132	186	44	examined	examine	VERB
aji-132	186	45	the	the	DET
aji-132	186	46	secretion	secretion	NOUN
aji-132	186	47	of	of	ADP
aji-132	186	48	immunoglobulins	immunoglobulin	NOUN
aji-132	186	49	from	from	ADP
aji-132	186	50	ra	ra	PROPN
aji-132	186	51	synovial	synovial	ADJ
aji-132	186	52	tissues	tissue	NOUN
aji-132	186	53	.	.	PUNCT
aji-132	187	1	the	the	DET
aji-132	187	2	experimentation	experimentation	NOUN
aji-132	187	3	was	be	AUX
aji-132	187	4	conducted	conduct	VERB
aji-132	187	5	utilizing	utilize	VERB
aji-132	187	6	severe	severe	ADJ
aji-132	187	7	combined	combined	ADJ
aji-132	187	8	immune	immune	ADJ
aji-132	187	9	deficiency	deficiency	NOUN
aji-132	187	10	(	(	PUNCT
aji-132	187	11	scid	scid	NOUN
aji-132	187	12	)	)	PUNCT
aji-132	187	13	mice	mouse	NOUN
aji-132	187	14	that	that	PRON
aji-132	187	15	were	be	AUX
aji-132	187	16	implanted	implant	VERB
aji-132	187	17	with	with	ADP
aji-132	187	18	human	human	ADJ
aji-132	187	19	rheumatoid	rheumatoid	NOUN
aji-132	187	20	arthritis	arthritis	NOUN
aji-132	187	21	(	(	PUNCT
aji-132	187	22	ra	ra	NOUN
aji-132	187	23	)	)	PUNCT
aji-132	187	24	tissue.consequently	tissue.consequently	ADV
aji-132	187	25	,	,	PUNCT
aji-132	187	26	the	the	DET
aji-132	187	27	sera	sera	NOUN
aji-132	187	28	of	of	ADP
aji-132	187	29	the	the	DET
aji-132	187	30	mice	mouse	NOUN
aji-132	187	31	exhibited	exhibit	VERB
aji-132	187	32	elevated	elevated	ADJ
aji-132	187	33	concentrations	concentration	NOUN
aji-132	187	34	of	of	ADP
aji-132	187	35	polyclonal	polyclonal	ADJ
aji-132	187	36	human	human	PROPN
aji-132	187	37	igg	igg	PROPN
aji-132	187	38	.	.	PUNCT
aji-132	188	1	furthermore	furthermore	ADV
aji-132	188	2	,	,	PUNCT
aji-132	188	3	the	the	DET
aji-132	188	4	iguratimod	iguratimod	NOUN
aji-132	188	5	-	-	PUNCT
aji-132	188	6	treated	treat	VERB
aji-132	188	7	group	group	NOUN
aji-132	188	8	demonstrated	demonstrate	VERB
aji-132	188	9	a	a	DET
aji-132	188	10	noteworthy	noteworthy	ADJ
aji-132	188	11	reduction	reduction	NOUN
aji-132	188	12	in	in	ADP
aji-132	188	13	igg	igg	PROPN
aji-132	188	14	levels	level	NOUN
aji-132	188	15	compared	compare	VERB
aji-132	188	16	to	to	ADP
aji-132	188	17	the	the	DET
aji-132	188	18	group	group	NOUN
aji-132	188	19	treated	treat	VERB
aji-132	188	20	with	with	ADP
aji-132	188	21	the	the	DET
aji-132	188	22	vehicle	vehicle	NOUN
aji-132	188	23	.	.	PUNCT
aji-132	189	1	in	in	ADP
aji-132	189	2	chronic	chronic	ADJ
aji-132	189	3	arthritis	arthritis	NOUN
aji-132	189	4	models	model	NOUN
aji-132	189	5	such	such	ADJ
aji-132	189	6	as	as	ADP
aji-132	189	7	adjuvant	adjuvant	NOUN
aji-132	189	8	-	-	PUNCT
aji-132	189	9	induced	induce	VERB
aji-132	189	10	arthritis	arthritis	NOUN
aji-132	189	11	(	(	PUNCT
aji-132	189	12	aia	aia	PROPN
aji-132	189	13	)	)	PUNCT
aji-132	189	14	rats	rat	NOUN
aji-132	189	15	and	and	CCONJ
aji-132	189	16	mrl	mrl	PROPN
aji-132	189	17	/	/	SYM
aji-132	189	18	lpr	lpr	PROPN
aji-132	189	19	mice	mouse	NOUN
aji-132	189	20	[	[	X
aji-132	189	21	11	11	NUM
aji-132	189	22	]	]	PUNCT
aji-132	189	23	,	,	PUNCT
aji-132	189	24	the	the	DET
aji-132	189	25	alleviation	alleviation	NOUN
aji-132	189	26	of	of	ADP
aji-132	189	27	arthritic	arthritic	ADJ
aji-132	189	28	lesions	lesion	NOUN
aji-132	189	29	by	by	ADP
aji-132	189	30	iguratimod	iguratimod	NOUN
aji-132	189	31	was	be	AUX
aji-132	189	32	concomitant	concomitant	ADJ
aji-132	189	33	with	with	ADP
aji-132	189	34	the	the	DET
aji-132	189	35	improvement	improvement	NOUN
aji-132	189	36	of	of	ADP
aji-132	189	37	hyperimmunoglobulinemia	hyperimmunoglobulinemia	NOUN
aji-132	190	1	[	[	X
aji-132	190	2	3,26	3,26	NOUN
aji-132	190	3	]	]	X
aji-132	190	4	.	.	PUNCT
aji-132	191	1	about	about	ADP
aji-132	191	2	the	the	DET
aji-132	191	3	clinical	clinical	ADJ
aji-132	191	4	effectiveness	effectiveness	NOUN
aji-132	191	5	of	of	ADP
aji-132	191	6	b	b	NOUN
aji-132	191	7	-	-	PUNCT
aji-132	191	8	celltargeted	celltargete	VERB
aji-132	191	9	anti	anti	ADJ
aji-132	191	10	-	-	ADJ
aji-132	191	11	cd20	cd20	ADJ
aji-132	191	12	antibody	antibody	NOUN
aji-132	191	13	in	in	ADP
aji-132	191	14	rheumatoid	rheumatoid	NOUN
aji-132	191	15	arthritis	arthritis	NOUN
aji-132	191	16	(	(	PUNCT
aji-132	191	17	ra	ra	NOUN
aji-132	191	18	)	)	PUNCT
aji-132	191	19	patients	patient	NOUN
aji-132	191	20	,	,	PUNCT
aji-132	191	21	[	[	X
aji-132	191	22	27	27	NUM
aji-132	191	23	]	]	PUNCT
aji-132	191	24	these	these	DET
aji-132	191	25	findings	finding	NOUN
aji-132	191	26	hold	hold	VERB
aji-132	191	27	significant	significant	ADJ
aji-132	191	28	importance	importance	NOUN
aji-132	191	29	in	in	ADP
aji-132	191	30	understanding	understand	VERB
aji-132	191	31	the	the	DET
aji-132	191	32	mechanisms	mechanism	NOUN
aji-132	191	33	behind	behind	ADP
aji-132	191	34	the	the	DET
aji-132	191	35	anti	anti	ADJ
aji-132	191	36	-	-	ADJ
aji-132	191	37	rheumatic	rheumatic	ADJ
aji-132	191	38	effects	effect	NOUN
aji-132	191	39	exhibited	exhibit	VERB
aji-132	191	40	by	by	ADP
aji-132	191	41	small	small	ADJ
aji-132	191	42	molecule	molecule	NOUN
aji-132	191	43	disease	disease	NOUN
aji-132	191	44	-	-	PUNCT
aji-132	191	45	modifying	modify	VERB
aji-132	191	46	antirheumatic	antirheumatic	ADJ
aji-132	191	47	drugs	drug	NOUN
aji-132	191	48	(	(	PUNCT
aji-132	191	49	dmards	dmard	NOUN
aji-132	191	50	)	)	PUNCT
aji-132	191	51	.	.	PUNCT
aji-132	192	1	2.2.3	2.2.3	NUM
aji-132	192	2	suppression	suppression	NOUN
aji-132	192	3	of	of	ADP
aji-132	192	4	cytokine	cytokine	ADJ
aji-132	192	5	synthesis	synthesis	NOUN
aji-132	192	6	“	"	PUNCT
aji-132	192	7	another	another	DET
aji-132	192	8	clear	clear	ADJ
aji-132	192	9	difference	difference	NOUN
aji-132	192	10	between	between	ADP
aji-132	192	11	iguratimod	iguratimod	NOUN
aji-132	192	12	and	and	CCONJ
aji-132	192	13	classical	classical	ADJ
aji-132	192	14	nsaids	nsaid	NOUN
aji-132	192	15	is	be	AUX
aji-132	192	16	the	the	DET
aji-132	192	17	inhibitory	inhibitory	ADJ
aji-132	192	18	effect	effect	NOUN
aji-132	192	19	on	on	ADP
aji-132	192	20	cytokine	cytokine	ADJ
aji-132	192	21	production	production	NOUN
aji-132	192	22	,	,	PUNCT
aji-132	192	23	as	as	SCONJ
aji-132	192	24	mentioned	mention	VERB
aji-132	192	25	above	above	ADV
aji-132	192	26	.	.	PUNCT
aji-132	193	1	when	when	SCONJ
aji-132	193	2	tested	test	VERB
aji-132	193	3	on	on	ADP
aji-132	193	4	cultured	cultured	ADJ
aji-132	193	5	monocytes	monocyte	NOUN
aji-132	193	6	/	/	SYM
aji-132	193	7	macrophages	macrophage	NOUN
aji-132	193	8	,	,	PUNCT
aji-132	193	9	iguratimod	iguratimod	PROPN
aji-132	193	10	demonstrated	demonstrate	VERB
aji-132	193	11	the	the	DET
aji-132	193	12	ability	ability	NOUN
aji-132	193	13	to	to	PART
aji-132	193	14	inhibit	inhibit	VERB
aji-132	193	15	the	the	DET
aji-132	193	16	production	production	NOUN
aji-132	193	17	of	of	ADP
aji-132	193	18	il-1β	il-1β	PROPN
aji-132	193	19	,	,	PUNCT
aji-132	193	20	tnfα	tnfα	NOUN
aji-132	193	21	,	,	PUNCT
aji-132	193	22	il-6	il-6	NOUN
aji-132	193	23	,	,	PUNCT
aji-132	193	24	il-8	il-8	NOUN
aji-132	193	25	,	,	PUNCT
aji-132	193	26	and	and	CCONJ
aji-132	193	27	monocyte	monocyte	PROPN
aji-132	193	28	chemoattractant	chemoattractant	PROPN
aji-132	193	29	protein-1	protein-1	PROPN
aji-132	193	30	(	(	PUNCT
aji-132	193	31	mcp-1	mcp-1	NOUN
aji-132	193	32	)	)	PUNCT
aji-132	193	33	with	with	ADP
aji-132	193	34	ic50	ic50	PROPN
aji-132	193	35	values	value	NOUN
aji-132	193	36	ranging	range	VERB
aji-132	193	37	from	from	ADP
aji-132	193	38	1	1	NUM
aji-132	193	39	to	to	PART
aji-132	193	40	20	20	NUM
aji-132	193	41	µg	µg	NOUN
aji-132	193	42	/	/	SYM
aji-132	193	43	ml	ml	NOUN
aji-132	193	44	”	"	PUNCT
aji-132	194	1	[	[	X
aji-132	194	2	28	28	NUM
aji-132	194	3	-	-	SYM
aji-132	194	4	31	31	NUM
aji-132	194	5	]	]	PUNCT
aji-132	194	6	.	.	PUNCT
aji-132	195	1	“	"	PUNCT
aji-132	195	2	in	in	ADP
aji-132	195	3	synovial	synovial	ADJ
aji-132	195	4	cells	cell	NOUN
aji-132	195	5	obtained	obtain	VERB
aji-132	195	6	from	from	ADP
aji-132	195	7	rheumatoid	rheumatoid	NOUN
aji-132	195	8	arthritis	arthritis	NOUN
aji-132	195	9	(	(	PUNCT
aji-132	195	10	ra	ra	NOUN
aji-132	195	11	)	)	PUNCT
aji-132	195	12	patients	patient	NOUN
aji-132	195	13	,	,	PUNCT
aji-132	195	14	iguratimod	iguratimod	PROPN
aji-132	195	15	markedly	markedly	ADV
aji-132	195	16	decreased	decrease	VERB
aji-132	195	17	the	the	DET
aji-132	195	18	synthesis	synthesis	NOUN
aji-132	195	19	of	of	ADP
aji-132	195	20	il-6	il-6	NOUN
aji-132	195	21	,	,	PUNCT
aji-132	195	22	il-8	il-8	NOUN
aji-132	195	23	,	,	PUNCT
aji-132	195	24	and	and	CCONJ
aji-132	195	25	colony	colony	NOUN
aji-132	195	26	-	-	PUNCT
aji-132	195	27	stimulating	stimulate	VERB
aji-132	195	28	factors	factor	NOUN
aji-132	195	29	(	(	PUNCT
aji-132	195	30	csfs	csfs	NOUN
aji-132	195	31	)	)	PUNCT
aji-132	195	32	within	within	ADP
aji-132	195	33	concentration	concentration	NOUN
aji-132	195	34	ranges	range	NOUN
aji-132	195	35	of	of	ADP
aji-132	195	36	0.3	0.3	NUM
aji-132	195	37	to	to	PART
aji-132	195	38	30	30	NUM
aji-132	195	39	µg	µg	NOUN
aji-132	195	40	/	/	SYM
aji-132	195	41	ml	ml	NOUN
aji-132	195	42	”	"	PUNCT
aji-132	196	1	[	[	X
aji-132	196	2	28,32,33	28,32,33	NUM
aji-132	196	3	]	]	X
aji-132	196	4	.	.	PUNCT
aji-132	197	1	“	"	PUNCT
aji-132	197	2	the	the	DET
aji-132	197	3	suppression	suppression	NOUN
aji-132	197	4	of	of	ADP
aji-132	197	5	mrna	mrna	PROPN
aji-132	197	6	expression	expression	NOUN
aji-132	197	7	coincided	coincide	VERB
aji-132	197	8	with	with	ADP
aji-132	197	9	iguratimod	iguratimod	PROPN
aji-132	197	10	's	's	PART
aji-132	197	11	inhibitory	inhibitory	ADJ
aji-132	197	12	effect	effect	NOUN
aji-132	197	13	on	on	ADP
aji-132	197	14	the	the	DET
aji-132	197	15	production	production	NOUN
aji-132	197	16	of	of	ADP
aji-132	197	17	these	these	DET
aji-132	197	18	cytokines”(29,31,33	cytokines”(29,31,33	PROPN
aji-132	197	19	)	)	PUNCT
aji-132	197	20	.	.	PUNCT
aji-132	198	1	therefore	therefore	ADV
aji-132	198	2	,	,	PUNCT
aji-132	198	3	it	it	PRON
aji-132	198	4	is	be	AUX
aji-132	198	5	reasonable	reasonable	ADJ
aji-132	198	6	to	to	PART
aji-132	198	7	suggest	suggest	VERB
aji-132	198	8	that	that	SCONJ
aji-132	198	9	iguratimod	iguratimod	PROPN
aji-132	198	10	suppresses	suppress	VERB
aji-132	198	11	the	the	DET
aji-132	198	12	expression	expression	NOUN
aji-132	198	13	of	of	ADP
aji-132	198	14	inflammatory	inflammatory	ADJ
aji-132	198	15	cytokines	cytokine	NOUN
aji-132	198	16	at	at	ADP
aji-132	198	17	the	the	DET
aji-132	198	18	gene	gene	NOUN
aji-132	198	19	level	level	NOUN
aji-132	198	20	.	.	PUNCT
aji-132	199	1	additionally	additionally	ADV
aji-132	199	2	,	,	PUNCT
aji-132	199	3	the	the	DET
aji-132	199	4	research	research	NOUN
aji-132	199	5	findings	finding	NOUN
aji-132	199	6	demonstrate	demonstrate	VERB
aji-132	199	7	[	[	X
aji-132	199	8	32	32	NUM
aji-132	199	9	]	]	PUNCT
aji-132	199	10	that	that	DET
aji-132	199	11	iguratimod	iguratimod	PROPN
aji-132	199	12	also	also	ADV
aji-132	199	13	impedes	impede	VERB
aji-132	199	14	the	the	DET
aji-132	199	15	increased	increase	VERB
aji-132	199	16	expression	expression	NOUN
aji-132	199	17	of	of	ADP
aji-132	199	18	co	co	ADJ
aji-132	199	19	-	-	ADJ
aji-132	199	20	stimulatory	stimulatory	ADJ
aji-132	199	21	molecules	molecule	NOUN
aji-132	199	22	like	like	ADP
aji-132	199	23	cd54	cd54	PROPN
aji-132	199	24	,	,	PUNCT
aji-132	199	25	cd58	cd58	PROPN
aji-132	199	26	,	,	PUNCT
aji-132	199	27	and	and	CCONJ
aji-132	199	28	cd106	cd106	X
aji-132	199	29	in	in	ADP
aji-132	199	30	synovial	synovial	ADJ
aji-132	199	31	cells	cell	NOUN
aji-132	199	32	upon	upon	SCONJ
aji-132	199	33	stimulation	stimulation	NOUN
aji-132	199	34	with	with	ADP
aji-132	199	35	ifn	ifn	PROPN
aji-132	199	36	-	-	PUNCT
aji-132	199	37	γ	γ	NOUN
aji-132	199	38	.	.	PUNCT
aji-132	200	1	“	"	PUNCT
aji-132	200	2	this	this	DET
aji-132	200	3	mechanism	mechanism	NOUN
aji-132	200	4	of	of	ADP
aji-132	200	5	action	action	NOUN
aji-132	200	6	seems	seem	VERB
aji-132	200	7	to	to	PART
aji-132	200	8	involve	involve	VERB
aji-132	200	9	the	the	DET
aji-132	200	10	prevention	prevention	NOUN
aji-132	200	11	of	of	ADP
aji-132	200	12	nuclear	nuclear	ADJ
aji-132	200	13	factor	factor	NOUN
aji-132	200	14	-	-	PUNCT
aji-132	200	15	kappa	kappa	PROPN
aji-132	200	16	b	b	PROPN
aji-132	200	17	(	(	PUNCT
aji-132	200	18	nf	nf	NOUN
aji-132	200	19	-	-	PUNCT
aji-132	200	20	κb	κb	NOUN
aji-132	200	21	)	)	PUNCT
aji-132	200	22	activation	activation	NOUN
aji-132	200	23	.	.	PUNCT
aji-132	201	1	the	the	DET
aji-132	201	2	inhibitory	inhibitory	ADJ
aji-132	201	3	effect	effect	NOUN
aji-132	201	4	on	on	ADP
aji-132	201	5	cytokine	cytokine	ADJ
aji-132	201	6	production	production	NOUN
aji-132	201	7	was	be	AUX
aji-132	201	8	similarly	similarly	ADV
aji-132	201	9	observed	observe	VERB
aji-132	201	10	in	in	ADP
aji-132	201	11	animal	animal	NOUN
aji-132	201	12	models	model	NOUN
aji-132	201	13	.	.	PUNCT
aji-132	202	1	in	in	ADP
aji-132	202	2	a	a	DET
aji-132	202	3	mouse	mouse	NOUN
aji-132	202	4	air	air	NOUN
aji-132	202	5	-	-	PUNCT
aji-132	202	6	pouch	pouch	NOUN
aji-132	202	7	inflammation	inflammation	NOUN
aji-132	202	8	model	model	NOUN
aji-132	202	9	,	,	PUNCT
aji-132	202	10	oral	oral	ADJ
aji-132	202	11	administration	administration	NOUN
aji-132	202	12	of	of	ADP
aji-132	202	13	iguratimod	iguratimod	PROPN
aji-132	202	14	at	at	ADP
aji-132	202	15	doses	dose	NOUN
aji-132	202	16	of	of	ADP
aji-132	202	17	30	30	NUM
aji-132	202	18	and	and	CCONJ
aji-132	202	19	100	100	NUM
aji-132	202	20	mg	mg	NUM
aji-132	202	21	/	/	SYM
aji-132	202	22	kg	kg	PROPN
aji-132	202	23	significantly	significantly	ADV
aji-132	202	24	decreased	decrease	VERB
aji-132	202	25	mcp-1	mcp-1	PRON
aji-132	202	26	production	production	NOUN
aji-132	202	27	induced	induce	VERB
aji-132	202	28	by	by	ADP
aji-132	202	29	tnfα	tnfα	NOUN
aji-132	202	30	injection	injection	NOUN
aji-132	202	31	”	"	PUNCT
aji-132	203	1	[	[	X
aji-132	203	2	29	29	NUM
aji-132	203	3	]	]	PUNCT
aji-132	203	4	.	.	PUNCT
aji-132	204	1	“	"	PUNCT
aji-132	204	2	moreover	moreover	ADV
aji-132	204	3	,	,	PUNCT
aji-132	204	4	at	at	ADP
aji-132	204	5	doses	dose	NOUN
aji-132	204	6	of	of	ADP
aji-132	204	7	10	10	NUM
aji-132	204	8	and	and	CCONJ
aji-132	204	9	30	30	NUM
aji-132	204	10	mg	mg	NUM
aji-132	204	11	/	/	SYM
aji-132	204	12	kg	kg	PROPN
aji-132	204	13	,	,	PUNCT
aji-132	204	14	iguratimod	iguratimod	PROPN
aji-132	204	15	reduced	reduce	VERB
aji-132	204	16	the	the	DET
aji-132	204	17	rise	rise	NOUN
aji-132	204	18	in	in	ADP
aji-132	204	19	serum	serum	NOUN
aji-132	204	20	tnfα	tnfα	NOUN
aji-132	204	21	and	and	CCONJ
aji-132	204	22	ifn	ifn	PROPN
aji-132	204	23	-	-	PUNCT
aji-132	204	24	γ	γ	NOUN
aji-132	204	25	levels	level	NOUN
aji-132	204	26	in	in	ADP
aji-132	204	27	the	the	DET
aji-132	204	28	concanavalin	concanavalin	NOUN
aji-132	204	29	a	a	PRON
aji-132	204	30	-	-	PUNCT
aji-132	204	31	induced	induce	VERB
aji-132	204	32	hepatitis	hepatitis	NOUN
aji-132	204	33	model	model	NOUN
aji-132	204	34	in	in	ADP
aji-132	204	35	mice	mouse	NOUN
aji-132	204	36	,	,	PUNCT
aji-132	204	37	along	along	ADP
aji-132	204	38	with	with	ADP
aji-132	204	39	serum	serum	NOUN
aji-132	204	40	transaminase	transaminase	NOUN
aji-132	204	41	levels	level	NOUN
aji-132	204	42	”	"	PUNCT
aji-132	205	1	[	[	X
aji-132	205	2	29	29	NUM
aji-132	205	3	]	]	PUNCT
aji-132	205	4	.	.	PUNCT
aji-132	206	1	“	"	PUNCT
aji-132	206	2	iguratimod	iguratimod	PROPN
aji-132	206	3	was	be	AUX
aji-132	206	4	also	also	ADV
aji-132	206	5	found	find	VERB
aji-132	206	6	to	to	PART
aji-132	206	7	suppress	suppress	VERB
aji-132	206	8	the	the	DET
aji-132	206	9	onset	onset	NOUN
aji-132	206	10	of	of	ADP
aji-132	206	11	active	active	ADJ
aji-132	206	12	experimental	experimental	ADJ
aji-132	206	13	autoimmune	autoimmune	ADJ
aji-132	206	14	encephalomyelitis	encephalomyelitis	NOUN
aji-132	206	15	(	(	PUNCT
aji-132	206	16	eae	eae	PROPN
aji-132	206	17	)	)	PUNCT
aji-132	206	18	in	in	ADP
aji-132	206	19	rats	rat	NOUN
aji-132	206	20	”	"	PUNCT
aji-132	207	1	[	[	X
aji-132	207	2	33	33	NUM
aji-132	207	3	]	]	PUNCT
aji-132	207	4	.	.	PUNCT
aji-132	208	1	“	"	PUNCT
aji-132	208	2	in	in	ADP
aji-132	208	3	this	this	DET
aji-132	208	4	model	model	NOUN
aji-132	208	5	,	,	PUNCT
aji-132	208	6	it	it	PRON
aji-132	208	7	was	be	AUX
aji-132	208	8	observed	observe	VERB
aji-132	208	9	to	to	PART
aji-132	208	10	inhibit	inhibit	VERB
aji-132	208	11	tnfα	tnfα	NOUN
aji-132	208	12	and	and	CCONJ
aji-132	208	13	ifn	ifn	PROPN
aji-132	208	14	-	-	PUNCT
aji-132	208	15	γ	γ	NOUN
aji-132	208	16	production	production	NOUN
aji-132	208	17	by	by	ADP
aji-132	208	18	antigen	antigen	NOUN
aji-132	208	19	-	-	PUNCT
aji-132	208	20	specific	specific	ADJ
aji-132	208	21	t	t	NOUN
aji-132	208	22	cells	cell	NOUN
aji-132	208	23	and	and	CCONJ
aji-132	208	24	the	the	DET
aji-132	208	25	infiltration	infiltration	NOUN
aji-132	208	26	of	of	ADP
aji-132	208	27	cells	cell	NOUN
aji-132	208	28	into	into	ADP
aji-132	208	29	the	the	DET
aji-132	208	30	spinal	spinal	ADJ
aji-132	208	31	cord	cord	NOUN
aji-132	208	32	of	of	ADP
aji-132	208	33	rats	rat	NOUN
aji-132	208	34	.	.	PUNCT
aji-132	209	1	notably	notably	ADV
aji-132	209	2	,	,	PUNCT
aji-132	209	3	iguratimod	iguratimod	PROPN
aji-132	209	4	exhibited	exhibit	VERB
aji-132	209	5	an	an	DET
aji-132	209	6	anti	anti	ADJ
aji-132	209	7	-	-	ADJ
aji-132	209	8	cachectic	cachectic	ADJ
aji-132	209	9	effect	effect	NOUN
aji-132	209	10	on	on	ADP
aji-132	209	11	adenocarcinoma	adenocarcinoma	ADJ
aji-132	209	12	colon	colon	NOUN
aji-132	209	13	-	-	PUNCT
aji-132	209	14	induced	induce	VERB
aji-132	209	15	cachexia	cachexia	NOUN
aji-132	209	16	in	in	ADP
aji-132	209	17	mice	mouse	NOUN
aji-132	209	18	by	by	ADP
aji-132	209	19	inhibiting	inhibit	VERB
aji-132	209	20	il-6	il-6	NOUN
aji-132	209	21	gene	gene	NOUN
aji-132	209	22	expression	expression	NOUN
aji-132	209	23	”	"	PUNCT
aji-132	210	1	[	[	X
aji-132	210	2	34	34	NUM
aji-132	210	3	]	]	PUNCT
aji-132	210	4	.	.	PUNCT
aji-132	211	1	“	"	PUNCT
aji-132	211	2	furthermore	furthermore	ADV
aji-132	211	3	,	,	PUNCT
aji-132	211	4	recent	recent	ADJ
aji-132	211	5	reports	report	NOUN
aji-132	211	6	indicate	indicate	VERB
aji-132	211	7	that	that	SCONJ
aji-132	211	8	cia	cia	PROPN
aji-132	211	9	rats	rat	NOUN
aji-132	211	10	treated	treat	VERB
aji-132	211	11	with	with	ADP
aji-132	211	12	iguratimod	iguratimod	NOUN
aji-132	211	13	showed	show	VERB
aji-132	211	14	reductions	reduction	NOUN
aji-132	211	15	in	in	ADP
aji-132	211	16	mrna	mrna	NOUN
aji-132	211	17	expression	expression	NOUN
aji-132	211	18	of	of	ADP
aji-132	211	19	il-17	il-17	X
aji-132	211	20	in	in	ADP
aji-132	211	21	peripheral	peripheral	ADJ
aji-132	211	22	lymphocytes	lymphocyte	NOUN
aji-132	211	23	and	and	CCONJ
aji-132	211	24	circulating	circulate	VERB
aji-132	211	25	il-17	il-17	ADV
aji-132	211	26	,	,	PUNCT
aji-132	211	27	suggesting	suggest	VERB
aji-132	211	28	that	that	SCONJ
aji-132	211	29	the	the	DET
aji-132	211	30	compound	compound	NOUN
aji-132	211	31	exerts	exert	VERB
aji-132	211	32	its	its	PRON
aji-132	211	33	immunoregulatory	immunoregulatory	ADJ
aji-132	211	34	and	and	CCONJ
aji-132	211	35	bone	bone	NOUN
aji-132	211	36	-	-	PUNCT
aji-132	211	37	preserving	preserve	VERB
aji-132	211	38	effects	effect	NOUN
aji-132	211	39	by	by	ADP
aji-132	211	40	shifting	shift	VERB
aji-132	211	41	responses	response	NOUN
aji-132	211	42	away	away	ADV
aji-132	211	43	from	from	ADP
aji-132	211	44	il-17	il-17	ADV
aji-132	211	45	-	-	PUNCT
aji-132	211	46	producing	produce	VERB
aji-132	211	47	t	t	NOUN
aji-132	211	48	cells	cell	NOUN
aji-132	211	49	(	(	PUNCT
aji-132	211	50	th17	th17	NOUN
aji-132	211	51	cells	cell	NOUN
aji-132	211	52	)	)	PUNCT
aji-132	211	53	”	"	PUNCT
aji-132	212	1	[	[	X
aji-132	212	2	35	35	NUM
aji-132	212	3	]	]	PUNCT
aji-132	212	4	.	.	PUNCT
aji-132	213	1	these	these	DET
aji-132	213	2	findings	finding	NOUN
aji-132	213	3	suggest	suggest	VERB
aji-132	213	4	that	that	SCONJ
aji-132	213	5	iguratimod	iguratimod	PROPN
aji-132	213	6	's	's	PART
aji-132	213	7	inhibition	inhibition	NOUN
aji-132	213	8	of	of	ADP
aji-132	213	9	cytokine	cytokine	ADJ
aji-132	213	10	production	production	NOUN
aji-132	213	11	may	may	AUX
aji-132	213	12	gupta	gupta	PROPN
aji-132	213	13	et	et	PROPN
aji-132	213	14	al	al	PROPN
aji-132	213	15	.	.	PROPN
aji-132	213	16	;	;	PUNCT
aji-132	214	1	asian	asian	PROPN
aji-132	214	2	j.	j.	PROPN
aji-132	214	3	immunol	immunol	PROPN
aji-132	214	4	.	.	PROPN
aji-132	214	5	,	,	PUNCT
aji-132	214	6	vol	vol	NOUN
aji-132	214	7	.	.	PROPN
aji-132	214	8	7	7	NUM
aji-132	214	9	,	,	PUNCT
aji-132	214	10	no	no	INTJ
aji-132	214	11	.	.	NOUN
aji-132	214	12	1	1	NUM
aji-132	214	13	,	,	PUNCT
aji-132	214	14	pp	pp	ADJ
aji-132	214	15	.	.	PUNCT
aji-132	215	1	79	79	NUM
aji-132	215	2	-	-	SYM
aji-132	215	3	89	89	NUM
aji-132	215	4	,	,	PUNCT
aji-132	215	5	2024	2024	NUM
aji-132	215	6	;	;	PUNCT
aji-132	215	7	article	article	NOUN
aji-132	215	8	no.aji.115805	no.aji.115805	VERB
aji-132	215	9	83	83	NUM
aji-132	215	10	contribute	contribute	VERB
aji-132	215	11	to	to	ADP
aji-132	215	12	its	its	PRON
aji-132	215	13	clinical	clinical	ADJ
aji-132	215	14	efficacy	efficacy	NOUN
aji-132	215	15	in	in	ADP
aji-132	215	16	treating	treat	VERB
aji-132	215	17	rheumatic	rheumatic	ADJ
aji-132	215	18	conditions	condition	NOUN
aji-132	215	19	,	,	PUNCT
aji-132	215	20	making	make	VERB
aji-132	215	21	it	it	PRON
aji-132	215	22	a	a	DET
aji-132	215	23	characteristic	characteristic	ADJ
aji-132	215	24	feature	feature	NOUN
aji-132	215	25	of	of	ADP
aji-132	215	26	this	this	DET
aji-132	215	27	drug	drug	NOUN
aji-132	215	28	.	.	PUNCT
aji-132	216	1	2.3	2.3	NUM
aji-132	216	2	osteoprotective	osteoprotective	ADJ
aji-132	216	3	mechanism	mechanism	NOUN
aji-132	216	4	“	"	PUNCT
aji-132	216	5	osteoporosis	osteoporosis	NOUN
aji-132	216	6	frequently	frequently	ADV
aji-132	216	7	arises	arise	VERB
aji-132	216	8	as	as	ADP
aji-132	216	9	a	a	DET
aji-132	216	10	secondary	secondary	ADJ
aji-132	216	11	consequence	consequence	NOUN
aji-132	216	12	of	of	ADP
aji-132	216	13	rheumatoid	rheumatoid	NOUN
aji-132	216	14	arthritis	arthritis	NOUN
aji-132	216	15	(	(	PUNCT
aji-132	216	16	ra	ra	NOUN
aji-132	216	17	)	)	PUNCT
aji-132	216	18	,	,	PUNCT
aji-132	216	19	potentially	potentially	ADV
aji-132	216	20	resulting	result	VERB
aji-132	216	21	in	in	ADP
aji-132	216	22	joint	joint	ADJ
aji-132	216	23	stiffness	stiffness	NOUN
aji-132	216	24	,	,	PUNCT
aji-132	216	25	malformation	malformation	NOUN
aji-132	216	26	,	,	PUNCT
aji-132	216	27	and	and	CCONJ
aji-132	216	28	significant	significant	ADJ
aji-132	216	29	impairment	impairment	NOUN
aji-132	216	30	in	in	ADP
aji-132	216	31	functionality	functionality	NOUN
aji-132	216	32	.	.	PUNCT
aji-132	217	1	employing	employ	VERB
aji-132	217	2	early	early	ADJ
aji-132	217	3	and	and	CCONJ
aji-132	217	4	efficient	efficient	ADJ
aji-132	217	5	measures	measure	NOUN
aji-132	217	6	to	to	PART
aji-132	217	7	safeguard	safeguard	VERB
aji-132	217	8	bone	bone	NOUN
aji-132	217	9	health	health	NOUN
aji-132	217	10	and	and	CCONJ
aji-132	217	11	enhance	enhance	VERB
aji-132	217	12	bone	bone	NOUN
aji-132	217	13	metabolism	metabolism	NOUN
aji-132	217	14	can	can	AUX
aji-132	217	15	be	be	AUX
aji-132	217	16	advantageous	advantageous	ADJ
aji-132	217	17	in	in	ADP
aji-132	217	18	thwarting	thwart	VERB
aji-132	217	19	joint	joint	ADJ
aji-132	217	20	deterioration.several	deterioration.several	ADJ
aji-132	217	21	signaling	signal	VERB
aji-132	217	22	pathways	pathway	NOUN
aji-132	217	23	are	be	AUX
aji-132	217	24	crucial	crucial	ADJ
aji-132	217	25	for	for	ADP
aji-132	217	26	osteoblast	osteoblast	ADJ
aji-132	217	27	proliferation	proliferation	NOUN
aji-132	217	28	,	,	PUNCT
aji-132	217	29	differentiation	differentiation	NOUN
aji-132	217	30	,	,	PUNCT
aji-132	217	31	and	and	CCONJ
aji-132	217	32	the	the	DET
aji-132	217	33	regeneration	regeneration	NOUN
aji-132	217	34	of	of	ADP
aji-132	217	35	damaged	damage	VERB
aji-132	217	36	bone	bone	NOUN
aji-132	217	37	and	and	CCONJ
aji-132	217	38	cartilage	cartilage	NOUN
aji-132	217	39	.	.	PUNCT
aji-132	218	1	these	these	PRON
aji-132	218	2	include	include	VERB
aji-132	218	3	the	the	DET
aji-132	218	4	bone	bone	NOUN
aji-132	218	5	morphogenetic	morphogenetic	ADJ
aji-132	218	6	protein	protein	NOUN
aji-132	218	7	(	(	PUNCT
aji-132	218	8	bmp)2	bmp)2	PROPN
aji-132	218	9	–	–	PUNCT
aji-132	218	10	smads	smad	NOUN
aji-132	218	11	pathway	pathway	NOUN
aji-132	218	12	,	,	PUNCT
aji-132	218	13	the	the	DET
aji-132	218	14	p38	p38	NOUN
aji-132	218	15	mitogen	mitogen	NOUN
aji-132	218	16	-	-	PUNCT
aji-132	218	17	activated	activate	VERB
aji-132	218	18	protein	protein	NOUN
aji-132	218	19	kinase	kinase	NOUN
aji-132	218	20	(	(	PUNCT
aji-132	218	21	mapk	mapk	NOUN
aji-132	218	22	)	)	PUNCT
aji-132	218	23	pathway	pathway	NOUN
aji-132	218	24	,	,	PUNCT
aji-132	218	25	and	and	CCONJ
aji-132	218	26	the	the	DET
aji-132	218	27	tnf	tnf	PROPN
aji-132	218	28	-	-	PUNCT
aji-132	218	29	α	α	PROPN
aji-132	218	30	/	/	SYM
aji-132	218	31	nf	nf	NOUN
aji-132	218	32	-	-	PUNCT
aji-132	218	33	κb	κb	NOUN
aji-132	218	34	pathway.research	pathway.research	PROPN
aji-132	218	35	has	have	AUX
aji-132	218	36	demonstrated	demonstrate	VERB
aji-132	218	37	that	that	SCONJ
aji-132	218	38	igu	igu	PROPN
aji-132	218	39	enhances	enhance	VERB
aji-132	218	40	the	the	DET
aji-132	218	41	expression	expression	NOUN
aji-132	218	42	of	of	ADP
aji-132	218	43	osterix	osterix	NOUN
aji-132	218	44	(	(	PUNCT
aji-132	218	45	osx	osx	PROPN
aji-132	218	46	)	)	PUNCT
aji-132	218	47	,	,	PUNCT
aji-132	218	48	a	a	DET
aji-132	218	49	key	key	ADJ
aji-132	218	50	factor	factor	NOUN
aji-132	218	51	in	in	ADP
aji-132	218	52	osteoblast	osteoblast	ADJ
aji-132	218	53	differentiation	differentiation	NOUN
aji-132	218	54	.	.	PUNCT
aji-132	219	1	bmp2	bmp2	PROPN
aji-132	219	2	has	have	VERB
aji-132	219	3	the	the	DET
aji-132	219	4	ability	ability	NOUN
aji-132	219	5	to	to	PART
aji-132	219	6	stimulate	stimulate	VERB
aji-132	219	7	osx	osx	NOUN
aji-132	219	8	expression	expression	NOUN
aji-132	219	9	by	by	ADP
aji-132	219	10	inducing	induce	VERB
aji-132	219	11	the	the	DET
aji-132	219	12	upstream	upstream	ADJ
aji-132	219	13	transcription	transcription	NOUN
aji-132	219	14	factor	factor	NOUN
aji-132	219	15	dlx5	dlx5	PROPN
aji-132	219	16	.	.	PUNCT
aji-132	220	1	additionally	additionally	ADV
aji-132	220	2	,	,	PUNCT
aji-132	220	3	the	the	DET
aji-132	220	4	p38	p38	NOUN
aji-132	220	5	–	–	PUNCT
aji-132	220	6	mapk	mapk	NOUN
aji-132	220	7	pathway	pathway	NOUN
aji-132	220	8	collaborates	collaborate	NOUN
aji-132	220	9	with	with	ADP
aji-132	220	10	the	the	DET
aji-132	220	11	bmp2	bmp2	ADJ
aji-132	220	12	–	–	PUNCT
aji-132	220	13	smads	smad	NOUN
aji-132	220	14	pathway	pathway	NOUN
aji-132	220	15	to	to	PART
aji-132	220	16	enhance	enhance	VERB
aji-132	220	17	osx	osx	PROPN
aji-132	220	18	phosphorylation	phosphorylation	NOUN
aji-132	220	19	”	"	PUNCT
aji-132	221	1	[	[	X
aji-132	221	2	36	36	NUM
aji-132	221	3	]	]	PUNCT
aji-132	221	4	.	.	PUNCT
aji-132	222	1	“	"	PUNCT
aji-132	222	2	igu	igu	PROPN
aji-132	222	3	has	have	AUX
aji-132	222	4	been	be	AUX
aji-132	222	5	found	find	VERB
aji-132	222	6	to	to	PART
aji-132	222	7	boost	boost	VERB
aji-132	222	8	osteoblast	osteoblast	ADJ
aji-132	222	9	differentiation	differentiation	NOUN
aji-132	222	10	by	by	ADP
aji-132	222	11	upregulating	upregulate	VERB
aji-132	222	12	the	the	DET
aji-132	222	13	expression	expression	NOUN
aji-132	222	14	of	of	ADP
aji-132	222	15	osx	osx	PROPN
aji-132	222	16	and	and	CCONJ
aji-132	222	17	dlx5	dlx5	PROPN
aji-132	222	18	”	"	PUNCT
aji-132	223	1	[	[	X
aji-132	223	2	37	37	NUM
aji-132	223	3	]	]	PUNCT
aji-132	223	4	.	.	PUNCT
aji-132	224	1	“	"	PUNCT
aji-132	224	2	the	the	DET
aji-132	224	3	p38	p38	NOUN
aji-132	224	4	mapk	mapk	NOUN
aji-132	224	5	belongs	belong	VERB
aji-132	224	6	to	to	ADP
aji-132	224	7	the	the	DET
aji-132	224	8	mapk	mapk	NOUN
aji-132	224	9	superfamily	superfamily	ADV
aji-132	224	10	and	and	CCONJ
aji-132	224	11	plays	play	VERB
aji-132	224	12	a	a	DET
aji-132	224	13	role	role	NOUN
aji-132	224	14	in	in	ADP
aji-132	224	15	the	the	DET
aji-132	224	16	initial	initial	ADJ
aji-132	224	17	phases	phase	NOUN
aji-132	224	18	of	of	ADP
aji-132	224	19	osteoblast	osteoblast	ADJ
aji-132	224	20	lineage	lineage	NOUN
aji-132	224	21	proliferation	proliferation	NOUN
aji-132	224	22	by	by	ADP
aji-132	224	23	phosphorylating	phosphorylate	VERB
aji-132	224	24	dlx5	dlx5	PROPN
aji-132	224	25	,	,	PUNCT
aji-132	224	26	runt	runt	NOUN
aji-132	224	27	-	-	PUNCT
aji-132	224	28	related	relate	VERB
aji-132	224	29	transcription	transcription	NOUN
aji-132	224	30	factor	factor	NOUN
aji-132	224	31	(	(	PUNCT
aji-132	224	32	runx)2	runx)2	NOUN
aji-132	224	33	,	,	PUNCT
aji-132	224	34	and	and	CCONJ
aji-132	224	35	osx	osx	PROPN
aji-132	224	36	(	(	PUNCT
aji-132	224	37	36	36	NUM
aji-132	224	38	)	)	PUNCT
aji-132	224	39	.	.	PUNCT
aji-132	225	1	igu	igu	PROPN
aji-132	225	2	has	have	VERB
aji-132	225	3	the	the	DET
aji-132	225	4	potential	potential	NOUN
aji-132	225	5	to	to	PART
aji-132	225	6	enhance	enhance	VERB
aji-132	225	7	the	the	DET
aji-132	225	8	activation	activation	NOUN
aji-132	225	9	of	of	ADP
aji-132	225	10	p38	p38	NOUN
aji-132	225	11	,	,	PUNCT
aji-132	225	12	thereby	thereby	ADV
aji-132	225	13	promoting	promote	VERB
aji-132	225	14	osteoblastic	osteoblastic	ADJ
aji-132	225	15	differentiation	differentiation	NOUN
aji-132	225	16	.	.	PUNCT
aji-132	226	1	additionally	additionally	ADV
aji-132	226	2	,	,	PUNCT
aji-132	226	3	the	the	DET
aji-132	226	4	tnf	tnf	PROPN
aji-132	226	5	-	-	PUNCT
aji-132	226	6	α	α	PROPN
aji-132	226	7	/	/	SYM
aji-132	226	8	nf	nf	NOUN
aji-132	226	9	-	-	PUNCT
aji-132	226	10	κb	κb	NOUN
aji-132	226	11	signaling	signal	VERB
aji-132	226	12	pathway	pathway	NOUN
aji-132	226	13	is	be	AUX
aji-132	226	14	implicated	implicate	VERB
aji-132	226	15	in	in	ADP
aji-132	226	16	osteoblast	osteoblast	ADJ
aji-132	226	17	proliferation	proliferation	NOUN
aji-132	226	18	,	,	PUNCT
aji-132	226	19	apoptosis	apoptosis	NOUN
aji-132	226	20	,	,	PUNCT
aji-132	226	21	and	and	CCONJ
aji-132	226	22	differentiation	differentiation	NOUN
aji-132	226	23	”	"	PUNCT
aji-132	227	1	[	[	X
aji-132	227	2	38	38	NUM
aji-132	227	3	]	]	PUNCT
aji-132	227	4	.	.	PUNCT
aji-132	228	1	nf	nf	X
aji-132	228	2	-	-	PUNCT
aji-132	228	3	κb	κb	PROPN
aji-132	228	4	facilitates	facilitate	VERB
aji-132	228	5	the	the	DET
aji-132	228	6	deterioration	deterioration	NOUN
aji-132	228	7	of	of	ADP
aji-132	228	8	osteocytes	osteocyte	NOUN
aji-132	228	9	by	by	ADP
aji-132	228	10	diminishing	diminish	VERB
aji-132	228	11	the	the	DET
aji-132	228	12	expression	expression	NOUN
aji-132	228	13	and	and	CCONJ
aji-132	228	14	phosphorylation	phosphorylation	NOUN
aji-132	228	15	of	of	ADP
aji-132	228	16	the	the	DET
aji-132	228	17	bmp	bmp	NOUN
aji-132	228	18	-	-	PUNCT
aji-132	228	19	smad1	smad1	ADJ
aji-132	228	20	signaling	signal	VERB
aji-132	228	21	pathway	pathway	NOUN
aji-132	228	22	.	.	PUNCT
aji-132	229	1	igu	igu	PROPN
aji-132	229	2	has	have	VERB
aji-132	229	3	the	the	DET
aji-132	229	4	capacity	capacity	NOUN
aji-132	229	5	to	to	PART
aji-132	229	6	sustain	sustain	VERB
aji-132	229	7	decreased	decrease	VERB
aji-132	229	8	nf	nf	ADJ
aji-132	229	9	-	-	PUNCT
aji-132	229	10	κb	κb	NOUN
aji-132	229	11	activation	activation	NOUN
aji-132	229	12	,	,	PUNCT
aji-132	229	13	thus	thus	ADV
aji-132	229	14	mitigating	mitigate	VERB
aji-132	229	15	the	the	DET
aji-132	229	16	inhibitory	inhibitory	ADJ
aji-132	229	17	effects	effect	NOUN
aji-132	229	18	of	of	ADP
aji-132	229	19	tnf	tnf	PROPN
aji-132	229	20	-	-	PUNCT
aji-132	229	21	α	α	PROPN
aji-132	229	22	on	on	ADP
aji-132	229	23	osteoblasts	osteoblast	NOUN
aji-132	229	24	.	.	PUNCT
aji-132	230	1	fig	fig	NOUN
aji-132	230	2	.	.	PUNCT
aji-132	231	1	2	2	NUM
aji-132	231	2	.	.	NOUN
aji-132	231	3	illustrates	illustrate	VERB
aji-132	231	4	the	the	DET
aji-132	231	5	inhibitory	inhibitory	ADJ
aji-132	231	6	effects	effect	NOUN
aji-132	231	7	of	of	ADP
aji-132	231	8	igu	igu	NOUN
aji-132	231	9	on	on	ADP
aji-132	231	10	the	the	DET
aji-132	231	11	immune	immune	ADJ
aji-132	231	12	response	response	NOUN
aji-132	231	13	,	,	PUNCT
aji-132	231	14	particularly	particularly	ADV
aji-132	231	15	in	in	ADP
aji-132	231	16	the	the	DET
aji-132	231	17	context	context	NOUN
aji-132	231	18	of	of	ADP
aji-132	231	19	rheumatoid	rheumatoid	NOUN
aji-132	231	20	arthritis	arthritis	NOUN
aji-132	231	21	(	(	PUNCT
aji-132	231	22	ra	ra	NOUN
aji-132	231	23	)	)	PUNCT
aji-132	231	24	in	in	ADP
aji-132	231	25	ra	ra	PROPN
aji-132	231	26	,	,	PUNCT
aji-132	231	27	the	the	DET
aji-132	231	28	initial	initial	ADJ
aji-132	231	29	interaction	interaction	NOUN
aji-132	231	30	between	between	ADP
aji-132	231	31	th1	th1	NOUN
aji-132	231	32	cells	cell	NOUN
aji-132	231	33	and	and	CCONJ
aji-132	231	34	antigen	antigen	NOUN
aji-132	231	35	-	-	PUNCT
aji-132	231	36	presenting	present	VERB
aji-132	231	37	cells	cell	NOUN
aji-132	231	38	(	(	PUNCT
aji-132	231	39	apcs	apc	NOUN
aji-132	231	40	)	)	PUNCT
aji-132	231	41	,	,	PUNCT
aji-132	231	42	such	such	ADJ
aji-132	231	43	as	as	ADP
aji-132	231	44	dendritic	dendritic	ADJ
aji-132	231	45	cells	cell	NOUN
aji-132	231	46	,	,	PUNCT
aji-132	231	47	involves	involve	VERB
aji-132	231	48	t	t	NOUN
aji-132	231	49	-	-	PUNCT
aji-132	231	50	cell	cell	NOUN
aji-132	231	51	receptors	receptor	NOUN
aji-132	231	52	(	(	PUNCT
aji-132	231	53	tcrs	tcrs	NOUN
aji-132	231	54	)	)	PUNCT
aji-132	231	55	and	and	CCONJ
aji-132	231	56	major	major	ADJ
aji-132	231	57	histocompatibility	histocompatibility	NOUN
aji-132	231	58	complex	complex	NOUN
aji-132	231	59	(	(	PUNCT
aji-132	231	60	mhc	mhc	PROPN
aji-132	231	61	)	)	PUNCT
aji-132	231	62	.	.	PUNCT
aji-132	232	1	various	various	ADJ
aji-132	232	2	environmental	environmental	ADJ
aji-132	232	3	factors	factor	NOUN
aji-132	232	4	influence	influence	VERB
aji-132	232	5	the	the	DET
aji-132	232	6	production	production	NOUN
aji-132	232	7	of	of	ADP
aji-132	232	8	autoantibodies	autoantibody	NOUN
aji-132	232	9	like	like	ADP
aji-132	232	10	anti	anti	ADJ
aji-132	232	11	-	-	ADJ
aji-132	232	12	citrullinated	citrullinated	ADJ
aji-132	232	13	protein	protein	NOUN
aji-132	232	14	antibodies	antibody	NOUN
aji-132	232	15	(	(	PUNCT
aji-132	232	16	acpa	acpa	NOUN
aji-132	232	17	)	)	PUNCT
aji-132	232	18	and	and	CCONJ
aji-132	232	19	rheumatoid	rheumatoid	NOUN
aji-132	232	20	factor	factor	NOUN
aji-132	232	21	(	(	PUNCT
aji-132	232	22	rf	rf	NOUN
aji-132	232	23	)	)	PUNCT
aji-132	232	24	.	.	PUNCT
aji-132	233	1	these	these	DET
aji-132	233	2	immune	immune	ADJ
aji-132	233	3	complexes	complex	NOUN
aji-132	233	4	activate	activate	VERB
aji-132	233	5	synovial	synovial	ADJ
aji-132	233	6	fibroblasts	fibroblast	NOUN
aji-132	233	7	(	(	PUNCT
aji-132	233	8	sfs	sfs	ADJ
aji-132	233	9	)	)	PUNCT
aji-132	233	10	and	and	CCONJ
aji-132	233	11	macrophages	macrophage	NOUN
aji-132	233	12	,	,	PUNCT
aji-132	233	13	leading	lead	VERB
aji-132	233	14	to	to	ADP
aji-132	233	15	the	the	DET
aji-132	233	16	production	production	NOUN
aji-132	233	17	of	of	ADP
aji-132	233	18	pro	pro	ADJ
aji-132	233	19	-	-	ADJ
aji-132	233	20	inflammatory	inflammatory	ADJ
aji-132	233	21	cytokines	cytokine	NOUN
aji-132	233	22	such	such	ADJ
aji-132	233	23	as	as	ADP
aji-132	233	24	tumor	tumor	NOUN
aji-132	233	25	necrosis	necrosis	NOUN
aji-132	233	26	factor	factor	NOUN
aji-132	233	27	-	-	PUNCT
aji-132	233	28	alpha	alpha	NOUN
aji-132	233	29	(	(	PUNCT
aji-132	233	30	tnf	tnf	PROPN
aji-132	233	31	-	-	PUNCT
aji-132	233	32	α	α	NOUN
aji-132	233	33	)	)	PUNCT
aji-132	233	34	and	and	CCONJ
aji-132	233	35	il-6	il-6	PRON
aji-132	233	36	.	.	PUNCT
aji-132	234	1	additionally	additionally	ADV
aji-132	234	2	,	,	PUNCT
aji-132	234	3	they	they	PRON
aji-132	234	4	affect	affect	VERB
aji-132	234	5	th17	th17	NOUN
aji-132	234	6	cells	cell	NOUN
aji-132	234	7	,	,	PUNCT
aji-132	234	8	which	which	PRON
aji-132	234	9	produce	produce	VERB
aji-132	234	10	il-17	il-17	ADV
aji-132	234	11	,	,	PUNCT
aji-132	234	12	further	far	ADV
aji-132	234	13	contributing	contribute	VERB
aji-132	234	14	to	to	ADP
aji-132	234	15	joint	joint	ADJ
aji-132	234	16	destruction	destruction	NOUN
aji-132	234	17	.	.	PUNCT
aji-132	235	1	igu	igu	PROPN
aji-132	235	2	intervenes	intervene	VERB
aji-132	235	3	in	in	ADP
aji-132	235	4	this	this	DET
aji-132	235	5	process	process	NOUN
aji-132	235	6	by	by	ADP
aji-132	235	7	impacting	impact	VERB
aji-132	235	8	the	the	DET
aji-132	235	9	production	production	NOUN
aji-132	235	10	of	of	ADP
aji-132	235	11	pro	pro	ADJ
aji-132	235	12	-	-	ADJ
aji-132	235	13	inflammatory	inflammatory	ADJ
aji-132	235	14	cytokines	cytokine	NOUN
aji-132	235	15	in	in	ADP
aji-132	235	16	both	both	CCONJ
aji-132	235	17	th1	th1	PROPN
aji-132	235	18	and	and	CCONJ
aji-132	235	19	th17	th17	PROPN
aji-132	235	20	cells	cell	NOUN
aji-132	235	21	,	,	PUNCT
aji-132	235	22	as	as	ADV
aji-132	235	23	well	well	ADV
aji-132	235	24	as	as	ADP
aji-132	235	25	affecting	affect	VERB
aji-132	235	26	the	the	DET
aji-132	235	27	production	production	NOUN
aji-132	235	28	of	of	ADP
aji-132	235	29	immunoglobulins	immunoglobulin	NOUN
aji-132	235	30	and	and	CCONJ
aji-132	235	31	antibodies	antibodie	VERB
aji-132	235	32	in	in	ADP
aji-132	235	33	b	b	NOUN
aji-132	235	34	cells	cell	NOUN
aji-132	235	35	.	.	PUNCT
aji-132	236	1	it	it	PRON
aji-132	236	2	also	also	ADV
aji-132	236	3	influences	influence	VERB
aji-132	236	4	bone	bone	NOUN
aji-132	236	5	metabolism	metabolism	NOUN
aji-132	236	6	by	by	ADP
aji-132	236	7	inhibiting	inhibit	VERB
aji-132	236	8	osteoclast	osteoclast	ADJ
aji-132	236	9	activation	activation	NOUN
aji-132	236	10	and	and	CCONJ
aji-132	236	11	promoting	promote	VERB
aji-132	236	12	osteoblast	osteoblast	ADJ
aji-132	236	13	differentiation	differentiation	NOUN
aji-132	236	14	.	.	PUNCT
aji-132	237	1	nf	nf	X
aji-132	237	2	-	-	PUNCT
aji-132	237	3	κb	κb	NOUN
aji-132	237	4	,	,	PUNCT
aji-132	237	5	a	a	DET
aji-132	237	6	central	central	ADJ
aji-132	237	7	player	player	NOUN
aji-132	237	8	in	in	ADP
aji-132	237	9	the	the	DET
aji-132	237	10	pathogenesis	pathogenesis	NOUN
aji-132	237	11	of	of	ADP
aji-132	237	12	ra	ra	PROPN
aji-132	237	13	,	,	PUNCT
aji-132	237	14	perpetuates	perpetuate	VERB
aji-132	237	15	the	the	DET
aji-132	237	16	chronic	chronic	ADJ
aji-132	237	17	cycle	cycle	NOUN
aji-132	237	18	of	of	ADP
aji-132	237	19	inflammation	inflammation	NOUN
aji-132	237	20	underlying	underlie	VERB
aji-132	237	21	its	its	PRON
aji-132	237	22	pathology	pathology	NOUN
aji-132	237	23	.	.	PUNCT
aji-132	238	1	inflammatory	inflammatory	ADJ
aji-132	238	2	mediators	mediator	NOUN
aji-132	238	3	like	like	ADP
aji-132	238	4	tnf	tnf	PROPN
aji-132	238	5	-	-	PUNCT
aji-132	238	6	α	α	NOUN
aji-132	238	7	activate	activate	VERB
aji-132	238	8	cells	cell	NOUN
aji-132	238	9	in	in	ADP
aji-132	238	10	the	the	DET
aji-132	238	11	synovium	synovium	NOUN
aji-132	238	12	,	,	PUNCT
aji-132	238	13	particularly	particularly	ADV
aji-132	238	14	macrophages	macrophage	NOUN
aji-132	238	15	and	and	CCONJ
aji-132	238	16	sfs	sfs	ADJ
aji-132	238	17	,	,	PUNCT
aji-132	238	18	largely	largely	ADV
aji-132	238	19	through	through	ADP
aji-132	238	20	nf	nf	ADJ
aji-132	238	21	-	-	PUNCT
aji-132	238	22	κb	κb	NOUN
aji-132	238	23	activation	activation	NOUN
aji-132	238	24	.	.	PUNCT
aji-132	239	1	sfs	sfs	PROPN
aji-132	239	2	,	,	PUNCT
aji-132	239	3	in	in	ADP
aji-132	239	4	response	response	NOUN
aji-132	239	5	to	to	ADP
aji-132	239	6	tnf	tnf	PROPN
aji-132	239	7	-	-	PUNCT
aji-132	239	8	α	α	PROPN
aji-132	239	9	or	or	CCONJ
aji-132	239	10	il-1	il-1	NUM
aji-132	239	11	,	,	PUNCT
aji-132	239	12	synthesize	synthesize	VERB
aji-132	239	13	many	many	ADJ
aji-132	239	14	nf	nf	NUM
aji-132	239	15	-	-	PUNCT
aji-132	239	16	κb	κb	NOUN
aji-132	239	17	-	-	PUNCT
aji-132	239	18	induced	induce	VERB
aji-132	239	19	genes	gene	NOUN
aji-132	239	20	,	,	PUNCT
aji-132	239	21	including	include	VERB
aji-132	239	22	chemokines	chemokine	NOUN
aji-132	239	23	and	and	CCONJ
aji-132	239	24	matrix	matrix	NOUN
aji-132	239	25	metalloproteinases	metalloproteinase	NOUN
aji-132	239	26	(	(	PUNCT
aji-132	239	27	mmps	mmp	NOUN
aji-132	239	28	)	)	PUNCT
aji-132	239	29	,	,	PUNCT
aji-132	239	30	which	which	PRON
aji-132	239	31	further	far	ADV
aji-132	239	32	promote	promote	VERB
aji-132	239	33	inflammation	inflammation	NOUN
aji-132	239	34	and	and	CCONJ
aji-132	239	35	joint	joint	ADJ
aji-132	239	36	destruction	destruction	NOUN
aji-132	239	37	gupta	gupta	PROPN
aji-132	239	38	et	et	PROPN
aji-132	239	39	al	al	PROPN
aji-132	239	40	.	.	PROPN
aji-132	239	41	;	;	PUNCT
aji-132	239	42	asian	asian	PROPN
aji-132	239	43	j.	j.	PROPN
aji-132	239	44	immunol	immunol	PROPN
aji-132	239	45	.	.	PROPN
aji-132	239	46	,	,	PUNCT
aji-132	239	47	vol	vol	NOUN
aji-132	239	48	.	.	PROPN
aji-132	240	1	7	7	NUM
aji-132	240	2	,	,	PUNCT
aji-132	240	3	no	no	INTJ
aji-132	240	4	.	.	NOUN
aji-132	240	5	1	1	NUM
aji-132	240	6	,	,	PUNCT
aji-132	240	7	pp	pp	ADJ
aji-132	240	8	.	.	PUNCT
aji-132	241	1	79	79	NUM
aji-132	241	2	-	-	SYM
aji-132	241	3	89	89	NUM
aji-132	241	4	,	,	PUNCT
aji-132	241	5	2024	2024	NUM
aji-132	241	6	;	;	PUNCT
aji-132	241	7	article	article	NOUN
aji-132	241	8	no.aji.115805	no.aji.115805	VERB
aji-132	241	9	84	84	NUM
aji-132	241	10	“	"	PUNCT
aji-132	241	11	additionally	additionally	ADV
aji-132	241	12	,	,	PUNCT
aji-132	241	13	igu	igu	PROPN
aji-132	241	14	fosters	foster	VERB
aji-132	241	15	the	the	DET
aji-132	241	16	formation	formation	NOUN
aji-132	241	17	of	of	ADP
aji-132	241	18	calcium	calcium	NOUN
aji-132	241	19	nodules	nodule	NOUN
aji-132	241	20	in	in	ADP
aji-132	241	21	vitro	vitro	X
aji-132	241	22	”	"	PUNCT
aji-132	242	1	[	[	X
aji-132	242	2	37	37	NUM
aji-132	242	3	]	]	PUNCT
aji-132	242	4	.	.	PUNCT
aji-132	243	1	“	"	PUNCT
aji-132	243	2	osteoclast	osteoclast	ADJ
aji-132	243	3	differentiation	differentiation	NOUN
aji-132	243	4	is	be	AUX
aji-132	243	5	primarily	primarily	ADV
aji-132	243	6	regulated	regulate	VERB
aji-132	243	7	by	by	ADP
aji-132	243	8	two	two	NUM
aji-132	243	9	essential	essential	ADJ
aji-132	243	10	cytokines	cytokine	NOUN
aji-132	243	11	:	:	PUNCT
aji-132	243	12	macrophage	macrophage	ADJ
aji-132	243	13	colonystimulating	colonystimulate	VERB
aji-132	243	14	factor	factor	NOUN
aji-132	243	15	(	(	PUNCT
aji-132	243	16	m	m	NOUN
aji-132	243	17	-	-	PUNCT
aji-132	243	18	csf	csf	ADJ
aji-132	243	19	)	)	PUNCT
aji-132	243	20	and	and	CCONJ
aji-132	243	21	receptor	receptor	NOUN
aji-132	243	22	activator	activator	NOUN
aji-132	243	23	of	of	ADP
aji-132	243	24	nuclear	nuclear	ADJ
aji-132	243	25	factor	factor	NOUN
aji-132	243	26	kappa	kappa	PROPN
aji-132	243	27	-	-	PROPN
aji-132	243	28	b	b	ADJ
aji-132	243	29	ligand	ligand	NOUN
aji-132	243	30	(	(	PUNCT
aji-132	243	31	rankl	rankl	PROPN
aji-132	243	32	)	)	PUNCT
aji-132	243	33	”	"	PUNCT
aji-132	244	1	[	[	X
aji-132	244	2	39	39	NUM
aji-132	244	3	]	]	PUNCT
aji-132	244	4	.	.	PUNCT
aji-132	245	1	“	"	PUNCT
aji-132	245	2	the	the	DET
aji-132	245	3	rankl	rankl	PROPN
aji-132	245	4	/	/	SYM
aji-132	245	5	osteoprotegerin	osteoprotegerin	NOUN
aji-132	245	6	(	(	PUNCT
aji-132	245	7	opg	opg	NOUN
aji-132	245	8	)	)	PUNCT
aji-132	245	9	system	system	NOUN
aji-132	245	10	is	be	AUX
aji-132	245	11	crucial	crucial	ADJ
aji-132	245	12	in	in	ADP
aji-132	245	13	bone	bone	NOUN
aji-132	245	14	erosion	erosion	NOUN
aji-132	245	15	associated	associate	VERB
aji-132	245	16	with	with	ADP
aji-132	245	17	rheumatoid	rheumatoid	NOUN
aji-132	245	18	arthritis	arthritis	NOUN
aji-132	245	19	(	(	PUNCT
aji-132	245	20	ra	ra	NOUN
aji-132	245	21	)	)	PUNCT
aji-132	245	22	.	.	PUNCT
aji-132	246	1	an	an	DET
aji-132	246	2	increase	increase	NOUN
aji-132	246	3	in	in	ADP
aji-132	246	4	the	the	DET
aji-132	246	5	rankl	rankl	PROPN
aji-132	246	6	/	/	SYM
aji-132	246	7	opg	opg	PROPN
aji-132	246	8	ratio	ratio	NOUN
aji-132	246	9	contributes	contribute	VERB
aji-132	246	10	to	to	ADP
aji-132	246	11	bone	bone	NOUN
aji-132	246	12	erosion	erosion	NOUN
aji-132	246	13	.	.	PUNCT
aji-132	247	1	igu	igu	PROPN
aji-132	247	2	has	have	VERB
aji-132	247	3	the	the	DET
aji-132	247	4	ability	ability	NOUN
aji-132	247	5	to	to	PART
aji-132	247	6	reduce	reduce	VERB
aji-132	247	7	the	the	DET
aji-132	247	8	production	production	NOUN
aji-132	247	9	of	of	ADP
aji-132	247	10	rankl	rankl	NOUN
aji-132	247	11	,	,	PUNCT
aji-132	247	12	leading	lead	VERB
aji-132	247	13	to	to	ADP
aji-132	247	14	a	a	DET
aji-132	247	15	significant	significant	ADJ
aji-132	247	16	decrease	decrease	NOUN
aji-132	247	17	in	in	ADP
aji-132	247	18	the	the	DET
aji-132	247	19	rankl	rankl	PROPN
aji-132	247	20	/	/	SYM
aji-132	247	21	opg	opg	PROPN
aji-132	247	22	ratio	ratio	NOUN
aji-132	247	23	both	both	CCONJ
aji-132	247	24	in	in	ADP
aji-132	247	25	serum	serum	NOUN
aji-132	247	26	and	and	CCONJ
aji-132	247	27	in	in	ADP
aji-132	247	28	ra	ra	PROPN
aji-132	247	29	fibroblast	fibroblast	ADJ
aji-132	247	30	-	-	PUNCT
aji-132	247	31	like	like	ADJ
aji-132	247	32	synoviocytes	synoviocyte	NOUN
aji-132	247	33	(	(	PUNCT
aji-132	247	34	flss	flss	ADV
aji-132	247	35	)	)	PUNCT
aji-132	247	36	induced	induce	VERB
aji-132	247	37	by	by	ADP
aji-132	247	38	il1β	il1β	PROPN
aji-132	247	39	after	after	ADP
aji-132	247	40	treatment	treatment	NOUN
aji-132	247	41	”	"	PUNCT
aji-132	247	42	[	[	X
aji-132	247	43	40	40	NUM
aji-132	247	44	]	]	PUNCT
aji-132	247	45	.	.	PUNCT
aji-132	248	1	“	"	PUNCT
aji-132	248	2	rankl	rankl	VERB
aji-132	248	3	and	and	CCONJ
aji-132	248	4	its	its	PRON
aji-132	248	5	receptor	receptor	NOUN
aji-132	248	6	rank	rank	NOUN
aji-132	248	7	interact	interact	VERB
aji-132	248	8	with	with	ADP
aji-132	248	9	osteoclast	osteoclast	ADJ
aji-132	248	10	precursor	precursor	NOUN
aji-132	248	11	cells	cell	NOUN
aji-132	248	12	,	,	PUNCT
aji-132	248	13	initiating	initiate	VERB
aji-132	248	14	downstream	downstream	ADJ
aji-132	248	15	pathways	pathway	NOUN
aji-132	248	16	such	such	ADJ
aji-132	248	17	as	as	ADP
aji-132	248	18	peroxisome	peroxisome	NOUN
aji-132	248	19	proliferator	proliferator	NOUN
aji-132	248	20	-	-	PUNCT
aji-132	248	21	activated	activate	VERB
aji-132	248	22	receptor	receptor	NOUN
aji-132	248	23	(	(	PUNCT
aji-132	248	24	ppar)-γ	ppar)-γ	NOUN
aji-132	248	25	,	,	PUNCT
aji-132	248	26	c	c	NOUN
aji-132	248	27	-	-	PUNCT
aji-132	248	28	fos	fos	NOUN
aji-132	248	29	,	,	PUNCT
aji-132	248	30	and	and	CCONJ
aji-132	248	31	nuclear	nuclear	ADJ
aji-132	248	32	factor	factor	NOUN
aji-132	248	33	of	of	ADP
aji-132	248	34	activated	activate	VERB
aji-132	248	35	t	t	NOUN
aji-132	248	36	cells	cell	NOUN
aji-132	248	37	(	(	PUNCT
aji-132	248	38	nfat)c1	nfat)c1	ADJ
aji-132	248	39	”	"	PUNCT
aji-132	248	40	[	[	X
aji-132	248	41	41	41	NUM
aji-132	248	42	]	]	PUNCT
aji-132	248	43	.	.	PUNCT
aji-132	249	1	“	"	PUNCT
aji-132	249	2	igu	igu	PROPN
aji-132	249	3	has	have	VERB
aji-132	249	4	the	the	DET
aji-132	249	5	ability	ability	NOUN
aji-132	249	6	to	to	PART
aji-132	249	7	inhibit	inhibit	VERB
aji-132	249	8	osteoclast	osteoclast	ADJ
aji-132	249	9	formation	formation	NOUN
aji-132	249	10	and	and	CCONJ
aji-132	249	11	bone	bone	NOUN
aji-132	249	12	resorption	resorption	NOUN
aji-132	249	13	stimulated	stimulate	VERB
aji-132	249	14	by	by	ADP
aji-132	249	15	rankl	rankl	NOUN
aji-132	249	16	through	through	ADP
aji-132	249	17	the	the	DET
aji-132	249	18	pparγ	pparγ	NOUN
aji-132	249	19	/	/	SYM
aji-132	249	20	c	c	NOUN
aji-132	249	21	-	-	PUNCT
aji-132	249	22	fos	fos	VERB
aji-132	249	23	signaling	signal	VERB
aji-132	249	24	pathway	pathway	NOUN
aji-132	249	25	.	.	PUNCT
aji-132	250	1	furthermore	furthermore	ADV
aji-132	250	2	,	,	PUNCT
aji-132	250	3	it	it	PRON
aji-132	250	4	decreases	decrease	VERB
aji-132	250	5	the	the	DET
aji-132	250	6	expression	expression	NOUN
aji-132	250	7	of	of	ADP
aji-132	250	8	nfatc1	nfatc1	ADJ
aji-132	250	9	and	and	CCONJ
aji-132	250	10	subsequent	subsequent	ADJ
aji-132	250	11	osteoclast	osteoclast	ADJ
aji-132	250	12	marker	marker	NOUN
aji-132	250	13	genes	gene	NOUN
aji-132	250	14	”	"	PUNCT
aji-132	251	1	[	[	X
aji-132	251	2	42	42	NUM
aji-132	251	3	]	]	PUNCT
aji-132	251	4	.	.	PUNCT
aji-132	252	1	gan	gan	AUX
aji-132	252	2	et	et	PROPN
aji-132	252	3	al	al	PROPN
aji-132	252	4	.	.	PROPN
aji-132	252	5	found	find	VERB
aji-132	252	6	that	that	SCONJ
aji-132	252	7	“	"	PUNCT
aji-132	252	8	igu	igu	PROPN
aji-132	252	9	effectively	effectively	ADV
aji-132	252	10	inhibited	inhibit	VERB
aji-132	252	11	rankl	rankl	NOUN
aji-132	252	12	-	-	PUNCT
aji-132	252	13	induced	induce	VERB
aji-132	252	14	osteoclast	osteoclast	ADJ
aji-132	252	15	differentiation	differentiation	NOUN
aji-132	252	16	,	,	PUNCT
aji-132	252	17	migration	migration	NOUN
aji-132	252	18	,	,	PUNCT
aji-132	252	19	and	and	CCONJ
aji-132	252	20	bone	bone	NOUN
aji-132	252	21	resorption	resorption	NOUN
aji-132	252	22	in	in	ADP
aji-132	252	23	raw264.7	raw264.7	PROPN
aji-132	252	24	cells	cell	NOUN
aji-132	252	25	,	,	PUNCT
aji-132	252	26	with	with	ADP
aji-132	252	27	the	the	DET
aji-132	252	28	effect	effect	NOUN
aji-132	252	29	varying	vary	VERB
aji-132	252	30	depending	depend	VERB
aji-132	252	31	on	on	ADP
aji-132	252	32	the	the	DET
aji-132	252	33	dosage	dosage	NOUN
aji-132	252	34	administered	administer	VERB
aji-132	252	35	”	"	PUNCT
aji-132	252	36	.	.	PUNCT
aji-132	253	1	“	"	PUNCT
aji-132	253	2	this	this	DET
aji-132	253	3	effect	effect	NOUN
aji-132	253	4	was	be	AUX
aji-132	253	5	attributed	attribute	VERB
aji-132	253	6	to	to	ADP
aji-132	253	7	the	the	DET
aji-132	253	8	activation	activation	NOUN
aji-132	253	9	of	of	ADP
aji-132	253	10	the	the	DET
aji-132	253	11	mapk	mapk	NOUN
aji-132	253	12	and	and	CCONJ
aji-132	253	13	nf	nf	ADJ
aji-132	253	14	-	-	PUNCT
aji-132	253	15	κb	κb	NOUN
aji-132	253	16	pathways	pathway	NOUN
aji-132	253	17	”	"	PUNCT
aji-132	254	1	[	[	X
aji-132	254	2	43	43	NUM
aji-132	254	3	]	]	PUNCT
aji-132	254	4	.	.	PUNCT
aji-132	255	1	“	"	PUNCT
aji-132	255	2	it	it	PRON
aji-132	255	3	indicates	indicate	VERB
aji-132	255	4	that	that	SCONJ
aji-132	255	5	igu	igu	PROPN
aji-132	255	6	directly	directly	ADV
aji-132	255	7	suppresses	suppress	VERB
aji-132	255	8	the	the	DET
aji-132	255	9	formation	formation	NOUN
aji-132	255	10	and	and	CCONJ
aji-132	255	11	activity	activity	NOUN
aji-132	255	12	of	of	ADP
aji-132	255	13	osteoclasts	osteoclast	NOUN
aji-132	255	14	.	.	PUNCT
aji-132	256	1	additionally	additionally	ADV
aji-132	256	2	,	,	PUNCT
aji-132	256	3	the	the	DET
aji-132	256	4	tnf	tnf	PROPN
aji-132	256	5	-	-	PUNCT
aji-132	256	6	α	α	PROPN
aji-132	256	7	/	/	SYM
aji-132	256	8	nf	nf	NOUN
aji-132	256	9	-	-	PUNCT
aji-132	256	10	κb	κb	NOUN
aji-132	256	11	signaling	signal	VERB
aji-132	256	12	pathway	pathway	NOUN
aji-132	256	13	inhibit	inhibit	VERB
aji-132	256	14	the	the	DET
aji-132	256	15	production	production	NOUN
aji-132	256	16	of	of	ADP
aji-132	256	17	matrix	matrix	NOUN
aji-132	256	18	metalloproteinases	metalloproteinase	NOUN
aji-132	256	19	(	(	PUNCT
aji-132	256	20	mmps	mmp	NOUN
aji-132	256	21	)	)	PUNCT
aji-132	256	22	”	"	PUNCT
aji-132	257	1	[	[	X
aji-132	257	2	38	38	NUM
aji-132	257	3	]	]	PUNCT
aji-132	257	4	.	.	PUNCT
aji-132	258	1	“	"	PUNCT
aji-132	258	2	mmps	mmp	NOUN
aji-132	258	3	are	be	AUX
aji-132	258	4	pivotal	pivotal	ADJ
aji-132	258	5	in	in	ADP
aji-132	258	6	the	the	DET
aji-132	258	7	degradation	degradation	NOUN
aji-132	258	8	of	of	ADP
aji-132	258	9	cartilage	cartilage	NOUN
aji-132	258	10	in	in	ADP
aji-132	258	11	rheumatoid	rheumatoid	NOUN
aji-132	258	12	arthritis	arthritis	NOUN
aji-132	258	13	(	(	PUNCT
aji-132	258	14	ra	ra	NOUN
aji-132	258	15	)	)	PUNCT
aji-132	258	16	,	,	PUNCT
aji-132	258	17	predominantly	predominantly	ADV
aji-132	258	18	synthesized	synthesize	VERB
aji-132	258	19	by	by	ADP
aji-132	258	20	fibroblast	fibroblast	ADJ
aji-132	258	21	-	-	PUNCT
aji-132	258	22	like	like	ADJ
aji-132	258	23	synoviocytes	synoviocyte	NOUN
aji-132	258	24	(	(	PUNCT
aji-132	258	25	flss	flss	ADJ
aji-132	258	26	)	)	PUNCT
aji-132	258	27	.	.	PUNCT
aji-132	259	1	du	du	PROPN
aji-132	259	2	et	et	PROPN
aji-132	259	3	al	al	PROPN
aji-132	259	4	.	.	PROPN
aji-132	259	5	conducted	conduct	VERB
aji-132	259	6	in	in	ADP
aji-132	259	7	vitro	vitro	X
aji-132	259	8	experiments	experiment	NOUN
aji-132	259	9	treating	treat	VERB
aji-132	259	10	flss	flss	ADJ
aji-132	259	11	with	with	ADP
aji-132	259	12	varying	vary	VERB
aji-132	259	13	concentrations	concentration	NOUN
aji-132	259	14	of	of	ADP
aji-132	259	15	igu	igu	PROPN
aji-132	259	16	,	,	PUNCT
aji-132	259	17	followed	follow	VERB
aji-132	259	18	by	by	ADP
aji-132	259	19	stimulation	stimulation	NOUN
aji-132	259	20	with	with	ADP
aji-132	259	21	tnf	tnf	PROPN
aji-132	259	22	-	-	PUNCT
aji-132	259	23	α	α	PROPN
aji-132	259	24	,	,	PUNCT
aji-132	259	25	il-1β	il-1β	PROPN
aji-132	259	26	,	,	PUNCT
aji-132	259	27	or	or	CCONJ
aji-132	259	28	il17a	il17a	NOUN
aji-132	259	29	.	.	PUNCT
aji-132	260	1	they	they	PRON
aji-132	260	2	observed	observe	VERB
aji-132	260	3	a	a	DET
aji-132	260	4	significant	significant	ADJ
aji-132	260	5	inhibition	inhibition	NOUN
aji-132	260	6	of	of	ADP
aji-132	260	7	mmp-3	mmp-3	NUM
aji-132	260	8	at	at	ADP
aji-132	260	9	5	5	NUM
aji-132	260	10	μg	μg	NOUN
aji-132	260	11	/	/	SYM
aji-132	260	12	ml	ml	X
aji-132	260	13	igu	igu	NOUN
aji-132	260	14	,	,	PUNCT
aji-132	260	15	while	while	SCONJ
aji-132	260	16	mmp-1	mmp-1	ADP
aji-132	260	17	inhibition	inhibition	NOUN
aji-132	260	18	occurred	occur	VERB
aji-132	260	19	at	at	ADP
aji-132	260	20	50	50	NUM
aji-132	260	21	μg	μg	NOUN
aji-132	260	22	/	/	SYM
aji-132	260	23	ml	ml	PROPN
aji-132	260	24	.	.	PUNCT
aji-132	261	1	clinical	clinical	ADJ
aji-132	261	2	trials	trial	NOUN
aji-132	261	3	revealed	reveal	VERB
aji-132	261	4	a	a	DET
aji-132	261	5	significantly	significantly	ADJ
aji-132	261	6	reduction	reduction	NOUN
aji-132	261	7	in	in	ADP
aji-132	261	8	mmp-1	mmp-1	PUNCT
aji-132	261	9	and	and	CCONJ
aji-132	261	10	mmp-3	mmp-3	NUM
aji-132	261	11	levels	level	NOUN
aji-132	261	12	following	follow	VERB
aji-132	261	13	24	24	NUM
aji-132	261	14	weeks	week	NOUN
aji-132	261	15	of	of	ADP
aji-132	261	16	igu	igu	PROPN
aji-132	261	17	treatment	treatment	NOUN
aji-132	261	18	(	(	PUNCT
aji-132	261	19	25	25	NUM
aji-132	261	20	mg	mg	PROPN
aji-132	261	21	,	,	PUNCT
aji-132	261	22	twice	twice	ADV
aji-132	261	23	daily	daily	ADV
aji-132	261	24	)	)	PUNCT
aji-132	261	25	”	"	PUNCT
aji-132	262	1	[	[	X
aji-132	262	2	44	44	NUM
aji-132	262	3	]	]	PUNCT
aji-132	262	4	.	.	PUNCT
aji-132	263	1	these	these	DET
aji-132	263	2	findings	finding	NOUN
aji-132	263	3	indicate	indicate	VERB
aji-132	263	4	that	that	SCONJ
aji-132	263	5	igu	igu	PROPN
aji-132	263	6	effectively	effectively	ADV
aji-132	263	7	prevents	prevent	VERB
aji-132	263	8	mmp-1	mmp-1	PUNCT
aji-132	263	9	and	and	CCONJ
aji-132	263	10	mmp-3	mmp-3	NOUN
aji-132	263	11	,	,	PUNCT
aji-132	263	12	thus	thus	ADV
aji-132	263	13	preserving	preserve	VERB
aji-132	263	14	cartilage	cartilage	NOUN
aji-132	263	15	integrity	integrity	NOUN
aji-132	263	16	.	.	PUNCT
aji-132	264	1	moreover	moreover	ADV
aji-132	264	2	,	,	PUNCT
aji-132	264	3	opg	opg	PROPN
aji-132	264	4	serves	serve	VERB
aji-132	264	5	as	as	ADP
aji-132	264	6	a	a	DET
aji-132	264	7	natural	natural	ADJ
aji-132	264	8	antagonist	antagonist	NOUN
aji-132	264	9	to	to	PART
aji-132	264	10	rankl	rankl	VERB
aji-132	264	11	,	,	PUNCT
aji-132	264	12	preventing	prevent	VERB
aji-132	264	13	its	its	PRON
aji-132	264	14	binding	binding	NOUN
aji-132	264	15	to	to	ADP
aji-132	264	16	the	the	DET
aji-132	264	17	osteoclast	osteoclast	ADJ
aji-132	264	18	receptor	receptor	NOUN
aji-132	264	19	.	.	PUNCT
aji-132	265	1	the	the	DET
aji-132	265	2	equilibrium	equilibrium	NOUN
aji-132	265	3	between	between	ADP
aji-132	265	4	rankl	rankl	NOUN
aji-132	265	5	and	and	CCONJ
aji-132	265	6	opg	opg	NOUN
aji-132	265	7	is	be	AUX
aji-132	265	8	critical	critical	ADJ
aji-132	265	9	for	for	ADP
aji-132	265	10	sustaining	sustain	VERB
aji-132	265	11	osteoclast	osteoclast	ADJ
aji-132	265	12	homeostasis	homeostasis	NOUN
aji-132	265	13	[	[	X
aji-132	265	14	45	45	NUM
aji-132	265	15	]	]	PUNCT
aji-132	265	16	.	.	PUNCT
aji-132	266	1	igu	igu	PROPN
aji-132	266	2	can	can	AUX
aji-132	266	3	suppress	suppress	VERB
aji-132	266	4	the	the	DET
aji-132	266	5	expression	expression	NOUN
aji-132	266	6	of	of	ADP
aji-132	266	7	mmp-3	mmp-3	NUM
aji-132	266	8	and	and	CCONJ
aji-132	266	9	the	the	DET
aji-132	266	10	rankl	rankl	PROPN
aji-132	266	11	/	/	SYM
aji-132	266	12	opg	opg	PROPN
aji-132	266	13	ratio	ratio	NOUN
aji-132	266	14	by	by	ADP
aji-132	266	15	inhibiting	inhibit	VERB
aji-132	266	16	the	the	DET
aji-132	266	17	phosphorylation	phosphorylation	NOUN
aji-132	266	18	of	of	ADP
aji-132	266	19	erk1/2	erk1/2	PROPN
aji-132	266	20	,	,	PUNCT
aji-132	266	21	consequently	consequently	ADV
aji-132	266	22	thwarting	thwart	VERB
aji-132	266	23	the	the	DET
aji-132	266	24	degradation	degradation	NOUN
aji-132	266	25	of	of	ADP
aji-132	266	26	bone	bone	NOUN
aji-132	266	27	in	in	ADP
aji-132	266	28	rheumatoid	rheumatoid	NOUN
aji-132	266	29	arthritis	arthritis	NOUN
aji-132	266	30	[	[	X
aji-132	266	31	46	46	NUM
aji-132	266	32	]	]	PUNCT
aji-132	266	33	.	.	PUNCT
aji-132	267	1	igu	igu	PROPN
aji-132	267	2	not	not	PART
aji-132	267	3	only	only	ADV
aji-132	267	4	enhances	enhance	VERB
aji-132	267	5	osteoblast	osteoblast	ADJ
aji-132	267	6	differentiation	differentiation	NOUN
aji-132	267	7	but	but	CCONJ
aji-132	267	8	also	also	ADV
aji-132	267	9	suppresses	suppress	VERB
aji-132	267	10	osteoclast	osteoclast	ADJ
aji-132	267	11	formation	formation	NOUN
aji-132	267	12	and	and	CCONJ
aji-132	267	13	the	the	DET
aji-132	267	14	production	production	NOUN
aji-132	267	15	of	of	ADP
aji-132	267	16	matrix	matrix	NOUN
aji-132	267	17	proteins	protein	NOUN
aji-132	267	18	through	through	ADP
aji-132	267	19	its	its	PRON
aji-132	267	20	interaction	interaction	NOUN
aji-132	267	21	with	with	ADP
aji-132	267	22	various	various	ADJ
aji-132	267	23	signaling	signal	VERB
aji-132	267	24	pathways	pathway	NOUN
aji-132	267	25	.	.	PUNCT
aji-132	268	1	consequently	consequently	ADV
aji-132	268	2	,	,	PUNCT
aji-132	268	3	igu	igu	PROPN
aji-132	268	4	plays	play	VERB
aji-132	268	5	a	a	DET
aji-132	268	6	crucial	crucial	ADJ
aji-132	268	7	role	role	NOUN
aji-132	268	8	in	in	ADP
aji-132	268	9	safeguarding	safeguard	VERB
aji-132	268	10	bone	bone	NOUN
aji-132	268	11	health	health	NOUN
aji-132	268	12	.	.	PUNCT
aji-132	269	1	fig	fig	NOUN
aji-132	269	2	.	.	PUNCT
aji-132	270	1	3	3	NUM
aji-132	270	2	illustrates	illustrate	VERB
aji-132	270	3	the	the	DET
aji-132	270	4	intricate	intricate	ADJ
aji-132	270	5	adjustments	adjustment	NOUN
aji-132	270	6	made	make	VERB
aji-132	270	7	by	by	ADP
aji-132	270	8	igu	igu	PROPN
aji-132	270	9	within	within	ADP
aji-132	270	10	the	the	DET
aji-132	270	11	signaling	signal	VERB
aji-132	270	12	pathways	pathway	NOUN
aji-132	270	13	.	.	PUNCT
aji-132	271	1	fig	fig	NOUN
aji-132	271	2	.	.	PUNCT
aji-132	272	1	3	3	X
aji-132	272	2	.	.	NOUN
aji-132	272	3	illustrates	illustrate	VERB
aji-132	272	4	the	the	DET
aji-132	272	5	osteoprotective	osteoprotective	ADJ
aji-132	272	6	mechanism	mechanism	NOUN
aji-132	272	7	of	of	ADP
aji-132	272	8	igu	igu	PROPN
aji-132	272	9	,	,	PUNCT
aji-132	272	10	highlighting	highlight	VERB
aji-132	272	11	its	its	PRON
aji-132	272	12	impact	impact	NOUN
aji-132	272	13	on	on	ADP
aji-132	272	14	various	various	ADJ
aji-132	272	15	signaling	signal	VERB
aji-132	272	16	pathways	pathway	NOUN
aji-132	272	17	crucial	crucial	ADJ
aji-132	272	18	for	for	ADP
aji-132	272	19	osteoblast	osteoblast	ADJ
aji-132	272	20	proliferation	proliferation	NOUN
aji-132	272	21	,	,	PUNCT
aji-132	272	22	differentiation	differentiation	NOUN
aji-132	272	23	,	,	PUNCT
aji-132	272	24	and	and	CCONJ
aji-132	272	25	bone	bone	NOUN
aji-132	272	26	/	/	SYM
aji-132	272	27	cartilage	cartilage	NOUN
aji-132	272	28	repair	repair	NOUN
aji-132	272	29	these	these	DET
aji-132	272	30	pathways	pathway	NOUN
aji-132	272	31	include	include	VERB
aji-132	272	32	the	the	DET
aji-132	272	33	bmp2	bmp2	ADJ
aji-132	272	34	-	-	PUNCT
aji-132	272	35	smads	smad	NOUN
aji-132	272	36	signaling	signal	VERB
aji-132	272	37	pathway	pathway	NOUN
aji-132	272	38	,	,	PUNCT
aji-132	272	39	the	the	DET
aji-132	272	40	p38	p38	NOUN
aji-132	272	41	-	-	PUNCT
aji-132	272	42	mapk	mapk	NOUN
aji-132	272	43	pathway	pathway	NOUN
aji-132	272	44	,	,	PUNCT
aji-132	272	45	and	and	CCONJ
aji-132	272	46	the	the	DET
aji-132	272	47	nf	nf	ADJ
aji-132	272	48	-	-	PUNCT
aji-132	272	49	κb	κb	NOUN
aji-132	272	50	pathway	pathway	NOUN
aji-132	272	51	.	.	PUNCT
aji-132	273	1	igu	igu	PROPN
aji-132	273	2	,	,	PUNCT
aji-132	273	3	or	or	CCONJ
aji-132	273	4	iguratimod	iguratimod	NOUN
aji-132	273	5	,	,	PUNCT
aji-132	273	6	facilitates	facilitate	VERB
aji-132	273	7	osteoblast	osteoblast	ADJ
aji-132	273	8	differentiation	differentiation	NOUN
aji-132	273	9	by	by	ADP
aji-132	273	10	upregulating	upregulate	VERB
aji-132	273	11	the	the	DET
aji-132	273	12	expression	expression	NOUN
aji-132	273	13	of	of	ADP
aji-132	273	14	osx	osx	PROPN
aji-132	273	15	and	and	CCONJ
aji-132	273	16	its	its	PRON
aji-132	273	17	upstream	upstream	ADJ
aji-132	273	18	regulator	regulator	NOUN
aji-132	273	19	dlx5	dlx5	PROPN
aji-132	273	20	,	,	PUNCT
aji-132	273	21	while	while	SCONJ
aji-132	273	22	also	also	ADV
aji-132	273	23	enhancing	enhance	VERB
aji-132	273	24	p38	p38	NOUN
aji-132	273	25	activation	activation	NOUN
aji-132	273	26	.	.	PUNCT
aji-132	274	1	furthermore	furthermore	ADV
aji-132	274	2	,	,	PUNCT
aji-132	274	3	igu	igu	PROPN
aji-132	274	4	inhibits	inhibit	VERB
aji-132	274	5	osteoclastogenesis	osteoclastogenesis	NOUN
aji-132	274	6	and	and	CCONJ
aji-132	274	7	bone	bone	NOUN
aji-132	274	8	resorption	resorption	NOUN
aji-132	274	9	induced	induce	VERB
aji-132	274	10	by	by	ADP
aji-132	274	11	rankl	rankl	NOUN
aji-132	274	12	via	via	ADP
aji-132	274	13	the	the	DET
aji-132	274	14	pparγ	pparγ	NOUN
aji-132	274	15	/	/	SYM
aji-132	274	16	c	c	NOUN
aji-132	274	17	-	-	PUNCT
aji-132	274	18	fos	fos	VERB
aji-132	274	19	signaling	signal	VERB
aji-132	274	20	pathway	pathway	NOUN
aji-132	274	21	.	.	PUNCT
aji-132	275	1	additionally	additionally	ADV
aji-132	275	2	,	,	PUNCT
aji-132	275	3	igu	igu	PROPN
aji-132	275	4	decreases	decrease	VERB
aji-132	275	5	the	the	DET
aji-132	275	6	expression	expression	NOUN
aji-132	275	7	of	of	ADP
aji-132	275	8	nuclear	nuclear	ADJ
aji-132	275	9	factor	factor	NOUN
aji-132	275	10	in	in	ADP
aji-132	275	11	activated	activate	VERB
aji-132	275	12	t	t	PROPN
aji-132	275	13	cell	cell	NOUN
aji-132	275	14	c1	c1	NOUN
aji-132	275	15	and	and	CCONJ
aji-132	275	16	downstream	downstream	ADJ
aji-132	275	17	osteoclast	osteoclast	ADJ
aji-132	275	18	marker	marker	NOUN
aji-132	275	19	genes	gene	NOUN
aji-132	275	20	gupta	gupta	PROPN
aji-132	275	21	et	et	PROPN
aji-132	275	22	al	al	PROPN
aji-132	275	23	.	.	PROPN
aji-132	275	24	;	;	PUNCT
aji-132	276	1	asian	asian	PROPN
aji-132	276	2	j.	j.	PROPN
aji-132	276	3	immunol	immunol	PROPN
aji-132	276	4	.	.	PROPN
aji-132	276	5	,	,	PUNCT
aji-132	276	6	vol	vol	NOUN
aji-132	276	7	.	.	PROPN
aji-132	276	8	7	7	NUM
aji-132	276	9	,	,	PUNCT
aji-132	276	10	no	no	INTJ
aji-132	276	11	.	.	NOUN
aji-132	276	12	1	1	NUM
aji-132	276	13	,	,	PUNCT
aji-132	276	14	pp	pp	ADJ
aji-132	276	15	.	.	PUNCT
aji-132	277	1	79	79	NUM
aji-132	277	2	-	-	SYM
aji-132	277	3	89	89	NUM
aji-132	277	4	,	,	PUNCT
aji-132	277	5	2024	2024	NUM
aji-132	277	6	;	;	PUNCT
aji-132	277	7	article	article	NOUN
aji-132	277	8	no.aji.115805	no.aji.115805	VERB
aji-132	277	9	85	85	NUM
aji-132	277	10	3	3	NUM
aji-132	277	11	.	.	PUNCT
aji-132	278	1	progress	progress	NOUN
aji-132	278	2	in	in	ADP
aji-132	278	3	clinical	clinical	ADJ
aji-132	278	4	research	research	NOUN
aji-132	278	5	numerous	numerous	ADJ
aji-132	278	6	clinical	clinical	ADJ
aji-132	278	7	trials	trial	NOUN
aji-132	278	8	have	have	AUX
aji-132	278	9	validated	validate	VERB
aji-132	278	10	igu	igu	PROPN
aji-132	278	11	as	as	ADP
aji-132	278	12	a	a	DET
aji-132	278	13	promising	promising	ADJ
aji-132	278	14	novel	novel	ADJ
aji-132	278	15	treatment	treatment	NOUN
aji-132	278	16	for	for	ADP
aji-132	278	17	rheumatoid	rheumatoid	NOUN
aji-132	278	18	arthritis	arthritis	NOUN
aji-132	278	19	(	(	PUNCT
aji-132	278	20	ra	ra	NOUN
aji-132	278	21	)	)	PUNCT
aji-132	278	22	.	.	PUNCT
aji-132	279	1	phase	phase	NOUN
aji-132	279	2	i	i	PRON
aji-132	279	3	,	,	PUNCT
aji-132	279	4	ii	ii	PROPN
aji-132	279	5	,	,	PUNCT
aji-132	279	6	and	and	CCONJ
aji-132	279	7	iii	iii	NUM
aji-132	279	8	trials	trial	NOUN
aji-132	279	9	have	have	AUX
aji-132	279	10	demonstrated	demonstrate	VERB
aji-132	279	11	the	the	DET
aji-132	279	12	effectiveness	effectiveness	NOUN
aji-132	279	13	and	and	CCONJ
aji-132	279	14	safety	safety	NOUN
aji-132	279	15	of	of	ADP
aji-132	279	16	igu	igu	PROPN
aji-132	279	17	monotherapy	monotherapy	NOUN
aji-132	279	18	over	over	ADP
aji-132	279	19	a	a	DET
aji-132	279	20	span	span	NOUN
aji-132	279	21	of	of	ADP
aji-132	279	22	24	24	NUM
aji-132	279	23	weeks	week	NOUN
aji-132	279	24	.	.	PUNCT
aji-132	280	1	typically	typically	ADV
aji-132	280	2	,	,	PUNCT
aji-132	280	3	igu	igu	PROPN
aji-132	280	4	exhibits	exhibit	VERB
aji-132	280	5	its	its	PRON
aji-132	280	6	therapeutic	therapeutic	ADJ
aji-132	280	7	effects	effect	NOUN
aji-132	280	8	within	within	ADP
aji-132	280	9	8	8	NUM
aji-132	280	10	weeks	week	NOUN
aji-132	280	11	,	,	PUNCT
aji-132	280	12	demonstrating	demonstrate	VERB
aji-132	280	13	a	a	DET
aji-132	280	14	faster	fast	ADJ
aji-132	280	15	onset	onset	NOUN
aji-132	280	16	compared	compare	VERB
aji-132	280	17	to	to	ADP
aji-132	280	18	methotrexate	methotrexate	VERB
aji-132	280	19	(	(	PUNCT
aji-132	280	20	mtx	mtx	NOUN
aji-132	280	21	)	)	PUNCT
aji-132	280	22	.	.	PUNCT
aji-132	281	1	igu	igu	PROPN
aji-132	281	2	treatment	treatment	NOUN
aji-132	281	3	exhibits	exhibit	VERB
aji-132	281	4	early	early	ADJ
aji-132	281	5	and	and	CCONJ
aji-132	281	6	sustained	sustained	ADJ
aji-132	281	7	efficacy	efficacy	NOUN
aji-132	281	8	.	.	PUNCT
aji-132	282	1	furthermore	furthermore	ADV
aji-132	282	2	,	,	PUNCT
aji-132	282	3	the	the	DET
aji-132	282	4	efficacy	efficacy	NOUN
aji-132	282	5	of	of	ADP
aji-132	282	6	a	a	DET
aji-132	282	7	50	50	NUM
aji-132	282	8	mg	mg	NOUN
aji-132	282	9	dosage	dosage	NOUN
aji-132	282	10	of	of	ADP
aji-132	282	11	igu	igu	PROPN
aji-132	282	12	(	(	PUNCT
aji-132	282	13	25	25	NUM
aji-132	282	14	mg	mg	NOUN
aji-132	282	15	twice	twice	ADV
aji-132	282	16	daily	daily	ADV
aji-132	282	17	)	)	PUNCT
aji-132	282	18	is	be	AUX
aji-132	282	19	comparable	comparable	ADJ
aji-132	282	20	to	to	ADP
aji-132	282	21	that	that	PRON
aji-132	282	22	of	of	ADP
aji-132	282	23	a	a	DET
aji-132	282	24	15	15	NUM
aji-132	282	25	mg	mg	NOUN
aji-132	282	26	dose	dose	NOUN
aji-132	282	27	of	of	ADP
aji-132	282	28	mtx	mtx	PROPN
aji-132	282	29	(	(	PUNCT
aji-132	282	30	15	15	NUM
aji-132	282	31	mg	mg	NOUN
aji-132	282	32	per	per	ADP
aji-132	282	33	week	week	NOUN
aji-132	282	34	)	)	PUNCT
aji-132	282	35	.	.	PUNCT
aji-132	283	1	a	a	DET
aji-132	283	2	multicenter	multicenter	NOUN
aji-132	283	3	,	,	PUNCT
aji-132	283	4	prospective	prospective	ADJ
aji-132	283	5	observational	observational	ADJ
aji-132	283	6	study	study	NOUN
aji-132	283	7	was	be	AUX
aji-132	283	8	conducted	conduct	VERB
aji-132	283	9	to	to	PART
aji-132	283	10	assess	assess	VERB
aji-132	283	11	the	the	DET
aji-132	283	12	long	long	ADJ
aji-132	283	13	-	-	PUNCT
aji-132	283	14	term	term	NOUN
aji-132	283	15	safety	safety	NOUN
aji-132	283	16	and	and	CCONJ
aji-132	283	17	efficacy	efficacy	NOUN
aji-132	283	18	of	of	ADP
aji-132	283	19	igu	igu	PROPN
aji-132	283	20	in	in	ADP
aji-132	283	21	rheumatoid	rheumatoid	NOUN
aji-132	283	22	arthritis	arthritis	NOUN
aji-132	283	23	(	(	PUNCT
aji-132	283	24	ra	ra	NOUN
aji-132	283	25	)	)	PUNCT
aji-132	283	26	patients	patient	NOUN
aji-132	283	27	.	.	PUNCT
aji-132	284	1	the	the	DET
aji-132	284	2	study	study	NOUN
aji-132	284	3	enrolled	enrol	VERB
aji-132	284	4	all	all	DET
aji-132	284	5	eligible	eligible	ADJ
aji-132	284	6	ra	ra	PROPN
aji-132	284	7	patients	patient	NOUN
aji-132	284	8	who	who	PRON
aji-132	284	9	had	have	AUX
aji-132	284	10	been	be	AUX
aji-132	284	11	treated	treat	VERB
aji-132	284	12	with	with	ADP
aji-132	284	13	igu	igu	PROPN
aji-132	284	14	since	since	SCONJ
aji-132	284	15	its	its	PRON
aji-132	284	16	introduction	introduction	NOUN
aji-132	284	17	to	to	ADP
aji-132	284	18	the	the	DET
aji-132	284	19	market	market	NOUN
aji-132	284	20	in	in	ADP
aji-132	284	21	2012	2012	NUM
aji-132	284	22	.	.	PUNCT
aji-132	285	1	efficacy	efficacy	NOUN
aji-132	285	2	was	be	AUX
aji-132	285	3	evaluated	evaluate	VERB
aji-132	285	4	using	use	VERB
aji-132	285	5	disease	disease	NOUN
aji-132	285	6	activity	activity	NOUN
aji-132	285	7	score	score	NOUN
aji-132	285	8	28	28	NUM
aji-132	285	9	(	(	PUNCT
aji-132	285	10	das28	das28	PROPN
aji-132	285	11	)	)	PUNCT
aji-132	285	12	,	,	PUNCT
aji-132	285	13	while	while	SCONJ
aji-132	285	14	adverse	adverse	ADJ
aji-132	285	15	drug	drug	NOUN
aji-132	285	16	reactions	reaction	NOUN
aji-132	285	17	such	such	ADJ
aji-132	285	18	as	as	ADP
aji-132	285	19	liver	liver	NOUN
aji-132	285	20	and	and	CCONJ
aji-132	285	21	renal	renal	ADJ
aji-132	285	22	dysfunction	dysfunction	NOUN
aji-132	285	23	,	,	PUNCT
aji-132	285	24	interstitial	interstitial	ADJ
aji-132	285	25	lung	lung	NOUN
aji-132	285	26	disease	disease	NOUN
aji-132	285	27	,	,	PUNCT
aji-132	285	28	gastrointestinal	gastrointestinal	ADJ
aji-132	285	29	and	and	CCONJ
aji-132	285	30	blood	blood	NOUN
aji-132	285	31	disorders	disorder	NOUN
aji-132	285	32	,	,	PUNCT
aji-132	285	33	and	and	CCONJ
aji-132	285	34	infections	infection	NOUN
aji-132	285	35	were	be	AUX
aji-132	285	36	monitored	monitor	VERB
aji-132	285	37	up	up	ADP
aji-132	285	38	to	to	ADP
aji-132	285	39	week	week	NOUN
aji-132	285	40	52	52	NUM
aji-132	285	41	.	.	PUNCT
aji-132	286	1	the	the	DET
aji-132	286	2	findings	finding	NOUN
aji-132	286	3	indicated	indicate	VERB
aji-132	286	4	that	that	SCONJ
aji-132	286	5	extended	extended	ADJ
aji-132	286	6	use	use	NOUN
aji-132	286	7	of	of	ADP
aji-132	286	8	igu	igu	PROPN
aji-132	286	9	demonstrated	demonstrate	VERB
aji-132	286	10	a	a	DET
aji-132	286	11	manageable	manageable	ADJ
aji-132	286	12	safety	safety	NOUN
aji-132	286	13	profile	profile	NOUN
aji-132	286	14	and	and	CCONJ
aji-132	286	15	led	lead	VERB
aji-132	286	16	to	to	ADP
aji-132	286	17	enhanced	enhanced	ADJ
aji-132	286	18	control	control	NOUN
aji-132	286	19	of	of	ADP
aji-132	286	20	rheumatoid	rheumatoid	NOUN
aji-132	286	21	arthritis	arthritis	NOUN
aji-132	286	22	(	(	PUNCT
aji-132	286	23	ra	ra	NOUN
aji-132	286	24	)	)	PUNCT
aji-132	286	25	activity	activity	NOUN
aji-132	286	26	.	.	PUNCT
aji-132	287	1	additionally	additionally	ADV
aji-132	287	2	,	,	PUNCT
aji-132	287	3	another	another	DET
aji-132	287	4	study	study	NOUN
aji-132	287	5	assessing	assess	VERB
aji-132	287	6	the	the	DET
aji-132	287	7	3	3	NUM
aji-132	287	8	-	-	PUNCT
aji-132	287	9	year	year	NOUN
aji-132	287	10	efficacy	efficacy	NOUN
aji-132	287	11	of	of	ADP
aji-132	287	12	igu	igu	PROPN
aji-132	287	13	in	in	ADP
aji-132	287	14	ra	ra	PROPN
aji-132	287	15	patients	patient	NOUN
aji-132	287	16	confirmed	confirm	VERB
aji-132	287	17	its	its	PRON
aji-132	287	18	effectiveness	effectiveness	NOUN
aji-132	287	19	and	and	CCONJ
aji-132	287	20	safety	safety	NOUN
aji-132	287	21	.	.	PUNCT
aji-132	288	1	these	these	DET
aji-132	288	2	outcomes	outcome	NOUN
aji-132	288	3	suggest	suggest	VERB
aji-132	288	4	that	that	SCONJ
aji-132	288	5	igu	igu	PROPN
aji-132	288	6	can	can	AUX
aji-132	288	7	be	be	AUX
aji-132	288	8	utilized	utilize	VERB
aji-132	288	9	for	for	ADP
aji-132	288	10	prolonged	prolonged	ADJ
aji-132	288	11	treatment	treatment	NOUN
aji-132	288	12	durations	duration	NOUN
aji-132	288	13	.	.	PUNCT
aji-132	289	1	methotrexate	methotrexate	NOUN
aji-132	289	2	(	(	PUNCT
aji-132	289	3	mtx	mtx	NOUN
aji-132	289	4	)	)	PUNCT
aji-132	289	5	serves	serve	VERB
aji-132	289	6	as	as	ADP
aji-132	289	7	a	a	DET
aji-132	289	8	cornerstone	cornerstone	NOUN
aji-132	289	9	in	in	ADP
aji-132	289	10	the	the	DET
aji-132	289	11	management	management	NOUN
aji-132	289	12	of	of	ADP
aji-132	289	13	rheumatoid	rheumatoid	NOUN
aji-132	289	14	arthritis	arthritis	NOUN
aji-132	289	15	(	(	PUNCT
aji-132	289	16	ra	ra	NOUN
aji-132	289	17	)	)	PUNCT
aji-132	289	18	,	,	PUNCT
aji-132	289	19	often	often	ADV
aji-132	289	20	forming	form	VERB
aji-132	289	21	the	the	DET
aji-132	289	22	foundation	foundation	NOUN
aji-132	289	23	of	of	ADP
aji-132	289	24	treatment	treatment	NOUN
aji-132	289	25	.	.	PUNCT
aji-132	290	1	typically	typically	ADV
aji-132	290	2	,	,	PUNCT
aji-132	290	3	ra	ra	PROPN
aji-132	290	4	management	management	NOUN
aji-132	290	5	entails	entail	VERB
aji-132	290	6	a	a	DET
aji-132	290	7	combination	combination	NOUN
aji-132	290	8	of	of	ADP
aji-132	290	9	several	several	ADJ
aji-132	290	10	anti	anti	ADJ
aji-132	290	11	-	-	ADJ
aji-132	290	12	rheumatic	rheumatic	ADJ
aji-132	290	13	medications	medication	NOUN
aji-132	290	14	.	.	PUNCT
aji-132	291	1	consequently	consequently	ADV
aji-132	291	2	,	,	PUNCT
aji-132	291	3	the	the	DET
aji-132	291	4	combination	combination	NOUN
aji-132	291	5	of	of	ADP
aji-132	291	6	igu	igu	PROPN
aji-132	291	7	with	with	ADP
aji-132	291	8	mtx	mtx	NOUN
aji-132	291	9	has	have	AUX
aji-132	291	10	become	become	VERB
aji-132	291	11	a	a	DET
aji-132	291	12	prevalent	prevalent	ADJ
aji-132	291	13	and	and	CCONJ
aji-132	291	14	novel	novel	ADJ
aji-132	291	15	therapeutic	therapeutic	ADJ
aji-132	291	16	approach	approach	NOUN
aji-132	291	17	for	for	ADP
aji-132	291	18	ra	ra	PROPN
aji-132	291	19	.	.	PUNCT
aji-132	292	1	ren	ren	PROPN
aji-132	292	2	et	et	PROPN
aji-132	292	3	al	al	PROPN
aji-132	292	4	.	.	PROPN
aji-132	292	5	conducted	conduct	VERB
aji-132	292	6	a	a	DET
aji-132	292	7	randomized	randomized	ADJ
aji-132	292	8	study	study	NOUN
aji-132	292	9	involving	involve	VERB
aji-132	292	10	82	82	NUM
aji-132	292	11	patients	patient	NOUN
aji-132	292	12	,	,	PUNCT
aji-132	292	13	dividing	divide	VERB
aji-132	292	14	them	they	PRON
aji-132	292	15	into	into	ADP
aji-132	292	16	two	two	NUM
aji-132	292	17	groups	group	NOUN
aji-132	292	18	.	.	PUNCT
aji-132	293	1	the	the	DET
aji-132	293	2	control	control	PROPN
aji-132	293	3	group	group	NOUN
aji-132	293	4	received	receive	VERB
aji-132	293	5	mtx	mtx	NOUN
aji-132	293	6	at	at	ADP
aji-132	293	7	a	a	DET
aji-132	293	8	dose	dose	NOUN
aji-132	293	9	of	of	ADP
aji-132	293	10	10	10	NUM
aji-132	293	11	mg	mg	NOUN
aji-132	293	12	once	once	ADV
aji-132	293	13	weekly	weekly	ADV
aji-132	293	14	,	,	PUNCT
aji-132	293	15	which	which	PRON
aji-132	293	16	was	be	AUX
aji-132	293	17	escalated	escalate	VERB
aji-132	293	18	to	to	ADP
aji-132	293	19	15	15	NUM
aji-132	293	20	mg	mg	NOUN
aji-132	293	21	once	once	ADV
aji-132	293	22	weekly	weekly	ADV
aji-132	293	23	after	after	ADP
aji-132	293	24	2	2	NUM
aji-132	293	25	weeks	week	NOUN
aji-132	293	26	.	.	PUNCT
aji-132	294	1	the	the	DET
aji-132	294	2	observation	observation	NOUN
aji-132	294	3	group	group	NOUN
aji-132	294	4	received	receive	VERB
aji-132	294	5	igu	igu	PROPN
aji-132	294	6	at	at	ADP
aji-132	294	7	a	a	DET
aji-132	294	8	dose	dose	NOUN
aji-132	294	9	of	of	ADP
aji-132	294	10	25	25	NUM
aji-132	294	11	mg	mg	NOUN
aji-132	294	12	twice	twice	ADV
aji-132	294	13	daily	daily	ADV
aji-132	294	14	in	in	ADP
aji-132	294	15	addition	addition	NOUN
aji-132	294	16	to	to	ADP
aji-132	294	17	the	the	DET
aji-132	294	18	regimen	regimen	NOUN
aji-132	294	19	followed	follow	VERB
aji-132	294	20	by	by	ADP
aji-132	294	21	the	the	DET
aji-132	294	22	control	control	NOUN
aji-132	294	23	group	group	NOUN
aji-132	294	24	,	,	PUNCT
aji-132	294	25	over	over	ADP
aji-132	294	26	a	a	DET
aji-132	294	27	period	period	NOUN
aji-132	294	28	of	of	ADP
aji-132	294	29	6	6	NUM
aji-132	294	30	months	month	NOUN
aji-132	294	31	.	.	PUNCT
aji-132	295	1	the	the	DET
aji-132	295	2	total	total	ADJ
aji-132	295	3	effective	effective	ADJ
aji-132	295	4	rate	rate	NOUN
aji-132	295	5	in	in	ADP
aji-132	295	6	the	the	DET
aji-132	295	7	observation	observation	NOUN
aji-132	295	8	group	group	NOUN
aji-132	295	9	was	be	AUX
aji-132	295	10	90.24	90.24	NUM
aji-132	295	11	%	%	NOUN
aji-132	295	12	,	,	PUNCT
aji-132	295	13	markedly	markedly	ADV
aji-132	295	14	surpassing	surpass	VERB
aji-132	295	15	that	that	PRON
aji-132	295	16	of	of	ADP
aji-132	295	17	the	the	DET
aji-132	295	18	control	control	NOUN
aji-132	295	19	group	group	NOUN
aji-132	295	20	,	,	PUNCT
aji-132	295	21	which	which	PRON
aji-132	295	22	stood	stand	VERB
aji-132	295	23	at	at	ADP
aji-132	295	24	78.05	78.05	NUM
aji-132	295	25	%	%	NOUN
aji-132	295	26	[	[	X
aji-132	295	27	41	41	NUM
aji-132	295	28	]	]	PUNCT
aji-132	295	29	.	.	PUNCT
aji-132	296	1	the	the	DET
aji-132	296	2	findings	finding	NOUN
aji-132	296	3	indicated	indicate	VERB
aji-132	296	4	that	that	SCONJ
aji-132	296	5	igu	igu	PROPN
aji-132	296	6	enhances	enhance	VERB
aji-132	296	7	the	the	DET
aji-132	296	8	therapeutic	therapeutic	ADJ
aji-132	296	9	efficacy	efficacy	NOUN
aji-132	296	10	of	of	ADP
aji-132	296	11	mtx	mtx	NOUN
aji-132	296	12	.	.	PUNCT
aji-132	297	1	when	when	SCONJ
aji-132	297	2	used	use	VERB
aji-132	297	3	in	in	ADP
aji-132	297	4	conjunction	conjunction	NOUN
aji-132	297	5	with	with	ADP
aji-132	297	6	leflunomide	leflunomide	ADJ
aji-132	297	7	(	(	PUNCT
aji-132	297	8	lef	lef	NOUN
aji-132	297	9	)	)	PUNCT
aji-132	297	10	for	for	ADP
aji-132	297	11	rheumatoid	rheumatoid	NOUN
aji-132	297	12	arthritis	arthritis	NOUN
aji-132	297	13	(	(	PUNCT
aji-132	297	14	ra	ra	NOUN
aji-132	297	15	)	)	PUNCT
aji-132	297	16	treatment	treatment	NOUN
aji-132	297	17	,	,	PUNCT
aji-132	297	18	methotrexate	methotrexate	NOUN
aji-132	297	19	(	(	PUNCT
aji-132	297	20	mtx	mtx	NOUN
aji-132	297	21	)	)	PUNCT
aji-132	297	22	frequently	frequently	ADV
aji-132	297	23	leads	lead	VERB
aji-132	297	24	to	to	ADP
aji-132	297	25	an	an	DET
aji-132	297	26	increased	increase	VERB
aji-132	297	27	incidence	incidence	NOUN
aji-132	297	28	of	of	ADP
aji-132	297	29	adverse	adverse	ADJ
aji-132	297	30	reactions	reaction	NOUN
aji-132	297	31	.	.	PUNCT
aji-132	298	1	in	in	ADP
aji-132	298	2	the	the	DET
aji-132	298	3	tranmod	tranmod	PROPN
aji-132	298	4	study	study	NOUN
aji-132	298	5	,	,	PUNCT
aji-132	298	6	66	66	NUM
aji-132	298	7	patients	patient	NOUN
aji-132	298	8	with	with	ADP
aji-132	298	9	refractory	refractory	NOUN
aji-132	298	10	rheumatoid	rheumatoid	VERB
aji-132	298	11	arthritis	arthritis	NOUN
aji-132	298	12	(	(	PUNCT
aji-132	298	13	ra	ra	NOUN
aji-132	298	14	)	)	PUNCT
aji-132	298	15	were	be	AUX
aji-132	298	16	randomly	randomly	ADV
aji-132	298	17	assigned	assign	VERB
aji-132	298	18	to	to	ADP
aji-132	298	19	two	two	NUM
aji-132	298	20	groups	group	NOUN
aji-132	298	21	.	.	PUNCT
aji-132	299	1	the	the	DET
aji-132	299	2	observation	observation	NOUN
aji-132	299	3	group	group	NOUN
aji-132	299	4	received	receive	VERB
aji-132	299	5	a	a	DET
aji-132	299	6	combination	combination	NOUN
aji-132	299	7	of	of	ADP
aji-132	299	8	methotrexate	methotrexate	NOUN
aji-132	299	9	(	(	PUNCT
aji-132	299	10	mtx	mtx	NOUN
aji-132	299	11	)	)	PUNCT
aji-132	299	12	at	at	ADP
aji-132	299	13	a	a	DET
aji-132	299	14	dose	dose	NOUN
aji-132	299	15	of	of	ADP
aji-132	299	16	10	10	NUM
aji-132	299	17	mg	mg	NOUN
aji-132	299	18	once	once	ADV
aji-132	299	19	weekly	weekly	ADJ
aji-132	299	20	and	and	CCONJ
aji-132	299	21	iguratimod	iguratimod	PROPN
aji-132	299	22	(	(	PUNCT
aji-132	299	23	igu	igu	PROPN
aji-132	299	24	)	)	PUNCT
aji-132	299	25	at	at	ADP
aji-132	299	26	a	a	DET
aji-132	299	27	dose	dose	NOUN
aji-132	299	28	of	of	ADP
aji-132	299	29	25	25	NUM
aji-132	299	30	mg	mg	NOUN
aji-132	299	31	twice	twice	ADV
aji-132	299	32	daily	daily	ADV
aji-132	299	33	,	,	PUNCT
aji-132	299	34	while	while	SCONJ
aji-132	299	35	the	the	DET
aji-132	299	36	control	control	NOUN
aji-132	299	37	group	group	NOUN
aji-132	299	38	received	receive	VERB
aji-132	299	39	mtx	mtx	NOUN
aji-132	299	40	(	(	PUNCT
aji-132	299	41	10	10	NUM
aji-132	299	42	mg	mg	ADP
aji-132	299	43	once	once	ADV
aji-132	299	44	weekly	weekly	ADV
aji-132	299	45	)	)	PUNCT
aji-132	299	46	combined	combine	VERB
aji-132	299	47	with	with	ADP
aji-132	299	48	leflunomide	leflunomide	ADJ
aji-132	299	49	(	(	PUNCT
aji-132	299	50	lef	lef	NOUN
aji-132	299	51	)	)	PUNCT
aji-132	299	52	at	at	ADP
aji-132	299	53	a	a	DET
aji-132	299	54	dose	dose	NOUN
aji-132	299	55	of	of	ADP
aji-132	299	56	10	10	NUM
aji-132	299	57	mg	mg	NOUN
aji-132	299	58	once	once	ADV
aji-132	299	59	daily	daily	ADV
aji-132	299	60	for	for	ADP
aji-132	299	61	a	a	DET
aji-132	299	62	duration	duration	NOUN
aji-132	299	63	of	of	ADP
aji-132	299	64	16	16	NUM
aji-132	299	65	weeks	week	NOUN
aji-132	299	66	.	.	PUNCT
aji-132	300	1	results	result	NOUN
aji-132	300	2	showed	show	VERB
aji-132	300	3	that	that	SCONJ
aji-132	300	4	both	both	DET
aji-132	300	5	groups	group	NOUN
aji-132	300	6	experienced	experience	VERB
aji-132	300	7	reductions	reduction	NOUN
aji-132	300	8	in	in	ADP
aji-132	300	9	disease	disease	NOUN
aji-132	300	10	activity	activity	NOUN
aji-132	300	11	score	score	NOUN
aji-132	300	12	28	28	NUM
aji-132	300	13	(	(	PUNCT
aji-132	300	14	das28	das28	PROPN
aji-132	300	15	)	)	PUNCT
aji-132	300	16	scores	score	NOUN
aji-132	300	17	compared	compare	VERB
aji-132	300	18	to	to	ADP
aji-132	300	19	before	before	ADP
aji-132	300	20	treatment	treatment	NOUN
aji-132	300	21	.	.	PUNCT
aji-132	301	1	at	at	ADP
aji-132	301	2	8	8	NUM
aji-132	301	3	weeks	week	NOUN
aji-132	301	4	,	,	PUNCT
aji-132	301	5	there	there	PRON
aji-132	301	6	was	be	VERB
aji-132	301	7	a	a	DET
aji-132	301	8	significant	significant	ADJ
aji-132	301	9	difference	difference	NOUN
aji-132	301	10	between	between	ADP
aji-132	301	11	the	the	DET
aji-132	301	12	two	two	NUM
aji-132	301	13	groups	group	NOUN
aji-132	301	14	in	in	ADP
aji-132	301	15	terms	term	NOUN
aji-132	301	16	of	of	ADP
aji-132	301	17	achieving	achieve	VERB
aji-132	301	18	american	american	PROPN
aji-132	301	19	college	college	PROPN
aji-132	301	20	of	of	ADP
aji-132	301	21	rheumatology	rheumatology	NOUN
aji-132	301	22	(	(	PUNCT
aji-132	301	23	acr)20	acr)20	NOUN
aji-132	301	24	and	and	CCONJ
aji-132	301	25	acr50	acr50	ADJ
aji-132	301	26	response	response	NOUN
aji-132	301	27	criteria	criterion	NOUN
aji-132	301	28	.	.	PUNCT
aji-132	302	1	however	however	ADV
aji-132	302	2	,	,	PUNCT
aji-132	302	3	by	by	ADP
aji-132	302	4	16	16	NUM
aji-132	302	5	weeks	week	NOUN
aji-132	302	6	,	,	PUNCT
aji-132	302	7	there	there	PRON
aji-132	302	8	was	be	VERB
aji-132	302	9	no	no	DET
aji-132	302	10	significant	significant	ADJ
aji-132	302	11	difference	difference	NOUN
aji-132	302	12	in	in	ADP
aji-132	302	13	acr20	acr20	NOUN
aji-132	302	14	,	,	PUNCT
aji-132	302	15	acr50	acr50	ADJ
aji-132	302	16	,	,	PUNCT
aji-132	302	17	and	and	CCONJ
aji-132	302	18	acr70	acr70	ADP
aji-132	302	19	response	response	NOUN
aji-132	302	20	rates	rate	NOUN
aji-132	302	21	between	between	ADP
aji-132	302	22	the	the	DET
aji-132	302	23	two	two	NUM
aji-132	302	24	groups	group	NOUN
aji-132	302	25	.	.	PUNCT
aji-132	303	1	compared	compare	VERB
aji-132	303	2	to	to	ADP
aji-132	303	3	the	the	DET
aji-132	303	4	combination	combination	NOUN
aji-132	303	5	of	of	ADP
aji-132	303	6	mtx	mtx	NOUN
aji-132	303	7	and	and	CCONJ
aji-132	303	8	lef	lef	NOUN
aji-132	303	9	,	,	PUNCT
aji-132	303	10	the	the	DET
aji-132	303	11	combination	combination	NOUN
aji-132	303	12	of	of	ADP
aji-132	303	13	mtx	mtx	NOUN
aji-132	303	14	and	and	CCONJ
aji-132	303	15	igu	igu	PROPN
aji-132	303	16	demonstrated	demonstrate	VERB
aji-132	303	17	superior	superior	ADJ
aji-132	303	18	short	short	ADJ
aji-132	303	19	-	-	PUNCT
aji-132	303	20	term	term	NOUN
aji-132	303	21	clinical	clinical	ADJ
aji-132	303	22	efficacy	efficacy	NOUN
aji-132	303	23	and	and	CCONJ
aji-132	303	24	fewer	few	ADJ
aji-132	303	25	adverse	adverse	ADJ
aji-132	303	26	reactions	reaction	NOUN
aji-132	303	27	in	in	ADP
aji-132	303	28	ra	ra	PROPN
aji-132	303	29	patients	patient	NOUN
aji-132	303	30	.	.	PUNCT
aji-132	304	1	furthermore	furthermore	ADV
aji-132	304	2	,	,	PUNCT
aji-132	304	3	igu	igu	PROPN
aji-132	304	4	is	be	AUX
aji-132	304	5	frequently	frequently	ADV
aji-132	304	6	employed	employ	VERB
aji-132	304	7	in	in	ADP
aji-132	304	8	conjunction	conjunction	NOUN
aji-132	304	9	with	with	ADP
aji-132	304	10	biological	biological	ADJ
aji-132	304	11	agents	agent	NOUN
aji-132	304	12	like	like	ADP
aji-132	304	13	tocilizumab	tocilizumab	NOUN
aji-132	304	14	and	and	CCONJ
aji-132	304	15	etanercept	etanercept	NOUN
aji-132	304	16	.	.	PUNCT
aji-132	305	1	this	this	PRON
aji-132	305	2	underscores	underscore	VERB
aji-132	305	3	the	the	DET
aji-132	305	4	versatility	versatility	NOUN
aji-132	305	5	of	of	ADP
aji-132	305	6	igu	igu	PROPN
aji-132	305	7	,	,	PUNCT
aji-132	305	8	as	as	SCONJ
aji-132	305	9	it	it	PRON
aji-132	305	10	can	can	AUX
aji-132	305	11	be	be	AUX
aji-132	305	12	combined	combine	VERB
aji-132	305	13	with	with	ADP
aji-132	305	14	various	various	ADJ
aji-132	305	15	anti	anti	ADJ
aji-132	305	16	-	-	ADJ
aji-132	305	17	rheumatic	rheumatic	ADJ
aji-132	305	18	medications	medication	NOUN
aji-132	305	19	for	for	ADP
aji-132	305	20	the	the	DET
aji-132	305	21	treatment	treatment	NOUN
aji-132	305	22	of	of	ADP
aji-132	305	23	rheumatoid	rheumatoid	NOUN
aji-132	305	24	arthritis	arthritis	NOUN
aji-132	305	25	(	(	PUNCT
aji-132	305	26	ra	ra	NOUN
aji-132	305	27	)	)	PUNCT
aji-132	305	28	.	.	PUNCT
aji-132	306	1	in	in	ADP
aji-132	306	2	real	real	ADJ
aji-132	306	3	-	-	PUNCT
aji-132	306	4	world	world	NOUN
aji-132	306	5	clinical	clinical	ADJ
aji-132	306	6	scenarios	scenario	NOUN
aji-132	306	7	,	,	PUNCT
aji-132	306	8	certain	certain	ADJ
aji-132	306	9	rheumatoid	rheumatoid	NOUN
aji-132	306	10	arthritis	arthritis	NOUN
aji-132	306	11	(	(	PUNCT
aji-132	306	12	ra	ra	NOUN
aji-132	306	13	)	)	PUNCT
aji-132	306	14	patients	patient	NOUN
aji-132	306	15	exhibit	exhibit	VERB
aji-132	306	16	insufficient	insufficient	ADJ
aji-132	306	17	response	response	NOUN
aji-132	306	18	to	to	ADP
aji-132	306	19	multiple	multiple	ADJ
aji-132	306	20	diseasemodifying	diseasemodifye	VERB
aji-132	306	21	antirheumatic	antirheumatic	ADJ
aji-132	306	22	drugs	drug	NOUN
aji-132	306	23	(	(	PUNCT
aji-132	306	24	dmards	dmard	NOUN
aji-132	306	25	)	)	PUNCT
aji-132	306	26	.	.	PUNCT
aji-132	307	1	a	a	DET
aji-132	307	2	study	study	NOUN
aji-132	307	3	verified	verify	VERB
aji-132	307	4	that	that	SCONJ
aji-132	307	5	the	the	DET
aji-132	307	6	effectiveness	effectiveness	NOUN
aji-132	307	7	and	and	CCONJ
aji-132	307	8	tolerability	tolerability	NOUN
aji-132	307	9	of	of	ADP
aji-132	307	10	igu	igu	PROPN
aji-132	307	11	in	in	ADP
aji-132	307	12	combination	combination	NOUN
aji-132	307	13	with	with	ADP
aji-132	307	14	mtx	mtx	NOUN
aji-132	307	15	therapy	therapy	NOUN
aji-132	307	16	persisted	persist	VERB
aji-132	307	17	for	for	ADP
aji-132	307	18	a	a	DET
aji-132	307	19	duration	duration	NOUN
aji-132	307	20	of	of	ADP
aji-132	307	21	up	up	ADP
aji-132	307	22	to	to	PART
aji-132	307	23	52	52	NUM
aji-132	307	24	weeks	week	NOUN
aji-132	307	25	in	in	ADP
aji-132	307	26	active	active	ADJ
aji-132	307	27	ra	ra	PROPN
aji-132	307	28	patients	patient	NOUN
aji-132	307	29	who	who	PRON
aji-132	307	30	had	have	AUX
aji-132	307	31	shown	show	VERB
aji-132	307	32	inadequate	inadequate	ADJ
aji-132	307	33	response	response	NOUN
aji-132	307	34	to	to	PART
aji-132	307	35	mtx	mtx	VERB
aji-132	307	36	alone	alone	ADV
aji-132	307	37	.	.	PUNCT
aji-132	308	1	in	in	ADP
aji-132	308	2	another	another	DET
aji-132	308	3	study	study	NOUN
aji-132	308	4	,	,	PUNCT
aji-132	308	5	131	131	NUM
aji-132	308	6	patients	patient	NOUN
aji-132	308	7	previously	previously	ADV
aji-132	308	8	treated	treat	VERB
aji-132	308	9	with	with	ADP
aji-132	308	10	traditional	traditional	ADJ
aji-132	308	11	disease	disease	NOUN
aji-132	308	12	-	-	PUNCT
aji-132	308	13	modifying	modify	VERB
aji-132	308	14	antirheumatic	antirheumatic	ADJ
aji-132	308	15	drugs	drug	NOUN
aji-132	308	16	(	(	PUNCT
aji-132	308	17	dmards	dmard	NOUN
aji-132	308	18	)	)	PUNCT
aji-132	308	19	were	be	AUX
aji-132	308	20	divided	divide	VERB
aji-132	308	21	into	into	ADP
aji-132	308	22	three	three	NUM
aji-132	308	23	groups	group	NOUN
aji-132	308	24	.	.	PUNCT
aji-132	309	1	group	group	NOUN
aji-132	309	2	1	1	NUM
aji-132	309	3	consisted	consist	VERB
aji-132	309	4	of	of	ADP
aji-132	309	5	44	44	NUM
aji-132	309	6	patients	patient	NOUN
aji-132	309	7	treated	treat	VERB
aji-132	309	8	with	with	ADP
aji-132	309	9	a	a	DET
aji-132	309	10	combination	combination	NOUN
aji-132	309	11	of	of	ADP
aji-132	309	12	igu	igu	PROPN
aji-132	309	13	(	(	PUNCT
aji-132	309	14	25	25	NUM
aji-132	309	15	mg	mg	PROPN
aji-132	309	16	,	,	PUNCT
aji-132	309	17	twice	twice	ADV
aji-132	309	18	daily	daily	ADV
aji-132	309	19	,	,	PUNCT
aji-132	309	20	orally	orally	ADV
aji-132	309	21	)	)	PUNCT
aji-132	309	22	and	and	CCONJ
aji-132	309	23	mtx	mtx	NOUN
aji-132	309	24	(	(	PUNCT
aji-132	309	25	10	10	NUM
aji-132	309	26	mg	mg	NOUN
aji-132	309	27	weekly	weekly	ADJ
aji-132	309	28	,	,	PUNCT
aji-132	309	29	orally	orally	ADV
aji-132	309	30	)	)	PUNCT
aji-132	309	31	.	.	PUNCT
aji-132	310	1	group	group	NOUN
aji-132	310	2	2	2	NUM
aji-132	310	3	included	include	VERB
aji-132	310	4	38	38	NUM
aji-132	310	5	patients	patient	NOUN
aji-132	310	6	who	who	PRON
aji-132	310	7	received	receive	VERB
aji-132	310	8	igu	igu	PROPN
aji-132	310	9	alone	alone	ADV
aji-132	310	10	(	(	PUNCT
aji-132	310	11	25	25	NUM
aji-132	310	12	mg	mg	NOUN
aji-132	310	13	twice	twice	ADV
aji-132	310	14	daily	daily	ADV
aji-132	310	15	,	,	PUNCT
aji-132	310	16	orally	orally	ADV
aji-132	310	17	)	)	PUNCT
aji-132	310	18	,	,	PUNCT
aji-132	310	19	while	while	SCONJ
aji-132	310	20	group	group	NOUN
aji-132	310	21	3	3	NUM
aji-132	310	22	comprised	comprise	VERB
aji-132	310	23	49	49	NUM
aji-132	310	24	patients	patient	NOUN
aji-132	310	25	who	who	PRON
aji-132	310	26	received	receive	VERB
aji-132	310	27	mtx	mtx	NOUN
aji-132	310	28	alone	alone	ADV
aji-132	310	29	(	(	PUNCT
aji-132	310	30	10	10	NUM
aji-132	310	31	mg	mg	NOUN
aji-132	310	32	weekly	weekly	ADJ
aji-132	310	33	,	,	PUNCT
aji-132	310	34	orally	orally	ADV
aji-132	310	35	)	)	PUNCT
aji-132	310	36	.	.	PUNCT
aji-132	311	1	therapeutic	therapeutic	ADJ
aji-132	311	2	effects	effect	NOUN
aji-132	311	3	with	with	ADP
aji-132	311	4	igu	igu	PROPN
aji-132	311	5	were	be	AUX
aji-132	311	6	observed	observe	VERB
aji-132	311	7	between	between	ADP
aji-132	311	8	4	4	NUM
aji-132	311	9	and	and	CCONJ
aji-132	311	10	10	10	NUM
aji-132	311	11	weeks	week	NOUN
aji-132	311	12	after	after	ADP
aji-132	311	13	treatment	treatment	NOUN
aji-132	311	14	initiation	initiation	NOUN
aji-132	311	15	,	,	PUNCT
aji-132	311	16	effectively	effectively	ADV
aji-132	311	17	addressing	address	VERB
aji-132	311	18	patients	patient	NOUN
aji-132	311	19	with	with	ADP
aji-132	311	20	inadequate	inadequate	ADJ
aji-132	311	21	responses	response	NOUN
aji-132	311	22	to	to	ADP
aji-132	311	23	prior	prior	ADJ
aji-132	311	24	dmard	dmard	ADJ
aji-132	311	25	treatments	treatment	NOUN
aji-132	311	26	.	.	PUNCT
aji-132	312	1	the	the	DET
aji-132	312	2	combination	combination	NOUN
aji-132	312	3	of	of	ADP
aji-132	312	4	igu	igu	PROPN
aji-132	312	5	with	with	ADP
aji-132	312	6	mtx	mtx	NOUN
aji-132	312	7	exhibited	exhibit	VERB
aji-132	312	8	superior	superior	ADJ
aji-132	312	9	efficacy	efficacy	NOUN
aji-132	312	10	compared	compare	VERB
aji-132	312	11	to	to	ADP
aji-132	312	12	igu	igu	PROPN
aji-132	312	13	gupta	gupta	PROPN
aji-132	312	14	et	et	PROPN
aji-132	312	15	al	al	PROPN
aji-132	312	16	.	.	PROPN
aji-132	312	17	;	;	PUNCT
aji-132	313	1	asian	asian	PROPN
aji-132	313	2	j.	j.	PROPN
aji-132	313	3	immunol	immunol	PROPN
aji-132	313	4	.	.	PROPN
aji-132	313	5	,	,	PUNCT
aji-132	313	6	vol	vol	NOUN
aji-132	313	7	.	.	PROPN
aji-132	313	8	7	7	NUM
aji-132	313	9	,	,	PUNCT
aji-132	313	10	no	no	INTJ
aji-132	313	11	.	.	NOUN
aji-132	313	12	1	1	NUM
aji-132	313	13	,	,	PUNCT
aji-132	313	14	pp	pp	ADJ
aji-132	313	15	.	.	PUNCT
aji-132	314	1	79	79	NUM
aji-132	314	2	-	-	SYM
aji-132	314	3	89	89	NUM
aji-132	314	4	,	,	PUNCT
aji-132	314	5	2024	2024	NUM
aji-132	314	6	;	;	PUNCT
aji-132	314	7	article	article	NOUN
aji-132	314	8	no.aji.115805	no.aji.115805	VERB
aji-132	314	9	86	86	NUM
aji-132	314	10	or	or	CCONJ
aji-132	314	11	mtx	mtx	NOUN
aji-132	314	12	monotherapy	monotherapy	NOUN
aji-132	314	13	.	.	PUNCT
aji-132	315	1	igu	igu	PROPN
aji-132	315	2	has	have	AUX
aji-132	315	3	demonstrated	demonstrate	VERB
aji-132	315	4	supplementary	supplementary	ADJ
aji-132	315	5	effectiveness	effectiveness	NOUN
aji-132	315	6	in	in	ADP
aji-132	315	7	rheumatoid	rheumatoid	NOUN
aji-132	315	8	arthritis	arthritis	NOUN
aji-132	315	9	(	(	PUNCT
aji-132	315	10	ra	ra	NOUN
aji-132	315	11	)	)	PUNCT
aji-132	315	12	patients	patient	NOUN
aji-132	315	13	who	who	PRON
aji-132	315	14	exhibit	exhibit	VERB
aji-132	315	15	inadequate	inadequate	ADJ
aji-132	315	16	responses	response	NOUN
aji-132	315	17	to	to	PART
aji-132	315	18	methotrexate	methotrexate	VERB
aji-132	315	19	(	(	PUNCT
aji-132	315	20	mtx	mtx	NOUN
aji-132	315	21	)	)	PUNCT
aji-132	315	22	.	.	PUNCT
aji-132	316	1	consequently	consequently	ADV
aji-132	316	2	,	,	PUNCT
aji-132	316	3	combining	combine	VERB
aji-132	316	4	igu	igu	PROPN
aji-132	316	5	with	with	ADP
aji-132	316	6	mtx	mtx	NOUN
aji-132	316	7	presents	present	NOUN
aji-132	316	8	a	a	DET
aji-132	316	9	promising	promising	ADJ
aji-132	316	10	emerging	emerge	VERB
aji-132	316	11	approach	approach	NOUN
aji-132	316	12	for	for	ADP
aji-132	316	13	treating	treat	VERB
aji-132	316	14	active	active	ADJ
aji-132	316	15	ra	ra	NOUN
aji-132	316	16	in	in	ADP
aji-132	316	17	individuals	individual	NOUN
aji-132	316	18	who	who	PRON
aji-132	316	19	have	have	VERB
aji-132	316	20	either	either	CCONJ
aji-132	316	21	inadequate	inadequate	ADJ
aji-132	316	22	responses	response	NOUN
aji-132	316	23	to	to	ADP
aji-132	316	24	or	or	CCONJ
aji-132	316	25	intolerance	intolerance	NOUN
aji-132	316	26	to	to	ADP
aji-132	316	27	traditional	traditional	ADJ
aji-132	316	28	diseasemodifying	diseasemodifye	VERB
aji-132	316	29	antirheumatic	antirheumatic	ADJ
aji-132	316	30	drugs	drug	NOUN
aji-132	316	31	(	(	PUNCT
aji-132	316	32	dmards	dmard	NOUN
aji-132	316	33	)	)	PUNCT
aji-132	316	34	.	.	PUNCT
aji-132	317	1	moreover	moreover	ADV
aji-132	317	2	,	,	PUNCT
aji-132	317	3	igu	igu	PROPN
aji-132	317	4	has	have	AUX
aji-132	317	5	shown	show	VERB
aji-132	317	6	additional	additional	ADJ
aji-132	317	7	effectiveness	effectiveness	NOUN
aji-132	317	8	and	and	CCONJ
aji-132	317	9	safety	safety	NOUN
aji-132	317	10	in	in	ADP
aji-132	317	11	ra	ra	PROPN
aji-132	317	12	patients	patient	NOUN
aji-132	317	13	who	who	PRON
aji-132	317	14	demonstrate	demonstrate	VERB
aji-132	317	15	inadequate	inadequate	ADJ
aji-132	317	16	responses	response	NOUN
aji-132	317	17	to	to	ADP
aji-132	317	18	biological	biological	ADJ
aji-132	317	19	dmards	dmard	NOUN
aji-132	317	20	,	,	PUNCT
aji-132	317	21	such	such	ADJ
aji-132	317	22	as	as	ADP
aji-132	317	23	tocilizumab	tocilizumab	NOUN
aji-132	317	24	.	.	PUNCT
aji-132	318	1	wang	wang	PROPN
aji-132	318	2	et	et	PROPN
aji-132	318	3	al	al	PROPN
aji-132	318	4	.	.	PROPN
aji-132	318	5	conducted	conduct	VERB
aji-132	318	6	a	a	DET
aji-132	318	7	self	self	NOUN
aji-132	318	8	-	-	PUNCT
aji-132	318	9	controlled	control	VERB
aji-132	318	10	study	study	NOUN
aji-132	318	11	involving	involve	VERB
aji-132	318	12	20	20	NUM
aji-132	318	13	rheumatoid	rheumatoid	NOUN
aji-132	318	14	arthritis	arthritis	NOUN
aji-132	318	15	(	(	PUNCT
aji-132	318	16	ra	ra	NOUN
aji-132	318	17	)	)	PUNCT
aji-132	318	18	patients	patient	NOUN
aji-132	318	19	with	with	ADP
aji-132	318	20	leukopenia	leukopenia	NOUN
aji-132	318	21	to	to	PART
aji-132	318	22	address	address	VERB
aji-132	318	23	the	the	DET
aji-132	318	24	challenge	challenge	NOUN
aji-132	318	25	of	of	ADP
aji-132	318	26	clinical	clinical	ADJ
aji-132	318	27	drug	drug	NOUN
aji-132	318	28	selection	selection	NOUN
aji-132	318	29	due	due	ADP
aji-132	318	30	to	to	ADP
aji-132	318	31	the	the	DET
aji-132	318	32	myelosuppressive	myelosuppressive	ADJ
aji-132	318	33	adverse	adverse	ADJ
aji-132	318	34	effects	effect	NOUN
aji-132	318	35	of	of	ADP
aji-132	318	36	many	many	ADJ
aji-132	318	37	disease	disease	NOUN
aji-132	318	38	-	-	PUNCT
aji-132	318	39	modifying	modify	VERB
aji-132	318	40	antirheumatic	antirheumatic	ADJ
aji-132	318	41	drugs	drug	NOUN
aji-132	318	42	(	(	PUNCT
aji-132	318	43	dmards	dmard	NOUN
aji-132	318	44	)	)	PUNCT
aji-132	318	45	.	.	PUNCT
aji-132	319	1	they	they	PRON
aji-132	319	2	administered	administer	VERB
aji-132	319	3	igu	igu	PROPN
aji-132	319	4	(	(	PUNCT
aji-132	319	5	25	25	NUM
aji-132	319	6	mg	mg	NOUN
aji-132	319	7	twice	twice	ADV
aji-132	319	8	daily	daily	ADV
aji-132	319	9	)	)	PUNCT
aji-132	319	10	in	in	ADP
aji-132	319	11	combination	combination	NOUN
aji-132	319	12	with	with	ADP
aji-132	319	13	methylprednisolone	methylprednisolone	NOUN
aji-132	319	14	(	(	PUNCT
aji-132	319	15	medrol	medrol	NOUN
aji-132	319	16	;	;	PUNCT
aji-132	319	17	8	8	NUM
aji-132	319	18	mg	mg	NOUN
aji-132	319	19	once	once	ADV
aji-132	319	20	daily	daily	ADV
aji-132	319	21	)	)	PUNCT
aji-132	319	22	during	during	ADP
aji-132	319	23	the	the	DET
aji-132	319	24	early	early	ADJ
aji-132	319	25	stage	stage	NOUN
aji-132	319	26	of	of	ADP
aji-132	319	27	the	the	DET
aji-132	319	28	disease	disease	NOUN
aji-132	319	29	.	.	PUNCT
aji-132	320	1	as	as	SCONJ
aji-132	320	2	white	white	ADJ
aji-132	320	3	blood	blood	NOUN
aji-132	320	4	cell	cell	NOUN
aji-132	320	5	counts	count	NOUN
aji-132	320	6	returned	return	VERB
aji-132	320	7	to	to	ADP
aji-132	320	8	normal	normal	ADJ
aji-132	320	9	with	with	ADP
aji-132	320	10	the	the	DET
aji-132	320	11	help	help	NOUN
aji-132	320	12	of	of	ADP
aji-132	320	13	hormones	hormone	NOUN
aji-132	320	14	during	during	ADP
aji-132	320	15	the	the	DET
aji-132	320	16	mid	mid	NOUN
aji-132	320	17	-	-	NOUN
aji-132	320	18	stage	stage	NOUN
aji-132	320	19	,	,	PUNCT
aji-132	320	20	mtx	mtx	PROPN
aji-132	320	21	was	be	AUX
aji-132	320	22	added	add	VERB
aji-132	320	23	to	to	ADP
aji-132	320	24	the	the	DET
aji-132	320	25	regimen	regiman	NOUN
aji-132	320	26	(	(	PUNCT
aji-132	320	27	7.5	7.5	NUM
aji-132	320	28	mg	mg	NOUN
aji-132	320	29	once	once	ADV
aji-132	320	30	weekly	weekly	ADV
aji-132	320	31	)	)	PUNCT
aji-132	320	32	,	,	PUNCT
aji-132	320	33	and	and	CCONJ
aji-132	320	34	methylprednisolone	methylprednisolone	NOUN
aji-132	320	35	was	be	AUX
aji-132	320	36	gradually	gradually	ADV
aji-132	320	37	discontinued	discontinue	VERB
aji-132	320	38	.	.	PUNCT
aji-132	321	1	subsequently	subsequently	ADV
aji-132	321	2	,	,	PUNCT
aji-132	321	3	igu	igu	PROPN
aji-132	321	4	(	(	PUNCT
aji-132	321	5	25	25	NUM
aji-132	321	6	mg	mg	NOUN
aji-132	321	7	twice	twice	ADV
aji-132	321	8	daily	daily	ADV
aji-132	321	9	)	)	PUNCT
aji-132	321	10	and	and	CCONJ
aji-132	321	11	mtx	mtx	NOUN
aji-132	321	12	(	(	PUNCT
aji-132	321	13	7.5	7.5	NUM
aji-132	321	14	mg	mg	NOUN
aji-132	321	15	once	once	ADV
aji-132	321	16	weekly	weekly	ADV
aji-132	321	17	)	)	PUNCT
aji-132	321	18	were	be	AUX
aji-132	321	19	employed	employ	VERB
aji-132	321	20	as	as	ADP
aji-132	321	21	longterm	longterm	ADJ
aji-132	321	22	maintenance	maintenance	NOUN
aji-132	321	23	therapy	therapy	NOUN
aji-132	321	24	for	for	ADP
aji-132	321	25	a	a	DET
aji-132	321	26	duration	duration	NOUN
aji-132	321	27	of	of	ADP
aji-132	321	28	12	12	NUM
aji-132	321	29	weeks	week	NOUN
aji-132	321	30	.	.	PUNCT
aji-132	322	1	results	result	NOUN
aji-132	322	2	indicated	indicate	VERB
aji-132	322	3	improvements	improvement	NOUN
aji-132	322	4	in	in	ADP
aji-132	322	5	erythrocyte	erythrocyte	PROPN
aji-132	322	6	sedimentation	sedimentation	NOUN
aji-132	322	7	rate	rate	NOUN
aji-132	322	8	(	(	PUNCT
aji-132	322	9	esr	esr	PROPN
aji-132	322	10	)	)	PUNCT
aji-132	322	11	,	,	PUNCT
aji-132	322	12	c	c	NOUN
aji-132	322	13	-	-	PUNCT
aji-132	322	14	reactive	reactive	ADJ
aji-132	322	15	protein	protein	NOUN
aji-132	322	16	(	(	PUNCT
aji-132	322	17	crp	crp	PROPN
aji-132	322	18	)	)	PUNCT
aji-132	322	19	,	,	PUNCT
aji-132	322	20	disease	disease	NOUN
aji-132	322	21	activity	activity	NOUN
aji-132	322	22	score	score	NOUN
aji-132	322	23	28	28	NUM
aji-132	322	24	(	(	PUNCT
aji-132	322	25	das28	das28	PROPN
aji-132	322	26	)	)	PUNCT
aji-132	322	27	,	,	PUNCT
aji-132	322	28	and	and	CCONJ
aji-132	322	29	white	white	ADJ
aji-132	322	30	blood	blood	NOUN
aji-132	322	31	cell	cell	NOUN
aji-132	322	32	counts	count	NOUN
aji-132	322	33	compared	compare	VERB
aji-132	322	34	to	to	ADP
aji-132	322	35	pre	pre	ADJ
aji-132	322	36	-	-	ADJ
aji-132	322	37	treatment	treatment	ADJ
aji-132	322	38	levels	level	NOUN
aji-132	322	39	.	.	PUNCT
aji-132	323	1	the	the	DET
aji-132	323	2	acr20	acr20	NOUN
aji-132	323	3	and	and	CCONJ
aji-132	323	4	acr50	acr50	ADJ
aji-132	323	5	response	response	NOUN
aji-132	323	6	rates	rate	NOUN
aji-132	323	7	were	be	AUX
aji-132	323	8	85	85	NUM
aji-132	323	9	%	%	NOUN
aji-132	323	10	and	and	CCONJ
aji-132	323	11	45	45	NUM
aji-132	323	12	%	%	NOUN
aji-132	323	13	,	,	PUNCT
aji-132	323	14	respectively	respectively	ADV
aji-132	323	15	,	,	PUNCT
aji-132	323	16	and	and	CCONJ
aji-132	323	17	the	the	DET
aji-132	323	18	overall	overall	ADJ
aji-132	323	19	rate	rate	NOUN
aji-132	323	20	of	of	ADP
aji-132	323	21	leukocyte	leukocyte	NOUN
aji-132	323	22	elevation	elevation	NOUN
aji-132	323	23	was	be	AUX
aji-132	323	24	95	95	NUM
aji-132	323	25	%	%	NOUN
aji-132	323	26	.	.	PUNCT
aji-132	324	1	only	only	ADV
aji-132	324	2	one	one	NUM
aji-132	324	3	case	case	NOUN
aji-132	324	4	experienced	experience	VERB
aji-132	324	5	mild	mild	ADJ
aji-132	324	6	liver	liver	NOUN
aji-132	324	7	damage	damage	NOUN
aji-132	324	8	during	during	ADP
aji-132	324	9	the	the	DET
aji-132	324	10	treatment	treatment	NOUN
aji-132	324	11	period	period	NOUN
aji-132	324	12	,	,	PUNCT
aji-132	324	13	which	which	PRON
aji-132	324	14	resolved	resolve	VERB
aji-132	324	15	with	with	ADP
aji-132	324	16	liver	liver	NOUN
aji-132	324	17	protection	protection	NOUN
aji-132	324	18	treatment	treatment	NOUN
aji-132	324	19	without	without	ADP
aji-132	324	20	discontinuing	discontinue	VERB
aji-132	324	21	anti	anti	ADJ
aji-132	324	22	-	-	ADJ
aji-132	324	23	rheumatic	rheumatic	ADJ
aji-132	324	24	therapy	therapy	NOUN
aji-132	324	25	.	.	PUNCT
aji-132	325	1	this	this	PRON
aji-132	325	2	underscores	underscore	VERB
aji-132	325	3	the	the	DET
aji-132	325	4	favorable	favorable	ADJ
aji-132	325	5	therapeutic	therapeutic	ADJ
aji-132	325	6	efficacy	efficacy	NOUN
aji-132	325	7	and	and	CCONJ
aji-132	325	8	high	high	ADJ
aji-132	325	9	safety	safety	NOUN
aji-132	325	10	profile	profile	NOUN
aji-132	325	11	of	of	ADP
aji-132	325	12	phased	phased	ADJ
aji-132	325	13	treatment	treatment	NOUN
aji-132	325	14	with	with	ADP
aji-132	325	15	igu	igu	PROPN
aji-132	325	16	,	,	PUNCT
aji-132	325	17	methylprednisolone	methylprednisolone	NOUN
aji-132	325	18	,	,	PUNCT
aji-132	325	19	and	and	CCONJ
aji-132	325	20	mtx	mtx	NOUN
aji-132	325	21	in	in	ADP
aji-132	325	22	ra	ra	PROPN
aji-132	325	23	patients	patient	NOUN
aji-132	325	24	with	with	ADP
aji-132	325	25	leukopenia	leukopenia	PROPN
aji-132	325	26	.	.	PUNCT
aji-132	326	1	the	the	DET
aji-132	326	2	aforementioned	aforementioned	ADJ
aji-132	326	3	clinical	clinical	ADJ
aji-132	326	4	trials	trial	NOUN
aji-132	326	5	have	have	AUX
aji-132	326	6	established	establish	VERB
aji-132	326	7	that	that	SCONJ
aji-132	326	8	igu	igu	PROPN
aji-132	326	9	is	be	AUX
aji-132	326	10	a	a	DET
aji-132	326	11	valuable	valuable	ADJ
aji-132	326	12	choice	choice	NOUN
aji-132	326	13	as	as	ADP
aji-132	326	14	an	an	DET
aji-132	326	15	initial	initial	ADJ
aji-132	326	16	treatment	treatment	NOUN
aji-132	326	17	for	for	ADP
aji-132	326	18	rheumatoid	rheumatoid	NOUN
aji-132	326	19	arthritis	arthritis	NOUN
aji-132	326	20	(	(	PUNCT
aji-132	326	21	ra	ra	NOUN
aji-132	326	22	)	)	PUNCT
aji-132	326	23	,	,	PUNCT
aji-132	326	24	demonstrating	demonstrate	VERB
aji-132	326	25	notable	notable	ADJ
aji-132	326	26	effectiveness	effectiveness	NOUN
aji-132	326	27	and	and	CCONJ
aji-132	326	28	safety	safety	NOUN
aji-132	326	29	whether	whether	SCONJ
aji-132	326	30	used	use	VERB
aji-132	326	31	independently	independently	ADV
aji-132	326	32	or	or	CCONJ
aji-132	326	33	in	in	ADP
aji-132	326	34	combination	combination	NOUN
aji-132	326	35	with	with	ADP
aji-132	326	36	other	other	ADJ
aji-132	326	37	medications	medication	NOUN
aji-132	326	38	.	.	PUNCT
aji-132	327	1	4	4	X
aji-132	327	2	.	.	X
aji-132	327	3	conclusion	conclusion	NOUN
aji-132	327	4	ra	ra	PROPN
aji-132	327	5	is	be	AUX
aji-132	327	6	a	a	DET
aji-132	327	7	chronic	chronic	ADJ
aji-132	327	8	autoimmune	autoimmune	ADJ
aji-132	327	9	disorder	disorder	NOUN
aji-132	327	10	characterized	characterize	VERB
aji-132	327	11	by	by	ADP
aji-132	327	12	synovial	synovial	ADJ
aji-132	327	13	inflammation	inflammation	NOUN
aji-132	327	14	,	,	PUNCT
aji-132	327	15	joint	joint	ADJ
aji-132	327	16	damage	damage	NOUN
aji-132	327	17	,	,	PUNCT
aji-132	327	18	and	and	CCONJ
aji-132	327	19	decreased	decrease	VERB
aji-132	327	20	joint	joint	ADJ
aji-132	327	21	function	function	NOUN
aji-132	327	22	.	.	PUNCT
aji-132	328	1	treatment	treatment	NOUN
aji-132	328	2	goals	goal	NOUN
aji-132	328	3	include	include	VERB
aji-132	328	4	achieving	achieve	VERB
aji-132	328	5	remission	remission	NOUN
aji-132	328	6	or	or	CCONJ
aji-132	328	7	low	low	ADJ
aji-132	328	8	disease	disease	NOUN
aji-132	328	9	activity	activity	NOUN
aji-132	328	10	to	to	PART
aji-132	328	11	prevent	prevent	VERB
aji-132	328	12	further	further	ADJ
aji-132	328	13	joint	joint	ADJ
aji-132	328	14	damage	damage	NOUN
aji-132	328	15	.	.	PUNCT
aji-132	329	1	iguratimod	iguratimod	PROPN
aji-132	329	2	exerts	exert	VERB
aji-132	329	3	its	its	PRON
aji-132	329	4	anti	anti	ADJ
aji-132	329	5	-	-	ADJ
aji-132	329	6	inflammatory	inflammatory	ADJ
aji-132	329	7	effects	effect	NOUN
aji-132	329	8	by	by	ADP
aji-132	329	9	inhibiting	inhibit	VERB
aji-132	329	10	nf	nf	ADJ
aji-132	329	11	-	-	PUNCT
aji-132	329	12	κb	κb	NOUN
aji-132	329	13	activation	activation	NOUN
aji-132	329	14	,	,	PUNCT
aji-132	329	15	cytokine	cytokine	ADJ
aji-132	329	16	production	production	NOUN
aji-132	329	17	,	,	PUNCT
aji-132	329	18	and	and	CCONJ
aji-132	329	19	cox-2	cox-2	VERB
aji-132	329	20	activity	activity	NOUN
aji-132	329	21	.	.	PUNCT
aji-132	330	1	it	it	PRON
aji-132	330	2	regulates	regulate	VERB
aji-132	330	3	humoral	humoral	ADJ
aji-132	330	4	immunity	immunity	NOUN
aji-132	330	5	by	by	ADP
aji-132	330	6	inhibiting	inhibit	VERB
aji-132	330	7	immunoglobulin	immunoglobulin	NOUN
aji-132	330	8	synthesis	synthesis	NOUN
aji-132	330	9	and	and	CCONJ
aji-132	330	10	b	b	NOUN
aji-132	330	11	cell	cell	NOUN
aji-132	330	12	differentiation	differentiation	NOUN
aji-132	330	13	.	.	PUNCT
aji-132	331	1	iguratimod	iguratimod	PROPN
aji-132	331	2	's	's	PART
aji-132	331	3	osteoprotective	osteoprotective	ADJ
aji-132	331	4	mechanism	mechanism	NOUN
aji-132	331	5	involves	involve	VERB
aji-132	331	6	enhancing	enhance	VERB
aji-132	331	7	osteoblast	osteoblast	ADJ
aji-132	331	8	differentiation	differentiation	NOUN
aji-132	331	9	and	and	CCONJ
aji-132	331	10	inhibiting	inhibit	VERB
aji-132	331	11	osteoclast	osteoclast	ADJ
aji-132	331	12	formation	formation	NOUN
aji-132	331	13	and	and	CCONJ
aji-132	331	14	activity.clinical	activity.clinical	ADJ
aji-132	331	15	trials	trial	NOUN
aji-132	331	16	have	have	AUX
aji-132	331	17	demonstrated	demonstrate	VERB
aji-132	331	18	the	the	DET
aji-132	331	19	efficacy	efficacy	NOUN
aji-132	331	20	and	and	CCONJ
aji-132	331	21	safety	safety	NOUN
aji-132	331	22	of	of	ADP
aji-132	331	23	iguratimod	iguratimod	NOUN
aji-132	331	24	in	in	ADP
aji-132	331	25	ra	ra	PROPN
aji-132	331	26	treatment	treatment	NOUN
aji-132	331	27	,	,	PUNCT
aji-132	331	28	both	both	CCONJ
aji-132	331	29	as	as	ADP
aji-132	331	30	monotherapy	monotherapy	NOUN
aji-132	331	31	and	and	CCONJ
aji-132	331	32	in	in	ADP
aji-132	331	33	combination	combination	NOUN
aji-132	331	34	with	with	ADP
aji-132	331	35	other	other	ADJ
aji-132	331	36	dmards	dmard	NOUN
aji-132	331	37	.	.	PUNCT
aji-132	332	1	combining	combine	VERB
aji-132	332	2	iguratimod	iguratimod	NOUN
aji-132	332	3	with	with	ADP
aji-132	332	4	methotrexate	methotrexate	NOUN
aji-132	332	5	or	or	CCONJ
aji-132	332	6	other	other	ADJ
aji-132	332	7	dmards	dmard	NOUN
aji-132	332	8	has	have	AUX
aji-132	332	9	shown	show	VERB
aji-132	332	10	superior	superior	ADJ
aji-132	332	11	efficacy	efficacy	NOUN
aji-132	332	12	compared	compare	VERB
aji-132	332	13	to	to	ADP
aji-132	332	14	monotherapy	monotherapy	NOUN
aji-132	332	15	.	.	PUNCT
aji-132	333	1	iguratimod	iguratimod	PROPN
aji-132	333	2	has	have	AUX
aji-132	333	3	shown	show	VERB
aji-132	333	4	promise	promise	NOUN
aji-132	333	5	in	in	ADP
aji-132	333	6	patients	patient	NOUN
aji-132	333	7	with	with	ADP
aji-132	333	8	inadequate	inadequate	ADJ
aji-132	333	9	responses	response	NOUN
aji-132	333	10	to	to	ADP
aji-132	333	11	traditional	traditional	ADJ
aji-132	333	12	dmards	dmard	NOUN
aji-132	333	13	or	or	CCONJ
aji-132	333	14	biological	biological	ADJ
aji-132	333	15	agents.phased	agents.phase	VERB
aji-132	333	16	treatment	treatment	NOUN
aji-132	333	17	with	with	ADP
aji-132	333	18	iguratimod	iguratimod	PROPN
aji-132	333	19	,	,	PUNCT
aji-132	333	20	methylprednisolone	methylprednisolone	NOUN
aji-132	333	21	,	,	PUNCT
aji-132	333	22	and	and	CCONJ
aji-132	333	23	methotrexate	methotrexate	NOUN
aji-132	333	24	has	have	AUX
aji-132	333	25	been	be	AUX
aji-132	333	26	effective	effective	ADJ
aji-132	333	27	in	in	ADP
aji-132	333	28	ra	ra	PROPN
aji-132	333	29	patients	patient	NOUN
aji-132	333	30	with	with	ADP
aji-132	333	31	leukopenia	leukopenia	PROPN
aji-132	333	32	.	.	PUNCT
aji-132	334	1	iguratimod	iguratimod	PROPN
aji-132	334	2	is	be	AUX
aji-132	334	3	a	a	DET
aji-132	334	4	valuable	valuable	ADJ
aji-132	334	5	treatment	treatment	NOUN
aji-132	334	6	option	option	NOUN
aji-132	334	7	for	for	ADP
aji-132	334	8	ra	ra	PROPN
aji-132	334	9	,	,	PUNCT
aji-132	334	10	offering	offer	VERB
aji-132	334	11	early	early	ADJ
aji-132	334	12	and	and	CCONJ
aji-132	334	13	sustained	sustain	VERB
aji-132	334	14	efficacy	efficacy	NOUN
aji-132	334	15	with	with	ADP
aji-132	334	16	a	a	DET
aji-132	334	17	manageable	manageable	ADJ
aji-132	334	18	safety	safety	NOUN
aji-132	334	19	profile	profile	NOUN
aji-132	334	20	.	.	PUNCT
aji-132	335	1	its	its	PRON
aji-132	335	2	mechanism	mechanism	NOUN
aji-132	335	3	of	of	ADP
aji-132	335	4	action	action	NOUN
aji-132	335	5	,	,	PUNCT
aji-132	335	6	including	include	VERB
aji-132	335	7	antiinflammatory	antiinflammatory	NOUN
aji-132	335	8	,	,	PUNCT
aji-132	335	9	immunomodulatory	immunomodulatory	ADJ
aji-132	335	10	,	,	PUNCT
aji-132	335	11	and	and	CCONJ
aji-132	335	12	osteoprotective	osteoprotective	ADJ
aji-132	335	13	effects	effect	NOUN
aji-132	335	14	,	,	PUNCT
aji-132	335	15	makes	make	VERB
aji-132	335	16	it	it	PRON
aji-132	335	17	a	a	DET
aji-132	335	18	promising	promising	ADJ
aji-132	335	19	candidate	candidate	NOUN
aji-132	335	20	for	for	ADP
aji-132	335	21	ra	ra	PROPN
aji-132	335	22	therapy	therapy	NOUN
aji-132	335	23	.	.	PUNCT
aji-132	336	1	competing	compete	VERB
aji-132	336	2	interests	interest	NOUN
aji-132	336	3	authors	author	NOUN
aji-132	336	4	have	have	AUX
aji-132	336	5	declared	declare	VERB
aji-132	336	6	that	that	SCONJ
aji-132	336	7	no	no	DET
aji-132	336	8	competing	compete	VERB
aji-132	336	9	interests	interest	NOUN
aji-132	336	10	exist	exist	VERB
aji-132	336	11	.	.	PUNCT
aji-132	337	1	references	reference	NOUN
aji-132	337	2	1	1	NUM
aji-132	337	3	.	.	PUNCT
aji-132	338	1	lee	lee	PROPN
aji-132	338	2	dm	dm	PROPN
aji-132	338	3	,	,	PUNCT
aji-132	338	4	weinblatt	weinblatt	PROPN
aji-132	338	5	me	i	PRON
aji-132	338	6	.	.	PUNCT
aji-132	339	1	rheumatoid	rheumatoid	VERB
aji-132	339	2	arthritis	arthritis	NOUN
aji-132	339	3	.	.	PUNCT
aji-132	340	1	lancet	lancet	NOUN
aji-132	340	2	.	.	PUNCT
aji-132	341	1	2001;358:903	2001;358:903	NUM
aji-132	341	2	-	-	PUNCT
aji-132	341	3	11	11	NUM
aji-132	341	4	.	.	NOUN
aji-132	342	1	2	2	X
aji-132	342	2	.	.	X
aji-132	342	3	american	american	PROPN
aji-132	342	4	college	college	PROPN
aji-132	342	5	of	of	ADP
aji-132	342	6	rheumatology	rheumatology	NOUN
aji-132	342	7	subcommittee	subcommittee	NOUN
aji-132	342	8	on	on	ADP
aji-132	342	9	rheumatoid	rheumatoid	VERB
aji-132	342	10	arthritis	arthritis	NOUN
aji-132	342	11	guidelines	guideline	NOUN
aji-132	342	12	.	.	PUNCT
aji-132	343	1	guidelines	guideline	NOUN
aji-132	343	2	for	for	ADP
aji-132	343	3	the	the	DET
aji-132	343	4	management	management	NOUN
aji-132	343	5	of	of	ADP
aji-132	343	6	rheumatoid	rheumatoid	NOUN
aji-132	343	7	arthritis	arthritis	NOUN
aji-132	343	8	:	:	PUNCT
aji-132	343	9	update	update	NOUN
aji-132	343	10	.	.	PUNCT
aji-132	344	1	arthritis	arthritis	NOUN
aji-132	344	2	rheum	rheum	NOUN
aji-132	344	3	.	.	PUNCT
aji-132	345	1	2002;46	2002;46	NUM
aji-132	345	2	:	:	PUNCT
aji-132	345	3	328	328	NUM
aji-132	345	4	-	-	SYM
aji-132	345	5	46	46	NUM
aji-132	345	6	3	3	NUM
aji-132	345	7	.	.	PUNCT
aji-132	346	1	aikawa	aikawa	PROPN
aji-132	346	2	y	y	PROPN
aji-132	346	3	,	,	PUNCT
aji-132	346	4	yamamoto	yamamoto	PROPN
aji-132	346	5	m	m	PROPN
aji-132	346	6	,	,	PUNCT
aji-132	346	7	yamamoto	yamamoto	PROPN
aji-132	346	8	t	t	PROPN
aji-132	346	9	,	,	PUNCT
aji-132	346	10	morimoto	morimoto	PROPN
aji-132	346	11	k	k	PROPN
aji-132	346	12	,	,	PUNCT
aji-132	346	13	tanaka	tanaka	PROPN
aji-132	346	14	k.	k.	PROPN
aji-132	347	1	an	an	DET
aji-132	347	2	anti	anti	ADJ
aji-132	347	3	-	-	ADJ
aji-132	347	4	rheumatic	rheumatic	ADJ
aji-132	347	5	agent	agent	NOUN
aji-132	347	6	t-614	t-614	PUNCT
aji-132	347	7	inhibits	inhibit	VERB
aji-132	347	8	nf	nf	ADJ
aji-132	347	9	-	-	PUNCT
aji-132	347	10	kappab	kappab	NOUN
aji-132	347	11	activation	activation	NOUN
aji-132	347	12	in	in	ADP
aji-132	347	13	lpsand	lpsand	ADP
aji-132	347	14	tnf	tnf	PROPN
aji-132	347	15	-	-	PUNCT
aji-132	347	16	alpha	alpha	NOUN
aji-132	347	17	-	-	PUNCT
aji-132	347	18	stimulated	stimulate	VERB
aji-132	347	19	thp-1	thp-1	NOUN
aji-132	347	20	cells	cell	NOUN
aji-132	347	21	without	without	ADP
aji-132	347	22	interfering	interfere	VERB
aji-132	347	23	with	with	ADP
aji-132	347	24	ikappabalpha	ikappabalpha	NOUN
aji-132	347	25	degradation	degradation	NOUN
aji-132	347	26	.	.	PUNCT
aji-132	348	1	inflammation	inflammation	NOUN
aji-132	348	2	res	re	NOUN
aji-132	348	3	.	.	PUNCT
aji-132	349	1	2002;51(4):188–194	2002;51(4):188–194	X
aji-132	349	2	.	.	PUNCT
aji-132	349	3	doi:10.1007	doi:10.1007	PROPN
aji-132	349	4	/	/	SYM
aji-132	349	5	pl00000291	pl00000291	PROPN
aji-132	349	6	4	4	NUM
aji-132	349	7	.	.	PUNCT
aji-132	350	1	tanaka	tanaka	PROPN
aji-132	350	2	k	k	PROPN
aji-132	350	3	,	,	PUNCT
aji-132	350	4	yamamoto	yamamoto	PROPN
aji-132	350	5	t	t	PROPN
aji-132	350	6	,	,	PUNCT
aji-132	350	7	aikawa	aikawa	PROPN
aji-132	350	8	y	y	PROPN
aji-132	350	9	,	,	PUNCT
aji-132	350	10	kizawa	kizawa	PROPN
aji-132	350	11	k	k	PROPN
aji-132	350	12	,	,	PUNCT
aji-132	350	13	muramoto	muramoto	PROPN
aji-132	350	14	k	k	PROPN
aji-132	350	15	,	,	PUNCT
aji-132	350	16	matsuno	matsuno	PROPN
aji-132	350	17	h	h	PROPN
aji-132	350	18	,	,	PUNCT
aji-132	350	19	et	et	PROPN
aji-132	350	20	al	al	PROPN
aji-132	350	21	.	.	PUNCT
aji-132	351	1	inhibitory	inhibitory	ADJ
aji-132	351	2	effects	effect	NOUN
aji-132	351	3	of	of	ADP
aji-132	351	4	an	an	DET
aji-132	351	5	anti	anti	ADJ
aji-132	351	6	-	-	ADJ
aji-132	351	7	rheumatic	rheumatic	ADJ
aji-132	351	8	agent	agent	NOUN
aji-132	351	9	t-614	t-614	PUNCT
aji-132	351	10	on	on	ADP
aji-132	351	11	immunoglobulin	immunoglobulin	NOUN
aji-132	351	12	production	production	NOUN
aji-132	351	13	by	by	ADP
aji-132	351	14	cultured	cultured	ADJ
aji-132	351	15	b	b	PROPN
aji-132	351	16	cells	cell	NOUN
aji-132	351	17	and	and	CCONJ
aji-132	351	18	rheumatoid	rheumatoid	VERB
aji-132	351	19	synovial	synovial	ADJ
aji-132	351	20	tissues	tissue	NOUN
aji-132	351	21	gupta	gupta	PROPN
aji-132	351	22	et	et	PROPN
aji-132	351	23	al	al	PROPN
aji-132	351	24	.	.	PROPN
aji-132	351	25	;	;	PUNCT
aji-132	351	26	asian	asian	PROPN
aji-132	351	27	j.	j.	PROPN
aji-132	351	28	immunol	immunol	PROPN
aji-132	351	29	.	.	PROPN
aji-132	351	30	,	,	PUNCT
aji-132	351	31	vol	vol	NOUN
aji-132	351	32	.	.	PROPN
aji-132	351	33	7	7	NUM
aji-132	351	34	,	,	PUNCT
aji-132	351	35	no	no	INTJ
aji-132	351	36	.	.	NOUN
aji-132	351	37	1	1	NUM
aji-132	351	38	,	,	PUNCT
aji-132	351	39	pp	pp	ADJ
aji-132	351	40	.	.	PUNCT
aji-132	352	1	79	79	NUM
aji-132	352	2	-	-	SYM
aji-132	352	3	89	89	NUM
aji-132	352	4	,	,	PUNCT
aji-132	352	5	2024	2024	NUM
aji-132	352	6	;	;	PUNCT
aji-132	352	7	article	article	NOUN
aji-132	352	8	no.aji.115805	no.aji.115805	PROPN
aji-132	352	9	87	87	NUM
aji-132	352	10	engrafted	engraft	VERB
aji-132	352	11	into	into	ADP
aji-132	352	12	scid	scid	PROPN
aji-132	352	13	mice	mouse	NOUN
aji-132	352	14	.	.	PUNCT
aji-132	353	1	rheumatol	rheumatol	NOUN
aji-132	353	2	.	.	PUNCT
aji-132	354	1	(	(	PUNCT
aji-132	354	2	oxford	oxford	PROPN
aji-132	354	3	)	)	PUNCT
aji-132	354	4	.	.	PUNCT
aji-132	355	1	2003;42(11):1365–1371	2003;42(11):1365–1371	X
aji-132	355	2	.	.	PUNCT
aji-132	356	1	doi	doi	NOUN
aji-132	356	2	:	:	PUNCT
aji-132	356	3	10.1093	10.1093	NUM
aji-132	356	4	/	/	SYM
aji-132	356	5	rheumatology	rheumatology	NOUN
aji-132	356	6	/	/	SYM
aji-132	356	7	keg381	keg381	PROPN
aji-132	356	8	5	5	NUM
aji-132	356	9	.	.	PUNCT
aji-132	357	1	kohno	kohno	PROPN
aji-132	357	2	m	m	PROPN
aji-132	357	3	,	,	PUNCT
aji-132	357	4	aikawa	aikawa	PROPN
aji-132	357	5	y	y	PROPN
aji-132	357	6	,	,	PUNCT
aji-132	357	7	tsubouchi	tsubouchi	PROPN
aji-132	357	8	y	y	PROPN
aji-132	357	9	,	,	PUNCT
aji-132	357	10	hashiramoto	hashiramoto	PROPN
aji-132	357	11	a	a	NOUN
aji-132	357	12	,	,	PUNCT
aji-132	357	13	yamada	yamada	PROPN
aji-132	357	14	r	r	PROPN
aji-132	357	15	,	,	PUNCT
aji-132	357	16	kawahito	kawahito	PROPN
aji-132	357	17	y	y	PROPN
aji-132	357	18	,	,	PUNCT
aji-132	357	19	et	et	PROPN
aji-132	357	20	al	al	PROPN
aji-132	357	21	.	.	PROPN
aji-132	357	22	inhibitory	inhibitory	ADJ
aji-132	357	23	effect	effect	NOUN
aji-132	357	24	of	of	ADP
aji-132	357	25	t-614	t-614	NOUN
aji-132	357	26	on	on	ADP
aji-132	357	27	tumor	tumor	NOUN
aji-132	357	28	necrosis	necrosis	NOUN
aji-132	357	29	factor	factor	NOUN
aji-132	357	30	-	-	PUNCT
aji-132	357	31	alpha	alpha	NOUN
aji-132	357	32	induced	induce	VERB
aji-132	357	33	cytokine	cytokine	ADJ
aji-132	357	34	production	production	NOUN
aji-132	357	35	and	and	CCONJ
aji-132	357	36	nuclear	nuclear	ADJ
aji-132	357	37	factor	factor	NOUN
aji-132	357	38	-	-	PUNCT
aji-132	357	39	kappab	kappab	NOUN
aji-132	357	40	activation	activation	NOUN
aji-132	357	41	in	in	ADP
aji-132	357	42	cultured	cultured	ADJ
aji-132	357	43	human	human	ADJ
aji-132	357	44	synovial	synovial	ADJ
aji-132	357	45	cells	cell	NOUN
aji-132	357	46	.	.	PUNCT
aji-132	358	1	j.	j.	PROPN
aji-132	358	2	rheumatol	rheumatol	PROPN
aji-132	358	3	.	.	PUNCT
aji-132	359	1	2001;28(12):2591	2001;28(12):2591	X
aji-132	359	2	–	–	PUNCT
aji-132	359	3	2596	2596	NUM
aji-132	359	4	.	.	PUNCT
aji-132	360	1	6	6	NUM
aji-132	360	2	.	.	X
aji-132	360	3	jiang	jiang	PROPN
aji-132	360	4	y	y	PROPN
aji-132	360	5	,	,	PUNCT
aji-132	360	6	lü	lü	PROPN
aji-132	360	7	w	w	PROPN
aji-132	360	8	,	,	PUNCT
aji-132	360	9	yu	yu	PROPN
aji-132	360	10	s	s	PROPN
aji-132	360	11	,	,	PUNCT
aji-132	360	12	yao	yao	PROPN
aji-132	360	13	l	l	NOUN
aji-132	360	14	,	,	PUNCT
aji-132	360	15	xu	xu	PROPN
aji-132	360	16	g	g	PROPN
aji-132	360	17	,	,	PUNCT
aji-132	360	18	zhang	zhang	PROPN
aji-132	360	19	x.	x.	PROPN
aji-132	360	20	inhibitory	inhibitory	ADJ
aji-132	360	21	effect	effect	NOUN
aji-132	360	22	of	of	ADP
aji-132	360	23	iguratimod	iguratimod	NOUN
aji-132	360	24	on	on	ADP
aji-132	360	25	tnfalpha	tnfalpha	ADJ
aji-132	360	26	production	production	NOUN
aji-132	360	27	and	and	CCONJ
aji-132	360	28	nf	nf	ADJ
aji-132	360	29	-	-	PUNCT
aji-132	360	30	kappab	kappab	NOUN
aji-132	360	31	activity	activity	NOUN
aji-132	360	32	in	in	ADP
aji-132	360	33	lps	lps	PROPN
aji-132	360	34	-	-	PUNCT
aji-132	360	35	stimulated	stimulated	ADJ
aji-132	360	36	rat	rat	NOUN
aji-132	360	37	alveolar	alveolar	ADJ
aji-132	360	38	macrophage	macrophage	ADJ
aji-132	360	39	cell	cell	NOUN
aji-132	360	40	line	line	NOUN
aji-132	360	41	.	.	PUNCT
aji-132	361	1	yao	yao	PROPN
aji-132	361	2	xue	xue	PROPN
aji-132	361	3	xue	xue	PROPN
aji-132	361	4	bao	bao	PROPN
aji-132	361	5	.	.	PUNCT
aji-132	362	1	2006;41(5):401–405	2006;41(5):401–405	X
aji-132	362	2	.	.	NOUN
aji-132	362	3	7	7	X
aji-132	362	4	.	.	X
aji-132	362	5	gan	gan	PROPN
aji-132	362	6	k	k	PROPN
aji-132	362	7	,	,	PUNCT
aji-132	362	8	yang	yang	PROPN
aji-132	362	9	l	l	PROPN
aji-132	362	10	,	,	PUNCT
aji-132	362	11	xu	xu	PROPN
aji-132	362	12	l	l	PROPN
aji-132	362	13	,	,	PUNCT
aji-132	362	14	feng	feng	PROPN
aji-132	362	15	x	x	PROPN
aji-132	362	16	,	,	PUNCT
aji-132	362	17	zhang	zhang	PROPN
aji-132	362	18	q	q	PROPN
aji-132	362	19	,	,	PUNCT
aji-132	362	20	wang	wang	PROPN
aji-132	362	21	f	f	PROPN
aji-132	362	22	,	,	PUNCT
aji-132	362	23	et	et	PROPN
aji-132	362	24	al	al	PROPN
aji-132	362	25	.	.	PROPN
aji-132	362	26	iguratimod	iguratimod	PROPN
aji-132	362	27	(	(	PUNCT
aji-132	362	28	t-614	t-614	NOUN
aji-132	362	29	)	)	PUNCT
aji-132	362	30	suppresses	suppress	VERB
aji-132	362	31	rankl	rankl	VERB
aji-132	362	32	-	-	PUNCT
aji-132	362	33	induced	induce	VERB
aji-132	362	34	osteoclast	osteoclast	ADJ
aji-132	362	35	differentiation	differentiation	NOUN
aji-132	362	36	and	and	CCONJ
aji-132	362	37	migration	migration	NOUN
aji-132	362	38	in	in	ADP
aji-132	362	39	raw264.7	raw264.7	PROPN
aji-132	362	40	cells	cell	NOUN
aji-132	362	41	via	via	ADP
aji-132	362	42	nf	nf	NOUN
aji-132	362	43	-	-	PUNCT
aji-132	362	44	κb	κb	NOUN
aji-132	362	45	and	and	CCONJ
aji-132	362	46	mapk	mapk	NOUN
aji-132	362	47	pathways	pathway	NOUN
aji-132	362	48	.	.	PUNCT
aji-132	363	1	int	int	NOUN
aji-132	363	2	immunopharmacol	immunopharmacol	PROPN
aji-132	363	3	.	.	PUNCT
aji-132	364	1	2016;35:294–300	2016;35:294–300	PROPN
aji-132	364	2	.	.	PUNCT
aji-132	364	3	doi:10.1016	doi:10.1016	PROPN
aji-132	364	4	/	/	SYM
aji-132	364	5	j.intimp.2016.03.038	j.intimp.2016.03.038	PROPN
aji-132	364	6	8	8	NUM
aji-132	364	7	.	.	PUNCT
aji-132	365	1	tanaka	tanaka	PROPN
aji-132	365	2	k	k	PROPN
aji-132	365	3	,	,	PUNCT
aji-132	365	4	shimotori	shimotori	PROPN
aji-132	365	5	t	t	PROPN
aji-132	365	6	,	,	PUNCT
aji-132	365	7	makino	makino	PROPN
aji-132	365	8	s	s	PROPN
aji-132	365	9	,	,	PUNCT
aji-132	365	10	aikawa	aikawa	PROPN
aji-132	365	11	y	y	PROPN
aji-132	365	12	,	,	PUNCT
aji-132	365	13	inaba	inaba	PROPN
aji-132	365	14	t	t	PROPN
aji-132	365	15	,	,	PUNCT
aji-132	365	16	yoshida	yoshida	PROPN
aji-132	365	17	c.	c.	PROPN
aji-132	365	18	pharmacological	pharmacological	PROPN
aji-132	365	19	studies	study	NOUN
aji-132	365	20	of	of	ADP
aji-132	365	21	the	the	DET
aji-132	365	22	new	new	ADJ
aji-132	365	23	antiinflammatory	antiinflammatory	NOUN
aji-132	365	24	agent	agent	NOUN
aji-132	365	25	3formylamino-7	3formylamino-7	NUM
aji-132	365	26	-	-	PUNCT
aji-132	365	27	methylsulfonylamino-6phenoxy-4h-1	methylsulfonylamino-6phenoxy-4h-1	NOUN
aji-132	365	28	-	-	PUNCT
aji-132	365	29	benzopyran-4	benzopyran-4	NOUN
aji-132	365	30	-	-	PUNCT
aji-132	365	31	o	o	NOUN
aji-132	365	32	ne	ne	PROPN
aji-132	365	33	.	.	PUNCT
aji-132	366	1	1st	1st	ADJ
aji-132	366	2	communication	communication	NOUN
aji-132	366	3	:	:	PUNCT
aji-132	367	1	antiinflammatory	antiinflammatory	NOUN
aji-132	367	2	,	,	PUNCT
aji-132	367	3	analgesic	analgesic	ADJ
aji-132	367	4	and	and	CCONJ
aji-132	367	5	other	other	ADJ
aji-132	367	6	related	related	ADJ
aji-132	367	7	properties	property	NOUN
aji-132	367	8	.	.	PUNCT
aji-132	368	1	arzncim.-forsch./drug	arzncim.-forsch./drug	NOUN
aji-132	368	2	rcs	rcs	PROPN
aji-132	368	3	.	.	PUNCT
aji-132	369	1	1992;42(7):935–44	1992;42(7):935–44	NUM
aji-132	369	2	.	.	NOUN
aji-132	369	3	9	9	NUM
aji-132	369	4	.	.	PUNCT
aji-132	370	1	tanaka	tanaka	PROPN
aji-132	370	2	k	k	PROPN
aji-132	370	3	,	,	PUNCT
aji-132	370	4	makino	makino	PROPN
aji-132	370	5	s	s	PROPN
aji-132	370	6	,	,	PUNCT
aji-132	370	7	shimotori	shimotori	PROPN
aji-132	370	8	t	t	PROPN
aji-132	370	9	,	,	PUNCT
aji-132	370	10	aikawa	aikawa	PROPN
aji-132	370	11	y	y	PROPN
aji-132	370	12	,	,	PUNCT
aji-132	370	13	inaba	inaba	PROPN
aji-132	370	14	t	t	PROPN
aji-132	370	15	,	,	PUNCT
aji-132	370	16	yoshida	yoshida	PROPN
aji-132	370	17	c.	c.	PROPN
aji-132	370	18	pharmacological	pharmacological	PROPN
aji-132	370	19	studies	study	NOUN
aji-132	370	20	of	of	ADP
aji-132	370	21	the	the	DET
aji-132	370	22	new	new	ADJ
aji-132	370	23	antiinflammatory	antiinflammatory	NOUN
aji-132	370	24	agent	agent	NOUN
aji-132	370	25	3formylamino-7	3formylamino-7	NUM
aji-132	370	26	-	-	PUNCT
aji-132	370	27	methylsulfonylamino-6phenoxy-4'-1	methylsulfonylamino-6phenoxy-4'-1	PRON
aji-132	370	28	-	-	PUNCT
aji-132	370	29	benzopyran-4	benzopyran-4	NOUN
aji-132	370	30	-	-	PUNCT
aji-132	370	31	o	o	NOUN
aji-132	370	32	ne	ne	PROPN
aji-132	370	33	.	.	PUNCT
aji-132	371	1	2nd	2nd	ADJ
aji-132	371	2	communication	communication	NOUN
aji-132	371	3	:	:	PUNCT
aji-132	371	4	effect	effect	NOUN
aji-132	371	5	on	on	ADP
aji-132	371	6	the	the	DET
aji-132	371	7	arachidonic	arachidonic	ADJ
aji-132	371	8	acid	acid	NOUN
aji-132	371	9	cascades	cascade	NOUN
aji-132	371	10	.	.	PUNCT
aji-132	372	1	arzncim.-forsch./drug	arzncim.-forsch./drug	NOUN
aji-132	372	2	rcs	rcs	PROPN
aji-132	372	3	.	.	PUNCT
aji-132	373	1	1992;42(7):945–50.google	1992;42(7):945–50.google	PROPN
aji-132	373	2	scholar	scholar	NOUN
aji-132	373	3	10	10	NUM
aji-132	373	4	.	.	PUNCT
aji-132	374	1	tanaka	tanaka	PROPN
aji-132	374	2	k	k	PROPN
aji-132	374	3	,	,	PUNCT
aji-132	374	4	shimotori	shimotori	PROPN
aji-132	374	5	t	t	PROPN
aji-132	374	6	,	,	PUNCT
aji-132	374	7	makino	makino	PROPN
aji-132	374	8	s	s	PROPN
aji-132	374	9	,	,	PUNCT
aji-132	374	10	eguchi	eguchi	NOUN
aji-132	374	11	m	m	PROPN
aji-132	374	12	,	,	PUNCT
aji-132	374	13	asaoka	asaoka	PROPN
aji-132	374	14	k	k	PROPN
aji-132	374	15	,	,	PUNCT
aji-132	374	16	kitamura	kitamura	PROPN
aji-132	374	17	r	r	PROPN
aji-132	374	18	,	,	PUNCT
aji-132	374	19	et	et	PROPN
aji-132	374	20	al	al	PROPN
aji-132	374	21	.	.	PROPN
aji-132	374	22	pharmacological	pharmacological	ADJ
aji-132	374	23	studies	study	NOUN
aji-132	374	24	on	on	ADP
aji-132	374	25	3formylamino-7	3formylamino-7	NUM
aji-132	374	26	-	-	PUNCT
aji-132	374	27	methylsulfonylamino6phenoxy-4h-1	methylsulfonylamino6phenoxy-4h-1	NOUN
aji-132	374	28	-	-	PUNCT
aji-132	374	29	benzopyran-4	benzopyran-4	NOUN
aji-132	374	30	-	-	PUNCT
aji-132	374	31	one	one	NUM
aji-132	374	32	(	(	PUNCT
aji-132	374	33	t-614	t-614	NOUN
aji-132	374	34	)	)	PUNCT
aji-132	374	35	,	,	PUNCT
aji-132	374	36	a	a	DET
aji-132	374	37	novel	novel	ADJ
aji-132	374	38	antiinflammatory	antiinflammatory	NOUN
aji-132	374	39	agent	agent	NOUN
aji-132	374	40	.	.	PUNCT
aji-132	375	1	3rd	3rd	ADJ
aji-132	375	2	communication	communication	NOUN
aji-132	375	3	:	:	PUNCT
aji-132	375	4	the	the	DET
aji-132	375	5	involvement	involvement	NOUN
aji-132	375	6	of	of	ADP
aji-132	375	7	bradykinin	bradykinin	PROPN
aji-132	375	8	in	in	ADP
aji-132	375	9	its	its	PRON
aji-132	375	10	analgesic	analgesic	ADJ
aji-132	375	11	actions	action	NOUN
aji-132	375	12	.	.	PUNCT
aji-132	376	1	j	j	PROPN
aji-132	376	2	pharmacobio	pharmacobio	NOUN
aji-132	376	3	-	-	PUNCT
aji-132	376	4	dyn	dyn	NOUN
aji-132	376	5	.	.	PUNCT
aji-132	377	1	1992;15(11):641–7	1992;15(11):641–7	NUM
aji-132	377	2	.	.	PUNCT
aji-132	378	1	doi	doi	NOUN
aji-132	378	2	:	:	PUNCT
aji-132	378	3	10.1248	10.1248	NUM
aji-132	378	4	/	/	SYM
aji-132	378	5	bpb1978.15.641	bpb1978.15.641	X
aji-132	378	6	11	11	NUM
aji-132	378	7	.	.	PUNCT
aji-132	379	1	tanaka	tanaka	PROPN
aji-132	379	2	k	k	PROPN
aji-132	379	3	,	,	PUNCT
aji-132	379	4	aikawa	aikawa	PROPN
aji-132	379	5	y	y	PROPN
aji-132	379	6	,	,	PUNCT
aji-132	379	7	kawasaki	kawasaki	PROPN
aji-132	379	8	h	h	PROPN
aji-132	379	9	,	,	PUNCT
aji-132	379	10	asaoka	asaoka	PROPN
aji-132	379	11	k	k	PROPN
aji-132	379	12	,	,	PUNCT
aji-132	379	13	inaba	inaba	PROPN
aji-132	379	14	t	t	PROPN
aji-132	379	15	,	,	PUNCT
aji-132	379	16	yoshida	yoshida	PROPN
aji-132	379	17	c.	c.	PROPN
aji-132	379	18	pharmacological	pharmacological	PROPN
aji-132	379	19	studies	study	NOUN
aji-132	379	20	on	on	ADP
aji-132	379	21	3	3	NUM
aji-132	379	22	-	-	PUNCT
aji-132	379	23	formylamino-7methylsulfonylamino6	formylamino-7methylsulfonylamino6	NOUN
aji-132	379	24	-	-	PUNCT
aji-132	379	25	phenoxy-4h-1benzopyran-4	phenoxy-4h-1benzopyran-4	NOUN
aji-132	379	26	-	-	NOUN
aji-132	379	27	one	one	NUM
aji-132	379	28	(	(	PUNCT
aji-132	379	29	t-614	t-614	NOUN
aji-132	379	30	)	)	PUNCT
aji-132	379	31	,	,	PUNCT
aji-132	379	32	a	a	DET
aji-132	379	33	novel	novel	ADJ
aji-132	379	34	antiinflammatory	antiinflammatory	NOUN
aji-132	379	35	agent	agent	NOUN
aji-132	379	36	.	.	PUNCT
aji-132	380	1	4th	4th	ADJ
aji-132	380	2	communication	communication	NOUN
aji-132	380	3	:	:	PUNCT
aji-132	380	4	inhibitory	inhibitory	ADJ
aji-132	380	5	effect	effect	NOUN
aji-132	380	6	on	on	ADP
aji-132	380	7	the	the	DET
aji-132	380	8	production	production	NOUN
aji-132	380	9	of	of	ADP
aji-132	380	10	interleukin-1	interleukin-1	NUM
aji-132	380	11	and	and	CCONJ
aji-132	380	12	interleukin6	interleukin6	PROPN
aji-132	380	13	.	.	PUNCT
aji-132	381	1	j	j	PROPN
aji-132	381	2	pharmacobio	pharmacobio	NOUN
aji-132	381	3	-	-	PUNCT
aji-132	381	4	dyn	dyn	NOUN
aji-132	381	5	.	.	PUNCT
aji-132	382	1	1992;15(11):649	1992;15(11):649	NUM
aji-132	382	2	–	–	PUNCT
aji-132	382	3	55	55	NUM
aji-132	382	4	.	.	PUNCT
aji-132	383	1	doi	doi	NOUN
aji-132	383	2	:	:	PUNCT
aji-132	383	3	10.1248	10.1248	NUM
aji-132	383	4	/	/	SYM
aji-132	383	5	bpb1978.15.649	bpb1978.15.649	NUM
aji-132	383	6	12	12	NUM
aji-132	383	7	.	.	PUNCT
aji-132	384	1	tanaka	tanaka	PROPN
aji-132	384	2	k	k	PROPN
aji-132	384	3	,	,	PUNCT
aji-132	384	4	kawasaki	kawasaki	PROPN
aji-132	384	5	h	h	PROPN
aji-132	384	6	,	,	PUNCT
aji-132	384	7	kurata	kurata	PROPN
aji-132	384	8	k	k	PROPN
aji-132	384	9	,	,	PUNCT
aji-132	384	10	aikawa	aikawa	PROPN
aji-132	384	11	y	y	PROPN
aji-132	384	12	,	,	PUNCT
aji-132	384	13	tsukamoto	tsukamoto	PROPN
aji-132	384	14	y	y	PROPN
aji-132	384	15	,	,	PUNCT
aji-132	384	16	inaba	inaba	PROPN
aji-132	384	17	t.	t.	PROPN
aji-132	384	18	t-614	t-614	PROPN
aji-132	384	19	,	,	PUNCT
aji-132	384	20	a	a	DET
aji-132	384	21	novel	novel	ADJ
aji-132	384	22	antirheumatic	antirheumatic	ADJ
aji-132	384	23	drug	drug	NOUN
aji-132	384	24	,	,	PUNCT
aji-132	384	25	inhibits	inhibit	VERB
aji-132	384	26	both	both	CCONJ
aji-132	384	27	the	the	DET
aji-132	384	28	activity	activity	NOUN
aji-132	384	29	and	and	CCONJ
aji-132	384	30	induction	induction	NOUN
aji-132	384	31	of	of	ADP
aji-132	384	32	cyclooxygenase-2	cyclooxygenase-2	NUM
aji-132	384	33	(	(	PUNCT
aji-132	384	34	cox-2	cox-2	NOUN
aji-132	384	35	)	)	PUNCT
aji-132	384	36	in	in	ADP
aji-132	384	37	cultured	cultured	ADJ
aji-132	384	38	fibroblasts	fibroblast	NOUN
aji-132	384	39	.	.	PUNCT
aji-132	385	1	jpn	jpn	PROPN
aji-132	385	2	j	j	PROPN
aji-132	385	3	pharmacol	pharmacol	PROPN
aji-132	385	4	.	.	PUNCT
aji-132	386	1	1995;67(4):305–14	1995;67(4):305–14	X
aji-132	386	2	.	.	PUNCT
aji-132	386	3	doi	doi	NOUN
aji-132	386	4	:	:	PUNCT
aji-132	386	5	10.1254	10.1254	NUM
aji-132	386	6	/	/	SYM
aji-132	386	7	jjp.67.305.59	jjp.67.305.59	PROPN
aji-132	386	8	13	13	NUM
aji-132	386	9	.	.	PUNCT
aji-132	387	1	tanaka	tanaka	PROPN
aji-132	387	2	k	k	PROPN
aji-132	387	3	,	,	PUNCT
aji-132	387	4	yamamoto	yamamoto	PROPN
aji-132	387	5	t	t	PROPN
aji-132	387	6	,	,	PUNCT
aji-132	387	7	aikawa	aikawa	PROPN
aji-132	387	8	y	y	PROPN
aji-132	387	9	,	,	PUNCT
aji-132	387	10	kizawa	kizawa	PROPN
aji-132	387	11	k	k	PROPN
aji-132	387	12	,	,	PUNCT
aji-132	387	13	muramoto	muramoto	PROPN
aji-132	387	14	k	k	PROPN
aji-132	387	15	,	,	PUNCT
aji-132	387	16	matsuno	matsuno	PROPN
aji-132	387	17	h	h	PROPN
aji-132	387	18	,	,	PUNCT
aji-132	387	19	et	et	PROPN
aji-132	387	20	al	al	PROPN
aji-132	387	21	.	.	PUNCT
aji-132	388	1	inhibitory	inhibitory	ADJ
aji-132	388	2	effects	effect	NOUN
aji-132	388	3	of	of	ADP
aji-132	388	4	an	an	DET
aji-132	388	5	anti	anti	ADJ
aji-132	388	6	-	-	ADJ
aji-132	388	7	rheumatic	rheumatic	ADJ
aji-132	388	8	agent	agent	NOUN
aji-132	388	9	t-614	t-614	PUNCT
aji-132	388	10	on	on	ADP
aji-132	388	11	immunoglobulin	immunoglobulin	NOUN
aji-132	388	12	production	production	NOUN
aji-132	388	13	by	by	ADP
aji-132	388	14	cultured	cultured	ADJ
aji-132	388	15	b	b	PROPN
aji-132	388	16	cells	cell	NOUN
aji-132	388	17	and	and	CCONJ
aji-132	388	18	rheumatoid	rheumatoid	VERB
aji-132	388	19	synovial	synovial	ADJ
aji-132	388	20	tissues	tissue	NOUN
aji-132	388	21	engrafted	engraft	VERB
aji-132	388	22	into	into	ADP
aji-132	388	23	scid	scid	PROPN
aji-132	388	24	mice	mouse	NOUN
aji-132	388	25	.	.	PUNCT
aji-132	389	1	rheumatol	rheumatol	NOUN
aji-132	389	2	(	(	PUNCT
aji-132	389	3	oxford	oxford	PROPN
aji-132	389	4	)	)	PUNCT
aji-132	389	5	.	.	PUNCT
aji-132	390	1	2003;42(11):1365–71	2003;42(11):1365–71	NUM
aji-132	390	2	.	.	PUNCT
aji-132	391	1	doi	doi	NOUN
aji-132	391	2	:	:	PUNCT
aji-132	391	3	10.1093	10.1093	NUM
aji-132	391	4	/	/	SYM
aji-132	391	5	rheumatology	rheumatology	NOUN
aji-132	391	6	/	/	SYM
aji-132	391	7	keg381	keg381	PROPN
aji-132	391	8	14	14	NUM
aji-132	391	9	.	.	PUNCT
aji-132	392	1	morimoto	morimoto	PROPN
aji-132	392	2	k	k	PROPN
aji-132	392	3	,	,	PUNCT
aji-132	392	4	miura	miura	PROPN
aji-132	392	5	a	a	PROPN
aji-132	392	6	,	,	PUNCT
aji-132	392	7	tanaka	tanaka	PROPN
aji-132	392	8	k.	k.	PROPN
aji-132	392	9	antiallodynic	antiallodynic	ADJ
aji-132	392	10	action	action	NOUN
aji-132	392	11	of	of	ADP
aji-132	392	12	the	the	DET
aji-132	392	13	disease	disease	NOUN
aji-132	392	14	-	-	PUNCT
aji-132	392	15	modifying	modify	VERB
aji-132	392	16	anti	anti	ADJ
aji-132	392	17	-	-	ADJ
aji-132	392	18	rheumatic	rheumatic	ADJ
aji-132	392	19	drug	drug	NOUN
aji-132	392	20	iguratimod	iguratimod	NOUN
aji-132	392	21	in	in	ADP
aji-132	392	22	a	a	DET
aji-132	392	23	rat	rat	NOUN
aji-132	392	24	model	model	NOUN
aji-132	392	25	of	of	ADP
aji-132	392	26	neuropathic	neuropathic	ADJ
aji-132	392	27	pain	pain	NOUN
aji-132	392	28	.	.	PUNCT
aji-132	393	1	inflamm	inflamm	PROPN
aji-132	393	2	res	re	NOUN
aji-132	393	3	.	.	PUNCT
aji-132	394	1	2017;66(10):855–62	2017;66(10):855–62	NUM
aji-132	394	2	.	.	PUNCT
aji-132	395	1	doi	doi	NOUN
aji-132	395	2	:	:	PUNCT
aji-132	395	3	10.1007	10.1007	NUM
aji-132	395	4	/	/	SYM
aji-132	395	5	s00011	s00011	NUM
aji-132	395	6	-	-	PUNCT
aji-132	395	7	017	017	NUM
aji-132	395	8	-	-	PUNCT
aji-132	395	9	1064	1064	NUM
aji-132	395	10	-	-	SYM
aji-132	395	11	0	0	NUM
aji-132	395	12	15	15	NUM
aji-132	395	13	.	.	PUNCT
aji-132	396	1	jiang	jiang	PROPN
aji-132	396	2	xp	xp	PROPN
aji-132	396	3	,	,	PUNCT
aji-132	396	4	huang	huang	PROPN
aji-132	396	5	xl	xl	PROPN
aji-132	396	6	,	,	PUNCT
aji-132	396	7	yang	yang	PROPN
aji-132	396	8	zp	zp	PROPN
aji-132	396	9	,	,	PUNCT
aji-132	396	10	wang	wang	PROPN
aji-132	396	11	sc	sc	PROPN
aji-132	396	12	,	,	PUNCT
aji-132	396	13	xie	xie	PROPN
aji-132	396	14	w	w	PROPN
aji-132	396	15	,	,	PUNCT
aji-132	396	16	miao	miao	PROPN
aji-132	396	17	l	l	PROPN
aji-132	396	18	,	,	PUNCT
aji-132	396	19	et	et	PROPN
aji-132	396	20	al	al	PROPN
aji-132	396	21	.	.	PROPN
aji-132	396	22	iguratimod	iguratimod	PROPN
aji-132	396	23	ameliorates	ameliorate	VERB
aji-132	396	24	inflammatory	inflammatory	ADJ
aji-132	396	25	responses	response	NOUN
aji-132	396	26	by	by	ADP
aji-132	396	27	modulating	modulate	VERB
aji-132	396	28	the	the	DET
aji-132	396	29	th17	th17	PROPN
aji-132	396	30	/	/	SYM
aji-132	396	31	treg	treg	PROPN
aji-132	396	32	paradigm	paradigm	NOUN
aji-132	396	33	in	in	ADP
aji-132	396	34	dextran	dextran	ADJ
aji-132	396	35	sulphate	sulphate	NOUN
aji-132	396	36	sodium	sodium	NOUN
aji-132	396	37	-	-	PUNCT
aji-132	396	38	induced	induce	VERB
aji-132	396	39	murine	murine	ADJ
aji-132	396	40	colitis	colitis	NOUN
aji-132	396	41	.	.	PUNCT
aji-132	397	1	mol	mol	ADP
aji-132	397	2	immunol	immunol	NOUN
aji-132	397	3	.	.	PUNCT
aji-132	398	1	2018;93:9–19	2018;93:9–19	NUM
aji-132	398	2	.	.	PUNCT
aji-132	399	1	doi:10.1016	doi:10.1016	PROPN
aji-132	399	2	/	/	SYM
aji-132	399	3	j.molimm.2017.10.008	j.molimm.2017.10.008	PROPN
aji-132	399	4	16	16	NUM
aji-132	399	5	.	.	PUNCT
aji-132	400	1	li	li	PROPN
aji-132	400	2	g	g	PROPN
aji-132	400	3	,	,	PUNCT
aji-132	400	4	yamasaki	yamasaki	PROPN
aji-132	400	5	r	r	PROPN
aji-132	400	6	,	,	PUNCT
aji-132	400	7	fang	fang	X
aji-132	400	8	m	m	PROPN
aji-132	400	9	,	,	PUNCT
aji-132	400	10	masaki	masaki	PROPN
aji-132	400	11	k	k	PROPN
aji-132	400	12	,	,	PUNCT
aji-132	400	13	ochi	ochi	PROPN
aji-132	400	14	h	h	PROPN
aji-132	400	15	,	,	PUNCT
aji-132	400	16	matsushita	matsushita	PROPN
aji-132	400	17	t	t	PROPN
aji-132	400	18	,	,	PUNCT
aji-132	400	19	et	et	PROPN
aji-132	400	20	al	al	PROPN
aji-132	400	21	.	.	PROPN
aji-132	400	22	novel	novel	PROPN
aji-132	400	23	diseasemodifying	diseasemodifye	VERB
aji-132	400	24	anti	anti	ADJ
aji-132	400	25	-	-	ADJ
aji-132	400	26	rheumatic	rheumatic	ADJ
aji-132	400	27	drug	drug	NOUN
aji-132	400	28	iguratimod	iguratimod	PROPN
aji-132	400	29	suppresses	suppress	VERB
aji-132	400	30	chronic	chronic	ADJ
aji-132	400	31	experimental	experimental	ADJ
aji-132	400	32	autoimmune	autoimmune	ADJ
aji-132	400	33	encephalomyelitis	encephalomyelitis	NOUN
aji-132	400	34	by	by	ADP
aji-132	400	35	downregulating	downregulating	NOUN
aji-132	400	36	activation	activation	NOUN
aji-132	400	37	of	of	ADP
aji-132	400	38	macrophages	macrophage	NOUN
aji-132	400	39	/	/	SYM
aji-132	400	40	microglia	microglia	NOUN
aji-132	400	41	through	through	ADP
aji-132	400	42	an	an	DET
aji-132	400	43	nf	nf	ADJ
aji-132	400	44	-	-	PUNCT
aji-132	400	45	κb	κb	NOUN
aji-132	400	46	pathway	pathway	NOUN
aji-132	400	47	.	.	PUNCT
aji-132	401	1	sci	sci	PROPN
aji-132	401	2	rep	rep	PROPN
aji-132	401	3	.	.	PROPN
aji-132	401	4	2018;8(1):1933	2018;8(1):1933	PROPN
aji-132	401	5	.	.	PUNCT
aji-132	401	6	doi	doi	NOUN
aji-132	401	7	:	:	PUNCT
aji-132	401	8	10.1038	10.1038	NUM
aji-132	401	9	/	/	SYM
aji-132	401	10	s41598	s41598	NOUN
aji-132	401	11	-	-	PUNCT
aji-132	401	12	018	018	NUM
aji-132	401	13	-	-	PUNCT
aji-132	401	14	20390	20390	NUM
aji-132	401	15	-	-	SYM
aji-132	401	16	5	5	NUM
aji-132	401	17	17	17	NUM
aji-132	401	18	.	.	PUNCT
aji-132	402	1	kohno	kohno	PROPN
aji-132	402	2	m	m	PROPN
aji-132	402	3	,	,	PUNCT
aji-132	402	4	aikawa	aikawa	PROPN
aji-132	402	5	y	y	PROPN
aji-132	402	6	,	,	PUNCT
aji-132	402	7	tsubouchi	tsubouchi	PROPN
aji-132	402	8	y	y	PROPN
aji-132	402	9	,	,	PUNCT
aji-132	402	10	hashiramoto	hashiramoto	PROPN
aji-132	402	11	a	a	NOUN
aji-132	402	12	,	,	PUNCT
aji-132	402	13	yamada	yamada	PROPN
aji-132	402	14	r	r	PROPN
aji-132	402	15	,	,	PUNCT
aji-132	402	16	kawahito	kawahito	PROPN
aji-132	402	17	y	y	PROPN
aji-132	402	18	,	,	PUNCT
aji-132	402	19	et	et	PROPN
aji-132	402	20	al	al	PROPN
aji-132	402	21	.	.	PROPN
aji-132	402	22	inhibitory	inhibitory	ADJ
aji-132	402	23	effect	effect	NOUN
aji-132	402	24	of	of	ADP
aji-132	402	25	t-614	t-614	NOUN
aji-132	402	26	on	on	ADP
aji-132	402	27	tumor	tumor	NOUN
aji-132	402	28	necrosis	necrosis	NOUN
aji-132	402	29	factor	factor	NOUN
aji-132	402	30	-	-	PUNCT
aji-132	402	31	alpha	alpha	NOUN
aji-132	402	32	induced	induce	VERB
aji-132	402	33	cytokine	cytokine	ADJ
aji-132	402	34	production	production	NOUN
aji-132	402	35	and	and	CCONJ
aji-132	402	36	nuclear	nuclear	ADJ
aji-132	402	37	factor	factor	NOUN
aji-132	402	38	-	-	PUNCT
aji-132	402	39	kappab	kappab	NOUN
aji-132	402	40	activation	activation	NOUN
aji-132	402	41	in	in	ADP
aji-132	402	42	cultured	cultured	ADJ
aji-132	402	43	human	human	ADJ
aji-132	402	44	synovial	synovial	ADJ
aji-132	402	45	cells	cell	NOUN
aji-132	402	46	.	.	PUNCT
aji-132	403	1	j	j	PROPN
aji-132	403	2	rheumatol	rheumatol	NOUN
aji-132	403	3	.	.	PUNCT
aji-132	404	1	2001;28(12):2591–6	2001;28(12):2591–6	NUM
aji-132	404	2	.	.	PUNCT
aji-132	405	1	18	18	NUM
aji-132	405	2	.	.	PUNCT
aji-132	406	1	aikawa	aikawa	PROPN
aji-132	406	2	y	y	PROPN
aji-132	406	3	,	,	PUNCT
aji-132	406	4	yamamoto	yamamoto	PROPN
aji-132	406	5	m	m	PROPN
aji-132	406	6	,	,	PUNCT
aji-132	406	7	yamamoto	yamamoto	PROPN
aji-132	406	8	t	t	PROPN
aji-132	406	9	,	,	PUNCT
aji-132	406	10	morimoto	morimoto	PROPN
aji-132	406	11	k	k	PROPN
aji-132	406	12	,	,	PUNCT
aji-132	406	13	tanaka	tanaka	PROPN
aji-132	406	14	k.	k.	PROPN
aji-132	407	1	an	an	DET
aji-132	407	2	anti	anti	ADJ
aji-132	407	3	-	-	ADJ
aji-132	407	4	rheumatic	rheumatic	ADJ
aji-132	407	5	agent	agent	NOUN
aji-132	407	6	t-614	t-614	PUNCT
aji-132	407	7	inhibits	inhibit	VERB
aji-132	407	8	nf	nf	ADJ
aji-132	407	9	-	-	PUNCT
aji-132	407	10	kappab	kappab	NOUN
aji-132	407	11	activation	activation	NOUN
aji-132	407	12	in	in	ADP
aji-132	407	13	lpsand	lpsand	ADP
aji-132	407	14	tnf	tnf	PROPN
aji-132	407	15	-	-	PUNCT
aji-132	407	16	alpha	alpha	NOUN
aji-132	407	17	-	-	PUNCT
aji-132	407	18	stimulated	stimulate	VERB
aji-132	407	19	thp-1	thp-1	NOUN
aji-132	407	20	cells	cell	NOUN
aji-132	407	21	without	without	ADP
aji-132	407	22	interfering	interfere	VERB
aji-132	407	23	with	with	ADP
aji-132	407	24	ikappabalpha	ikappabalpha	NOUN
aji-132	407	25	degradation	degradation	NOUN
aji-132	407	26	.	.	PUNCT
aji-132	408	1	inflammation	inflammation	NOUN
aji-132	408	2	res	re	NOUN
aji-132	408	3	.	.	PUNCT
aji-132	409	1	2002;51	2002;51	NUM
aji-132	409	2	(	(	PUNCT
aji-132	409	3	4	4	NUM
aji-132	409	4	):	):	PUNCT
aji-132	409	5	188–94	188–94	NUM
aji-132	409	6	.	.	PUNCT
aji-132	409	7	doi:10.1007	doi:10.1007	PROPN
aji-132	409	8	/	/	SYM
aji-132	409	9	pl00000291	pl00000291	PROPN
aji-132	409	10	gupta	gupta	PROPN
aji-132	409	11	et	et	PROPN
aji-132	409	12	al	al	PROPN
aji-132	409	13	.	.	PROPN
aji-132	409	14	;	;	PUNCT
aji-132	409	15	asian	asian	PROPN
aji-132	409	16	j.	j.	PROPN
aji-132	409	17	immunol	immunol	PROPN
aji-132	409	18	.	.	PROPN
aji-132	409	19	,	,	PUNCT
aji-132	409	20	vol	vol	NOUN
aji-132	409	21	.	.	PROPN
aji-132	410	1	7	7	NUM
aji-132	410	2	,	,	PUNCT
aji-132	410	3	no	no	INTJ
aji-132	410	4	.	.	NOUN
aji-132	410	5	1	1	NUM
aji-132	410	6	,	,	PUNCT
aji-132	410	7	pp	pp	ADJ
aji-132	410	8	.	.	PUNCT
aji-132	411	1	79	79	NUM
aji-132	411	2	-	-	SYM
aji-132	411	3	89	89	NUM
aji-132	411	4	,	,	PUNCT
aji-132	411	5	2024	2024	NUM
aji-132	411	6	;	;	PUNCT
aji-132	411	7	article	article	NOUN
aji-132	411	8	no.aji.115805	no.aji.115805	VERB
aji-132	411	9	88	88	NUM
aji-132	411	10	19	19	NUM
aji-132	411	11	.	.	PUNCT
aji-132	412	1	jiang	jiang	PROPN
aji-132	412	2	h	h	PROPN
aji-132	412	3	,	,	PUNCT
aji-132	412	4	gao	gao	PROPN
aji-132	412	5	h	h	PROPN
aji-132	412	6	,	,	PUNCT
aji-132	412	7	wang	wang	PROPN
aji-132	412	8	q	q	PROPN
aji-132	412	9	,	,	PUNCT
aji-132	412	10	wang	wang	PROPN
aji-132	412	11	m	m	PROPN
aji-132	412	12	,	,	PUNCT
aji-132	412	13	wu	wu	PROPN
aji-132	412	14	b.	b.	PROPN
aji-132	412	15	molecular	molecular	ADJ
aji-132	412	16	mechanisms	mechanism	NOUN
aji-132	412	17	and	and	CCONJ
aji-132	412	18	clinical	clinical	ADJ
aji-132	412	19	application	application	NOUN
aji-132	412	20	of	of	ADP
aji-132	412	21	iguratimod	iguratimod	PROPN
aji-132	412	22	:	:	PUNCT
aji-132	412	23	a	a	DET
aji-132	412	24	review	review	NOUN
aji-132	412	25	.	.	PUNCT
aji-132	412	26	biomed	biome	VERB
aji-132	412	27	pharmacother	pharmacother	ADJ
aji-132	412	28	.	.	PUNCT
aji-132	413	1	2020;122	2020;122	NUM
aji-132	413	2	:	:	PUNCT
aji-132	413	3	109704	109704	NUM
aji-132	413	4	.	.	PUNCT
aji-132	414	1	doi:10.1016	doi:10.1016	PROPN
aji-132	414	2	/	/	SYM
aji-132	414	3	j.biopha.2019.109704	j.biopha.2019.109704	PROPN
aji-132	414	4	20	20	NUM
aji-132	414	5	.	.	PUNCT
aji-132	415	1	li	li	PROPN
aji-132	415	2	b	b	PROPN
aji-132	415	3	,	,	PUNCT
aji-132	415	4	li	li	PROPN
aji-132	415	5	p	p	PROPN
aji-132	415	6	,	,	PUNCT
aji-132	415	7	bi	bi	PROPN
aji-132	415	8	l.	l.	PROPN
aji-132	415	9	iguratimod	iguratimod	PROPN
aji-132	415	10	dose	dose	PROPN
aji-132	415	11	dependently	dependently	ADV
aji-132	415	12	inhibits	inhibit	VERB
aji-132	415	13	the	the	DET
aji-132	415	14	expression	expression	NOUN
aji-132	415	15	of	of	ADP
aji-132	415	16	citrullinated	citrullinate	VERB
aji-132	415	17	proteins	protein	NOUN
aji-132	415	18	and	and	CCONJ
aji-132	415	19	peptidylarginine	peptidylarginine	ADJ
aji-132	415	20	deiminases	deiminase	NOUN
aji-132	415	21	2	2	NUM
aji-132	415	22	and	and	CCONJ
aji-132	415	23	4	4	NUM
aji-132	415	24	in	in	ADP
aji-132	415	25	neutrophils	neutrophil	NOUN
aji-132	415	26	from	from	ADP
aji-132	415	27	rheumatoid	rheumatoid	ADJ
aji-132	415	28	arthritis	arthritis	NOUN
aji-132	415	29	patients	patient	NOUN
aji-132	415	30	.	.	PUNCT
aji-132	416	1	clin	clin	PROPN
aji-132	416	2	rheumatol	rheumatol	NOUN
aji-132	416	3	.	.	PUNCT
aji-132	417	1	2020;39(3):899–907	2020;39(3):899–907	X
aji-132	417	2	.	.	PUNCT
aji-132	417	3	doi:10.1007	doi:10.1007	VERB
aji-132	417	4	/	/	SYM
aji-132	417	5	s10067	s10067	NOUN
aji-132	417	6	-	-	PUNCT
aji-132	417	7	019	019	NUM
aji-132	417	8	-	-	PUNCT
aji-132	417	9	04835	04835	NUM
aji-132	417	10	-	-	SYM
aji-132	417	11	4	4	NUM
aji-132	417	12	21	21	NUM
aji-132	417	13	.	.	PUNCT
aji-132	417	14	yan	yan	PROPN
aji-132	418	1	q	q	X
aji-132	418	2	,	,	PUNCT
aji-132	418	3	du	du	PROPN
aji-132	418	4	f	f	PROPN
aji-132	418	5	,	,	PUNCT
aji-132	418	6	huang	huang	PROPN
aji-132	418	7	x	x	PROPN
aji-132	418	8	,	,	PUNCT
aji-132	418	9	fu	fu	PROPN
aji-132	418	10	q	q	NOUN
aji-132	418	11	,	,	PUNCT
aji-132	418	12	chen	chen	PROPN
aji-132	418	13	s	s	PROPN
aji-132	418	14	,	,	PUNCT
aji-132	418	15	dai	dai	PROPN
aji-132	418	16	d	d	PROPN
aji-132	418	17	,	,	PUNCT
aji-132	418	18	et	et	PROPN
aji-132	418	19	al	al	PROPN
aji-132	418	20	.	.	PROPN
aji-132	418	21	prevention	prevention	NOUN
aji-132	418	22	of	of	ADP
aji-132	418	23	immune	immune	ADJ
aji-132	418	24	nephritis	nephritis	NOUN
aji-132	418	25	by	by	ADP
aji-132	418	26	the	the	DET
aji-132	418	27	small	small	ADJ
aji-132	418	28	molecular	molecular	ADJ
aji-132	418	29	weight	weight	NOUN
aji-132	418	30	immunomodulator	immunomodulator	NOUN
aji-132	418	31	iguratimod	iguratimod	PROPN
aji-132	418	32	in	in	ADP
aji-132	418	33	mrl	mrl	PROPN
aji-132	418	34	/	/	SYM
aji-132	418	35	lpr	lpr	PROPN
aji-132	418	36	mice	mouse	NOUN
aji-132	418	37	.	.	PUNCT
aji-132	419	1	plos	plos	PROPN
aji-132	419	2	one	one	NUM
aji-132	419	3	.	.	PUNCT
aji-132	420	1	2014;9(10):e108273	2014;9(10):e108273	NOUN
aji-132	420	2	.	.	PUNCT
aji-132	420	3	doi:10.1371	doi:10.1371	PROPN
aji-132	420	4	/	/	SYM
aji-132	421	1	journal.pone.0108273	journal.pone.0108273	PROPN
aji-132	421	2	22	22	NUM
aji-132	421	3	.	.	PUNCT
aji-132	422	1	ye	ye	PRON
aji-132	422	2	y	y	PROPN
aji-132	422	3	,	,	PUNCT
aji-132	422	4	liu	liu	PROPN
aji-132	422	5	m	m	PROPN
aji-132	422	6	,	,	PUNCT
aji-132	422	7	tang	tang	PROPN
aji-132	422	8	l	l	PROPN
aji-132	422	9	,	,	PUNCT
aji-132	422	10	du	du	PROPN
aji-132	422	11	f	f	PROPN
aji-132	422	12	,	,	PUNCT
aji-132	422	13	liu	liu	PROPN
aji-132	422	14	y	y	PROPN
aji-132	422	15	,	,	PUNCT
aji-132	422	16	hao	hao	PROPN
aji-132	422	17	p	p	PROPN
aji-132	422	18	,	,	PUNCT
aji-132	423	1	et	et	PROPN
aji-132	423	2	al	al	PROPN
aji-132	423	3	.	.	PROPN
aji-132	423	4	iguratimod	iguratimod	PROPN
aji-132	423	5	represses	repress	VERB
aji-132	423	6	b	b	X
aji-132	423	7	cell	cell	NOUN
aji-132	423	8	terminal	terminal	NOUN
aji-132	423	9	differentiation	differentiation	NOUN
aji-132	423	10	linked	link	VERB
aji-132	423	11	with	with	ADP
aji-132	423	12	the	the	DET
aji-132	423	13	inhibition	inhibition	NOUN
aji-132	423	14	of	of	ADP
aji-132	423	15	pkc	pkc	PROPN
aji-132	423	16	/	/	SYM
aji-132	423	17	egr1	egr1	PROPN
aji-132	423	18	axis	axis	NOUN
aji-132	423	19	.	.	PUNCT
aji-132	424	1	arthritis	arthritis	NOUN
aji-132	424	2	res	re	NOUN
aji-132	424	3	.	.	PUNCT
aji-132	425	1	ther	ther	PROPN
aji-132	425	2	.	.	PUNCT
aji-132	426	1	2019;21(1):92	2019;21(1):92	X
aji-132	426	2	.	.	PUNCT
aji-132	426	3	doi:10.1186	doi:10.1186	PROPN
aji-132	426	4	/	/	SYM
aji-132	426	5	s13075	s13075	VERB
aji-132	426	6	-	-	PUNCT
aji-132	426	7	019	019	NUM
aji-132	426	8	-	-	PUNCT
aji-132	426	9	1874	1874	NUM
aji-132	426	10	-	-	SYM
aji-132	426	11	2	2	NUM
aji-132	426	12	23	23	NUM
aji-132	426	13	.	.	PUNCT
aji-132	427	1	tanaka	tanaka	PROPN
aji-132	427	2	k	k	PROPN
aji-132	427	3	,	,	PUNCT
aji-132	427	4	yamamoto	yamamoto	PROPN
aji-132	427	5	t	t	PROPN
aji-132	427	6	,	,	PUNCT
aji-132	427	7	taniguchi	taniguchi	PROPN
aji-132	427	8	y	y	PROPN
aji-132	427	9	,	,	PUNCT
aji-132	427	10	muramoto	muramoto	PROPN
aji-132	427	11	k.	k.	PROPN
aji-132	427	12	inhibition	inhibition	NOUN
aji-132	427	13	of	of	ADP
aji-132	427	14	immunoglobulin	immunoglobulin	NOUN
aji-132	427	15	production	production	NOUN
aji-132	427	16	by	by	ADP
aji-132	427	17	t-614	t-614	X
aji-132	427	18	(	(	PUNCT
aji-132	427	19	iguratimod	iguratimod	PROPN
aji-132	427	20	)	)	PUNCT
aji-132	427	21	,	,	PUNCT
aji-132	427	22	a	a	DET
aji-132	427	23	novel	novel	ADJ
aji-132	427	24	dmard	dmard	NOUN
aji-132	427	25	,	,	PUNCT
aji-132	427	26	in	in	ADP
aji-132	427	27	cultured	cultured	ADJ
aji-132	427	28	b	b	NOUN
aji-132	427	29	cells	cell	NOUN
aji-132	427	30	and	and	CCONJ
aji-132	427	31	in	in	ADP
aji-132	427	32	animal	animal	NOUN
aji-132	427	33	models	model	NOUN
aji-132	427	34	of	of	ADP
aji-132	427	35	arthritis	arthritis	NOUN
aji-132	427	36	.	.	PUNCT
aji-132	428	1	arthritis	arthritis	NOUN
aji-132	428	2	rheum	rheum	NOUN
aji-132	428	3	.	.	PUNCT
aji-132	429	1	2004;50	2004;50	NUM
aji-132	429	2	:	:	PUNCT
aji-132	429	3	s369	s369	PROPN
aji-132	429	4	.	.	PUNCT
aji-132	430	1	24	24	NUM
aji-132	430	2	.	.	PUNCT
aji-132	431	1	yamamoto	yamamoto	PROPN
aji-132	431	2	t	t	PROPN
aji-132	431	3	,	,	PUNCT
aji-132	431	4	aikawa	aikawa	PROPN
aji-132	431	5	y	y	PROPN
aji-132	431	6	,	,	PUNCT
aji-132	431	7	funaki	funaki	PROPN
aji-132	431	8	j	j	PROPN
aji-132	431	9	,	,	PUNCT
aji-132	431	10	et	et	PROPN
aji-132	431	11	al	al	PROPN
aji-132	431	12	.	.	PROPN
aji-132	431	13	immunopharmacological	immunopharmacological	ADJ
aji-132	431	14	studies	study	NOUN
aji-132	431	15	of	of	ADP
aji-132	431	16	a	a	DET
aji-132	431	17	disease	disease	NOUN
aji-132	431	18	-	-	PUNCT
aji-132	431	19	modifying	modify	VERB
aji-132	431	20	antirheumatic	antirheumatic	ADJ
aji-132	431	21	drug	drug	NOUN
aji-132	431	22	iguratimod	iguratimod	NOUN
aji-132	431	23	(	(	PUNCT
aji-132	431	24	t-614	t-614	NOUN
aji-132	431	25	)	)	PUNCT
aji-132	431	26	;	;	PUNCT
aji-132	431	27	its	its	PRON
aji-132	431	28	effect	effect	NOUN
aji-132	431	29	on	on	ADP
aji-132	431	30	immunogloblin	immunogloblin	NOUN
aji-132	431	31	production	production	NOUN
aji-132	431	32	and	and	CCONJ
aji-132	431	33	lymphocyte	lymphocyte	ADJ
aji-132	431	34	proliferation	proliferation	NOUN
aji-132	431	35	.	.	PUNCT
aji-132	432	1	jpn	jpn	PROPN
aji-132	432	2	pharmacol	pharmacol	PROPN
aji-132	432	3	ther	ther	ADV
aji-132	432	4	.	.	PUNCT
aji-132	433	1	2007	2007	NUM
aji-132	433	2	;	;	PUNCT
aji-132	433	3	35:561	35:561	NUM
aji-132	433	4	-	-	SYM
aji-132	433	5	9	9	NUM
aji-132	433	6	.	.	NUM
aji-132	434	1	25	25	NUM
aji-132	434	2	.	.	PUNCT
aji-132	435	1	muramoto	muramoto	PROPN
aji-132	435	2	k	k	PROPN
aji-132	435	3	,	,	PUNCT
aji-132	435	4	yamamoto	yamamoto	PROPN
aji-132	435	5	t	t	PROPN
aji-132	435	6	,	,	PUNCT
aji-132	435	7	hishinuma	hishinuma	PROPN
aji-132	435	8	i	i	PRON
aji-132	435	9	,	,	PUNCT
aji-132	435	10	tanaka	tanaka	PROPN
aji-132	435	11	k.	k.	PROPN
aji-132	436	1	pharmacological	pharmacological	PROPN
aji-132	436	2	profile	profile	NOUN
aji-132	436	3	of	of	ADP
aji-132	436	4	a	a	DET
aji-132	436	5	novel	novel	ADJ
aji-132	436	6	dmard	dmard	NOUN
aji-132	436	7	;	;	PUNCT
aji-132	436	8	t-614	t-614	PUNCT
aji-132	436	9	(	(	PUNCT
aji-132	436	10	iguratimod	iguratimod	NOUN
aji-132	436	11	)	)	PUNCT
aji-132	436	12	on	on	ADP
aji-132	436	13	ig	ig	PROPN
aji-132	436	14	production	production	NOUN
aji-132	436	15	from	from	ADP
aji-132	436	16	b	b	NOUN
aji-132	436	17	cells	cell	NOUN
aji-132	436	18	.	.	PUNCT
aji-132	437	1	in	in	ADP
aji-132	437	2	:	:	PUNCT
aji-132	437	3	abstracts	abstract	NOUN
aji-132	437	4	of	of	ADP
aji-132	437	5	the	the	DET
aji-132	437	6	2004	2004	NUM
aji-132	437	7	international	international	ADJ
aji-132	437	8	conference	conference	NOUN
aji-132	437	9	on	on	ADP
aji-132	437	10	b	b	PROPN
aji-132	437	11	cells	cell	NOUN
aji-132	437	12	and	and	CCONJ
aji-132	437	13	autoimmunity	autoimmunity	NOUN
aji-132	437	14	;	;	PUNCT
aji-132	437	15	quebec	quebec	PROPN
aji-132	437	16	,	,	PUNCT
aji-132	437	17	canada	canada	PROPN
aji-132	437	18	.	.	PUNCT
aji-132	438	1	26	26	NUM
aji-132	438	2	.	.	PUNCT
aji-132	439	1	tanaka	tanaka	PROPN
aji-132	439	2	k	k	PROPN
aji-132	439	3	,	,	PUNCT
aji-132	439	4	shimotori	shimotori	PROPN
aji-132	439	5	t	t	PROPN
aji-132	439	6	,	,	PUNCT
aji-132	439	7	taniguchi	taniguchi	PROPN
aji-132	439	8	y	y	PROPN
aji-132	439	9	,	,	PUNCT
aji-132	439	10	et	et	PROPN
aji-132	439	11	al	al	PROPN
aji-132	439	12	.	.	PROPN
aji-132	439	13	pharmacological	pharmacological	ADJ
aji-132	439	14	studies	study	NOUN
aji-132	439	15	on	on	ADP
aji-132	439	16	t-614	t-614	NUM
aji-132	439	17	,	,	PUNCT
aji-132	439	18	a	a	DET
aji-132	439	19	novel	novel	ADJ
aji-132	439	20	antiinflammatory	antiinflammatory	NOUN
aji-132	439	21	agent	agent	NOUN
aji-132	439	22	:	:	PUNCT
aji-132	439	23	effect	effect	NOUN
aji-132	439	24	on	on	ADP
aji-132	439	25	type	type	NOUN
aji-132	439	26	ii	ii	PROPN
aji-132	439	27	collagen	collagen	NOUN
aji-132	439	28	-	-	PUNCT
aji-132	439	29	induced	induce	VERB
aji-132	439	30	arthritis	arthritis	NOUN
aji-132	439	31	in	in	ADP
aji-132	439	32	dba/1j	dba/1j	PROPN
aji-132	439	33	mice	mouse	NOUN
aji-132	439	34	and	and	CCONJ
aji-132	439	35	spontaneous	spontaneous	ADJ
aji-132	439	36	arthritis	arthritis	NOUN
aji-132	439	37	in	in	ADP
aji-132	439	38	mrl	mrl	PROPN
aji-132	439	39	/	/	SYM
aji-132	439	40	l	l	NOUN
aji-132	439	41	mice	mouse	NOUN
aji-132	439	42	.	.	PUNCT
aji-132	440	1	int	int	PROPN
aji-132	440	2	j	j	PROPN
aji-132	440	3	immunother	immunother	PROPN
aji-132	440	4	.	.	PUNCT
aji-132	441	1	1993;9:69	1993;9:69	PROPN
aji-132	441	2	-	-	PUNCT
aji-132	441	3	78	78	NUM
aji-132	441	4	.	.	PUNCT
aji-132	442	1	27	27	NUM
aji-132	442	2	.	.	PUNCT
aji-132	443	1	urata	urata	PROPN
aji-132	443	2	n	n	PROPN
aji-132	443	3	,	,	PUNCT
aji-132	443	4	yamamoto	yamamoto	PROPN
aji-132	443	5	m	m	PROPN
aji-132	443	6	,	,	PUNCT
aji-132	443	7	taniguchi	taniguchi	PROPN
aji-132	443	8	y	y	PROPN
aji-132	443	9	,	,	PUNCT
aji-132	443	10	et	et	PROPN
aji-132	443	11	al	al	PROPN
aji-132	443	12	.	.	PROPN
aji-132	443	13	effect	effect	NOUN
aji-132	443	14	of	of	ADP
aji-132	443	15	a	a	DET
aji-132	443	16	disease	disease	NOUN
aji-132	443	17	-	-	PUNCT
aji-132	443	18	modifying	modify	VERB
aji-132	443	19	antirheumatic	antirheumatic	ADJ
aji-132	443	20	drug	drug	NOUN
aji-132	443	21	iguratimod	iguratimod	NOUN
aji-132	443	22	(	(	PUNCT
aji-132	443	23	t-614	t-614	NOUN
aji-132	443	24	)	)	PUNCT
aji-132	443	25	on	on	ADP
aji-132	443	26	chronic	chronic	ADJ
aji-132	443	27	arthritis	arthritis	NOUN
aji-132	443	28	in	in	ADP
aji-132	443	29	experimental	experimental	ADJ
aji-132	443	30	animals	animal	NOUN
aji-132	443	31	.	.	PUNCT
aji-132	444	1	jpn	jpn	PROPN
aji-132	444	2	pharmacol	pharmacol	PROPN
aji-132	444	3	ther	ther	ADV
aji-132	444	4	.	.	PUNCT
aji-132	445	1	2007;35:571	2007;35:571	NUM
aji-132	445	2	-	-	SYM
aji-132	445	3	82	82	NUM
aji-132	445	4	.	.	PUNCT
aji-132	446	1	28	28	NUM
aji-132	446	2	.	.	X
aji-132	446	3	de	de	PROPN
aji-132	446	4	vita	vita	PROPN
aji-132	446	5	s	s	PROPN
aji-132	446	6	,	,	PUNCT
aji-132	446	7	zaja	zaja	PROPN
aji-132	446	8	f	f	PROPN
aji-132	446	9	,	,	PUNCT
aji-132	446	10	sacco	sacco	PROPN
aji-132	446	11	s	s	PROPN
aji-132	446	12	,	,	PUNCT
aji-132	446	13	et	et	PROPN
aji-132	446	14	al	al	PROPN
aji-132	446	15	.	.	PROPN
aji-132	447	1	efficacy	efficacy	NOUN
aji-132	447	2	of	of	ADP
aji-132	447	3	selective	selective	ADJ
aji-132	447	4	b	b	PROPN
aji-132	447	5	cell	cell	NOUN
aji-132	447	6	blockade	blockade	NOUN
aji-132	447	7	in	in	ADP
aji-132	447	8	the	the	DET
aji-132	447	9	treatment	treatment	NOUN
aji-132	447	10	of	of	ADP
aji-132	447	11	rheumatoid	rheumatoid	NOUN
aji-132	447	12	arthritis	arthritis	NOUN
aji-132	447	13	:	:	PUNCT
aji-132	447	14	evidence	evidence	NOUN
aji-132	447	15	for	for	ADP
aji-132	447	16	a	a	DET
aji-132	447	17	pathogenetic	pathogenetic	ADJ
aji-132	447	18	role	role	NOUN
aji-132	447	19	of	of	ADP
aji-132	447	20	b	b	NOUN
aji-132	447	21	cells	cell	NOUN
aji-132	447	22	.	.	PUNCT
aji-132	448	1	arthritis	arthritis	NOUN
aji-132	448	2	rheum	rheum	NOUN
aji-132	448	3	.	.	PUNCT
aji-132	449	1	2002;46	2002;46	NUM
aji-132	449	2	:	:	PUNCT
aji-132	449	3	2029	2029	NUM
aji-132	449	4	-	-	SYM
aji-132	449	5	33	33	NUM
aji-132	449	6	.	.	NOUN
aji-132	450	1	29	29	NUM
aji-132	450	2	.	.	PUNCT
aji-132	451	1	yamamoto	yamamoto	PROPN
aji-132	451	2	m	m	PROPN
aji-132	451	3	,	,	PUNCT
aji-132	451	4	urata	urata	PROPN
aji-132	451	5	n	n	CCONJ
aji-132	451	6	,	,	PUNCT
aji-132	451	7	yamamoto	yamamoto	PROPN
aji-132	451	8	t	t	PROPN
aji-132	451	9	,	,	PUNCT
aji-132	451	10	et	et	PROPN
aji-132	451	11	al	al	PROPN
aji-132	451	12	.	.	PROPN
aji-132	451	13	effect	effect	NOUN
aji-132	451	14	of	of	ADP
aji-132	451	15	a	a	DET
aji-132	451	16	disease	disease	NOUN
aji-132	451	17	-	-	PUNCT
aji-132	451	18	modifying	modify	VERB
aji-132	451	19	antirheumatic	antirheumatic	ADJ
aji-132	451	20	drug	drug	NOUN
aji-132	451	21	iguratimod	iguratimod	NOUN
aji-132	451	22	(	(	PUNCT
aji-132	451	23	t-614	t-614	NOUN
aji-132	451	24	)	)	PUNCT
aji-132	451	25	on	on	ADP
aji-132	451	26	inflammatory	inflammatory	ADJ
aji-132	451	27	cytokine	cytokine	NOUN
aji-132	451	28	production	production	NOUN
aji-132	451	29	.	.	PUNCT
aji-132	452	1	jpn	jpn	PROPN
aji-132	452	2	pharmacol	pharmacol	PROPN
aji-132	452	3	ther	ther	ADV
aji-132	452	4	.	.	PUNCT
aji-132	453	1	2007;35:551	2007;35:551	NUM
aji-132	453	2	-	-	SYM
aji-132	453	3	9	9	NUM
aji-132	453	4	.	.	NOUN
aji-132	453	5	30	30	NUM
aji-132	453	6	.	.	PUNCT
aji-132	454	1	jiang	jiang	PROPN
aji-132	454	2	y	y	PROPN
aji-132	454	3	,	,	PUNCT
aji-132	454	4	lü	lü	PROPN
aji-132	454	5	w	w	PROPN
aji-132	454	6	,	,	PUNCT
aji-132	454	7	yu	yu	PROPN
aji-132	454	8	sq	sq	PROPN
aji-132	454	9	,	,	PUNCT
aji-132	454	10	et	et	PROPN
aji-132	454	11	al	al	PROPN
aji-132	454	12	.	.	PROPN
aji-132	454	13	inhibitory	inhibitory	ADJ
aji-132	454	14	effect	effect	NOUN
aji-132	454	15	of	of	ADP
aji-132	454	16	iguratimod	iguratimod	NOUN
aji-132	454	17	on	on	ADP
aji-132	454	18	tnfα	tnfα	NOUN
aji-132	454	19	production	production	NOUN
aji-132	454	20	and	and	CCONJ
aji-132	454	21	nf	nf	ADJ
aji-132	454	22	-	-	PUNCT
aji-132	454	23	κb	κb	NOUN
aji-132	454	24	activity	activity	NOUN
aji-132	454	25	in	in	ADP
aji-132	454	26	lps	lps	PROPN
aji-132	454	27	-	-	PUNCT
aji-132	454	28	stimulated	stimulated	ADJ
aji-132	454	29	rat	rat	NOUN
aji-132	454	30	alveolar	alveolar	ADJ
aji-132	454	31	macrophage	macrophage	ADJ
aji-132	454	32	cell	cell	NOUN
aji-132	454	33	line	line	NOUN
aji-132	454	34	.	.	PUNCT
aji-132	455	1	yao	yao	PROPN
aji-132	455	2	xue	xue	PROPN
aji-132	455	3	xue	xue	PROPN
aji-132	455	4	bao	bao	PROPN
aji-132	455	5	.	.	PUNCT
aji-132	456	1	2006;41:401	2006;41:401	X
aji-132	456	2	-	-	SYM
aji-132	456	3	5	5	NUM
aji-132	456	4	.	.	NOUN
aji-132	456	5	31	31	NUM
aji-132	456	6	.	.	PUNCT
aji-132	457	1	kohno	kohno	PROPN
aji-132	457	2	m	m	PROPN
aji-132	457	3	,	,	PUNCT
aji-132	457	4	aikawa	aikawa	PROPN
aji-132	457	5	y	y	PROPN
aji-132	457	6	,	,	PUNCT
aji-132	457	7	tsubouchi	tsubouchi	PROPN
aji-132	457	8	y	y	PROPN
aji-132	457	9	,	,	PUNCT
aji-132	457	10	et	et	PROPN
aji-132	457	11	al	al	PROPN
aji-132	457	12	.	.	PROPN
aji-132	457	13	inhibitory	inhibitory	ADJ
aji-132	457	14	effect	effect	NOUN
aji-132	457	15	of	of	ADP
aji-132	457	16	t-614	t-614	NOUN
aji-132	457	17	on	on	ADP
aji-132	457	18	tumor	tumor	NOUN
aji-132	457	19	necrosis	necrosis	NOUN
aji-132	457	20	factor	factor	NOUN
aji-132	457	21	-	-	PUNCT
aji-132	457	22	α	α	NOUN
aji-132	457	23	induced	induce	VERB
aji-132	457	24	cytokine	cytokine	ADJ
aji-132	457	25	production	production	NOUN
aji-132	457	26	and	and	CCONJ
aji-132	457	27	nuclear	nuclear	ADJ
aji-132	457	28	factor	factor	NOUN
aji-132	457	29	-	-	PUNCT
aji-132	457	30	κb	κb	NOUN
aji-132	457	31	activation	activation	NOUN
aji-132	457	32	in	in	ADP
aji-132	457	33	cultured	cultured	ADJ
aji-132	457	34	human	human	ADJ
aji-132	457	35	synovial	synovial	ADJ
aji-132	457	36	cells	cell	NOUN
aji-132	457	37	.	.	PUNCT
aji-132	458	1	j	j	PROPN
aji-132	458	2	rheumatol	rheumatol	NOUN
aji-132	458	3	.	.	PUNCT
aji-132	459	1	2001;28:2591	2001;28:2591	NUM
aji-132	459	2	-	-	SYM
aji-132	459	3	6	6	NUM
aji-132	459	4	.	.	NOUN
aji-132	459	5	32	32	NUM
aji-132	459	6	.	.	PUNCT
aji-132	460	1	kawakami	kawakami	PROPN
aji-132	460	2	a	a	PROPN
aji-132	460	3	,	,	PUNCT
aji-132	460	4	tsuboi	tsuboi	PROPN
aji-132	460	5	m	m	PROPN
aji-132	460	6	,	,	PUNCT
aji-132	460	7	urayama	urayama	NOUN
aji-132	460	8	s	s	PROPN
aji-132	460	9	,	,	PUNCT
aji-132	460	10	et	et	PROPN
aji-132	460	11	al	al	PROPN
aji-132	460	12	.	.	PROPN
aji-132	460	13	inhibitory	inhibitory	ADJ
aji-132	460	14	effect	effect	NOUN
aji-132	460	15	of	of	ADP
aji-132	460	16	a	a	DET
aji-132	460	17	new	new	ADJ
aji-132	460	18	anti	anti	ADJ
aji-132	460	19	-	-	ADJ
aji-132	460	20	rheumatic	rheumatic	ADJ
aji-132	460	21	drug	drug	NOUN
aji-132	460	22	t-614	t-614	PUNCT
aji-132	460	23	on	on	ADP
aji-132	460	24	costimulatory	costimulatory	ADJ
aji-132	460	25	molecule	molecule	NOUN
aji-132	460	26	expression	expression	NOUN
aji-132	460	27	,	,	PUNCT
aji-132	460	28	cytokine	cytokine	ADJ
aji-132	460	29	production	production	NOUN
aji-132	460	30	,	,	PUNCT
aji-132	460	31	and	and	CCONJ
aji-132	460	32	antigen	antigen	ADJ
aji-132	460	33	presentation	presentation	NOUN
aji-132	460	34	by	by	ADP
aji-132	460	35	synovial	synovial	ADJ
aji-132	460	36	cells	cell	NOUN
aji-132	460	37	.	.	PUNCT
aji-132	461	1	j	j	PROPN
aji-132	461	2	lab	lab	PROPN
aji-132	461	3	clin	clin	PROPN
aji-132	461	4	med	med	PROPN
aji-132	461	5	.	.	PUNCT
aji-132	462	1	1999;133:566	1999;133:566	NUM
aji-132	462	2	-	-	PUNCT
aji-132	462	3	74	74	NUM
aji-132	462	4	.	.	PUNCT
aji-132	463	1	33	33	NUM
aji-132	463	2	.	.	PUNCT
aji-132	464	1	aikawa	aikawa	PROPN
aji-132	464	2	y	y	PROPN
aji-132	464	3	,	,	PUNCT
aji-132	464	4	tanuma	tanuma	PRON
aji-132	464	5	n	n	CCONJ
aji-132	464	6	,	,	PUNCT
aji-132	464	7	shin	shin	PROPN
aji-132	464	8	t	t	PROPN
aji-132	464	9	,	,	PUNCT
aji-132	464	10	et	et	PROPN
aji-132	464	11	al	al	PROPN
aji-132	464	12	.	.	PUNCT
aji-132	465	1	a	a	DET
aji-132	465	2	new	new	ADJ
aji-132	465	3	anti	anti	ADJ
aji-132	465	4	-	-	ADJ
aji-132	465	5	rheumatic	rheumatic	ADJ
aji-132	465	6	drug	drug	NOUN
aji-132	465	7	,	,	PUNCT
aji-132	465	8	t-614	t-614	PRON
aji-132	465	9	,	,	PUNCT
aji-132	465	10	effectively	effectively	ADV
aji-132	465	11	suppresses	suppress	VERB
aji-132	465	12	the	the	DET
aji-132	465	13	development	development	NOUN
aji-132	465	14	of	of	ADP
aji-132	465	15	autoimmune	autoimmune	ADJ
aji-132	465	16	encephalomyelitis	encephalomyelitis	NOUN
aji-132	465	17	.	.	PUNCT
aji-132	466	1	j	j	PROPN
aji-132	466	2	neuroimmunol	neuroimmunol	PROPN
aji-132	466	3	.	.	PUNCT
aji-132	467	1	1998;89:35	1998;89:35	NUM
aji-132	467	2	-	-	SYM
aji-132	467	3	42	42	NUM
aji-132	467	4	.	.	PUNCT
aji-132	468	1	34	34	NUM
aji-132	468	2	.	.	PUNCT
aji-132	469	1	tanaka	tanaka	PROPN
aji-132	469	2	k	k	PROPN
aji-132	469	3	,	,	PUNCT
aji-132	469	4	urata	urata	PROPN
aji-132	469	5	n	n	CCONJ
aji-132	469	6	,	,	PUNCT
aji-132	469	7	mikami	mikami	PROPN
aji-132	469	8	m	m	PROPN
aji-132	469	9	,	,	PUNCT
aji-132	469	10	et	et	PROPN
aji-132	469	11	al	al	PROPN
aji-132	469	12	.	.	PROPN
aji-132	469	13	effect	effect	NOUN
aji-132	469	14	of	of	ADP
aji-132	469	15	iguratimod	iguratimod	PROPN
aji-132	469	16	and	and	CCONJ
aji-132	469	17	other	other	ADJ
aji-132	469	18	anti	anti	ADJ
aji-132	469	19	-	-	ADJ
aji-132	469	20	rheumatic	rheumatic	ADJ
aji-132	469	21	drugs	drug	NOUN
aji-132	469	22	on	on	ADP
aji-132	469	23	adenocarcinoma	adenocarcinoma	ADJ
aji-132	469	24	colon	colon	NOUN
aji-132	469	25	26	26	NUM
aji-132	469	26	induced	induce	VERB
aji-132	469	27	cachexia	cachexia	NOUN
aji-132	469	28	in	in	ADP
aji-132	469	29	mice	mouse	NOUN
aji-132	469	30	.	.	PUNCT
aji-132	470	1	inflamm	inflamm	PROPN
aji-132	470	2	res	res	PROPN
aji-132	470	3	.	.	PUNCT
aji-132	471	1	2007;56:17	2007;56:17	NUM
aji-132	471	2	-	-	PUNCT
aji-132	471	3	23	23	NUM
aji-132	471	4	.	.	PUNCT
aji-132	472	1	35	35	NUM
aji-132	472	2	.	.	PUNCT
aji-132	473	1	du	du	PROPN
aji-132	473	2	f	f	PROPN
aji-132	473	3	,	,	PUNCT
aji-132	473	4	lü	lü	X
aji-132	473	5	lj	lj	PROPN
aji-132	473	6	,	,	PUNCT
aji-132	473	7	fu	fu	PROPN
aji-132	473	8	q	q	PROPN
aji-132	473	9	,	,	PUNCT
aji-132	473	10	et	et	PROPN
aji-132	473	11	al	al	PROPN
aji-132	473	12	.	.	PUNCT
aji-132	474	1	t-614	t-614	PROPN
aji-132	474	2	,	,	PUNCT
aji-132	474	3	a	a	DET
aji-132	474	4	novel	novel	ADJ
aji-132	474	5	immunomodulator	immunomodulator	NOUN
aji-132	474	6	,	,	PUNCT
aji-132	474	7	attenuates	attenuate	VERB
aji-132	474	8	joint	joint	ADJ
aji-132	474	9	inflammation	inflammation	NOUN
aji-132	474	10	and	and	CCONJ
aji-132	474	11	articular	articular	ADJ
aji-132	474	12	damage	damage	NOUN
aji-132	474	13	in	in	ADP
aji-132	474	14	collagen	collagen	NOUN
aji-132	474	15	-	-	PUNCT
aji-132	474	16	induced	induce	VERB
aji-132	474	17	arthritis	arthritis	NOUN
aji-132	474	18	.	.	PUNCT
aji-132	475	1	arthritis	arthritis	NOUN
aji-132	475	2	res	re	NOUN
aji-132	475	3	ther	ther	ADV
aji-132	475	4	.	.	PUNCT
aji-132	476	1	2008;10	2008;10	NOUN
aji-132	476	2	:	:	PUNCT
aji-132	476	3	r136	r136	PROPN
aji-132	476	4	.	.	PROPN
aji-132	477	1	36	36	NUM
aji-132	477	2	.	.	PUNCT
aji-132	477	3	ulsamer	ulsamer	PROPN
aji-132	477	4	a	a	PRON
aji-132	477	5	,	,	PUNCT
aji-132	477	6	ortuno	ortuno	PROPN
aji-132	477	7	mj	mj	PROPN
aji-132	477	8	,	,	PUNCT
aji-132	477	9	ruiz	ruiz	NOUN
aji-132	477	10	s	s	PROPN
aji-132	477	11	,	,	PUNCT
aji-132	478	1	et	et	PROPN
aji-132	478	2	al	al	PROPN
aji-132	478	3	.	.	PUNCT
aji-132	478	4	bmp2	bmp2	PROPN
aji-132	478	5	induces	induce	VERB
aji-132	478	6	osterix	osterix	NOUN
aji-132	478	7	expression	expression	NOUN
aji-132	478	8	through	through	ADP
aji-132	478	9	upregulation	upregulation	NOUN
aji-132	478	10	of	of	ADP
aji-132	478	11	dlx5	dlx5	PROPN
aji-132	478	12	and	and	CCONJ
aji-132	478	13	its	its	PRON
aji-132	478	14	phosphorylation	phosphorylation	NOUN
aji-132	478	15	by	by	ADP
aji-132	478	16	p38	p38	NOUN
aji-132	478	17	,	,	PUNCT
aji-132	478	18	j.	j.	PROPN
aji-132	478	19	biol	biol	PROPN
aji-132	478	20	.	.	PUNCT
aji-132	479	1	chem	chem	NOUN
aji-132	479	2	.	.	PUNCT
aji-132	480	1	2008;283(7):3816	2008;283(7):3816	NUM
aji-132	480	2	–	–	PUNCT
aji-132	480	3	3826	3826	NUM
aji-132	480	4	.	.	PUNCT
aji-132	481	1	37	37	NUM
aji-132	481	2	.	.	PUNCT
aji-132	482	1	song	song	PROPN
aji-132	482	2	j	j	PROPN
aji-132	482	3	,	,	PUNCT
aji-132	482	4	liu	liu	PROPN
aji-132	482	5	h	h	PROPN
aji-132	482	6	,	,	PUNCT
aji-132	482	7	zhu	zhu	PROPN
aji-132	482	8	q	q	X
aji-132	482	9	,	,	PUNCT
aji-132	482	10	et	et	PROPN
aji-132	482	11	al	al	PROPN
aji-132	482	12	.	.	PROPN
aji-132	482	13	,	,	PUNCT
aji-132	482	14	t-614	t-614	PRON
aji-132	482	15	promotes	promote	VERB
aji-132	482	16	osteoblastic	osteoblastic	ADJ
aji-132	482	17	cell	cell	NOUN
aji-132	482	18	differentiation	differentiation	NOUN
aji-132	482	19	by	by	ADP
aji-132	482	20	increasing	increase	VERB
aji-132	482	21	dlx5	dlx5	NOUN
aji-132	482	22	expression	expression	NOUN
aji-132	482	23	and	and	CCONJ
aji-132	482	24	regulating	regulate	VERB
aji-132	482	25	the	the	DET
aji-132	482	26	activation	activation	NOUN
aji-132	482	27	of	of	ADP
aji-132	482	28	p38	p38	NOUN
aji-132	482	29	and	and	CCONJ
aji-132	482	30	nf	nf	NOUN
aji-132	482	31	-	-	PUNCT
aji-132	482	32	kappab	kappab	NOUN
aji-132	482	33	,	,	PUNCT
aji-132	482	34	biomed	biome	VERB
aji-132	482	35	res	re	NOUN
aji-132	482	36	.	.	PUNCT
aji-132	483	1	int	int	NOUN
aji-132	483	2	.	.	PUNCT
aji-132	484	1	2018;(2018	2018;(2018	NUM
aji-132	484	2	)	)	PUNCT
aji-132	484	3	4901591	4901591	NUM
aji-132	484	4	.	.	PUNCT
aji-132	485	1	38	38	NUM
aji-132	485	2	.	.	PUNCT
aji-132	486	1	yamaguchi	yamaguchi	PROPN
aji-132	486	2	m	m	PROPN
aji-132	486	3	,	,	PUNCT
aji-132	486	4	arbiser	arbiser	PROPN
aji-132	486	5	jl	jl	PROPN
aji-132	486	6	,	,	PUNCT
aji-132	486	7	weitzmann	weitzmann	PROPN
aji-132	486	8	mn	mn	PROPN
aji-132	486	9	.	.	PROPN
aji-132	487	1	honokiol	honokiol	PROPN
aji-132	487	2	stimulates	stimulate	VERB
aji-132	487	3	osteoblastogenesis	osteoblastogenesis	ADV
aji-132	487	4	by	by	ADP
aji-132	487	5	suppressing	suppress	VERB
aji-132	487	6	nf	nf	ADJ
aji-132	487	7	-	-	PUNCT
aji-132	487	8	kappab	kappab	NOUN
aji-132	487	9	activation	activation	NOUN
aji-132	487	10	,	,	PUNCT
aji-132	487	11	int	int	NOUN
aji-132	487	12	.	.	PUNCT
aji-132	488	1	j.	j.	PROPN
aji-132	488	2	mol	mol	PROPN
aji-132	488	3	.	.	PROPN
aji-132	488	4	med	med	PROPN
aji-132	488	5	.	.	PUNCT
aji-132	489	1	2011;28(6):1049–1053	2011;28(6):1049–1053	VERB
aji-132	489	2	.	.	PUNCT
aji-132	490	1	39	39	NUM
aji-132	490	2	.	.	PUNCT
aji-132	491	1	lacey	lacey	PROPN
aji-132	491	2	dl	dl	PROPN
aji-132	491	3	,	,	PUNCT
aji-132	491	4	timms	timms	PROPN
aji-132	491	5	e	e	PROPN
aji-132	491	6	,	,	PUNCT
aji-132	491	7	tan	tan	PROPN
aji-132	491	8	hl	hl	NOUN
aji-132	491	9	,	,	PUNCT
aji-132	491	10	et	et	PROPN
aji-132	491	11	al	al	PROPN
aji-132	491	12	.	.	PROPN
aji-132	491	13	,	,	PUNCT
aji-132	491	14	osteoprotegerin	osteoprotegerin	PROPN
aji-132	491	15	ligand	ligand	NOUN
aji-132	491	16	is	be	AUX
aji-132	491	17	a	a	DET
aji-132	491	18	cytokine	cytokine	NOUN
aji-132	491	19	that	that	SCONJ
aji-132	491	20	gupta	gupta	PROPN
aji-132	491	21	et	et	PROPN
aji-132	491	22	al	al	PROPN
aji-132	491	23	.	.	PROPN
aji-132	491	24	;	;	PUNCT
aji-132	492	1	asian	asian	PROPN
aji-132	492	2	j.	j.	PROPN
aji-132	492	3	immunol	immunol	PROPN
aji-132	492	4	.	.	PROPN
aji-132	492	5	,	,	PUNCT
aji-132	492	6	vol	vol	NOUN
aji-132	492	7	.	.	PROPN
aji-132	492	8	7	7	NUM
aji-132	492	9	,	,	PUNCT
aji-132	492	10	no	no	INTJ
aji-132	492	11	.	.	NOUN
aji-132	492	12	1	1	NUM
aji-132	492	13	,	,	PUNCT
aji-132	492	14	pp	pp	ADJ
aji-132	492	15	.	.	PUNCT
aji-132	493	1	79	79	NUM
aji-132	493	2	-	-	SYM
aji-132	493	3	89	89	NUM
aji-132	493	4	,	,	PUNCT
aji-132	493	5	2024	2024	NUM
aji-132	493	6	;	;	PUNCT
aji-132	493	7	article	article	NOUN
aji-132	493	8	no.aji.115805	no.aji.115805	VERB
aji-132	493	9	89	89	NUM
aji-132	493	10	regulates	regulate	VERB
aji-132	493	11	osteoclast	osteoclast	ADJ
aji-132	493	12	differentiation	differentiation	NOUN
aji-132	493	13	and	and	CCONJ
aji-132	493	14	activation	activation	NOUN
aji-132	493	15	,	,	PUNCT
aji-132	493	16	cell	cell	NOUN
aji-132	493	17	.	.	PUNCT
aji-132	494	1	1998;93(2):165–176	1998;93(2):165–176	NUM
aji-132	494	2	.	.	PUNCT
aji-132	495	1	40	40	NUM
aji-132	495	2	.	.	PUNCT
aji-132	496	1	wang	wang	PROPN
aji-132	496	2	xt	xt	PROPN
aji-132	496	3	,	,	PUNCT
aji-132	496	4	li	li	PROPN
aji-132	496	5	p	p	PROPN
aji-132	496	6	,	,	PUNCT
aji-132	496	7	xu	xu	PROPN
aji-132	496	8	ts	ts	PROPN
aji-132	496	9	,	,	PUNCT
aji-132	496	10	ding	de	VERB
aji-132	496	11	r	r	NOUN
aji-132	496	12	,	,	PUNCT
aji-132	496	13	zhang	zhang	PROPN
aji-132	496	14	x	x	PROPN
aji-132	496	15	,	,	PUNCT
aji-132	496	16	bi	bi	NOUN
aji-132	496	17	lq	lq	PROPN
aji-132	496	18	.	.	PROPN
aji-132	496	19	effect	effect	NOUN
aji-132	496	20	of	of	ADP
aji-132	496	21	iguratimod	iguratimod	NOUN
aji-132	496	22	and	and	CCONJ
aji-132	496	23	methotrexate	methotrexate	VERB
aji-132	496	24	on	on	ADP
aji-132	496	25	rankl	rankl	NOUN
aji-132	496	26	and	and	CCONJ
aji-132	496	27	opg	opg	NOUN
aji-132	496	28	expression	expression	NOUN
aji-132	496	29	in	in	ADP
aji-132	496	30	serum	serum	NOUN
aji-132	496	31	and	and	CCONJ
aji-132	496	32	il-1beta	il-1beta	ADV
aji-132	496	33	-	-	PUNCT
aji-132	496	34	induced	induce	VERB
aji-132	496	35	fibroblast	fibroblast	ADJ
aji-132	496	36	-	-	PUNCT
aji-132	496	37	like	like	ADJ
aji-132	496	38	synoviocytes	synoviocyte	NOUN
aji-132	496	39	from	from	ADP
aji-132	496	40	patients	patient	NOUN
aji-132	496	41	with	with	ADP
aji-132	496	42	rheumatoid	rheumatoid	NOUN
aji-132	496	43	arthritis	arthritis	NOUN
aji-132	496	44	,	,	PUNCT
aji-132	496	45	cell	cell	NOUN
aji-132	496	46	.	.	PUNCT
aji-132	497	1	mol	mol	PROPN
aji-132	497	2	.	.	PUNCT
aji-132	498	1	biol	biol	PROPN
aji-132	498	2	.	.	PUNCT
aji-132	499	1	(	(	PUNCT
aji-132	499	2	noisy	noisy	ADV
aji-132	499	3	-	-	PUNCT
aji-132	499	4	le	le	NOUN
aji-132	499	5	-	-	NOUN
aji-132	499	6	grand	grand	NOUN
aji-132	499	7	)	)	PUNCT
aji-132	499	8	.	.	PUNCT
aji-132	500	1	2016;62(12):44–50	2016;62(12):44–50	NOUN
aji-132	500	2	.	.	PROPN
aji-132	501	1	41	41	NUM
aji-132	501	2	.	.	PUNCT
aji-132	502	1	ren	ren	PROPN
aji-132	502	2	yh	yh	PROPN
aji-132	502	3	,	,	PUNCT
aji-132	502	4	dong	dong	PROPN
aji-132	502	5	w	w	PROPN
aji-132	502	6	,	,	PUNCT
aji-132	502	7	liu	liu	PROPN
aji-132	502	8	h	h	PROPN
aji-132	502	9	,	,	PUNCT
aji-132	502	10	liu	liu	PROPN
aji-132	502	11	l.	l.	PROPN
aji-132	502	12	clinical	clinical	ADJ
aji-132	502	13	observation	observation	NOUN
aji-132	502	14	of	of	ADP
aji-132	502	15	iguratimod	iguratimod	PROPN
aji-132	502	16	combined	combine	VERB
aji-132	502	17	with	with	ADP
aji-132	502	18	methotrexate	methotrexate	NOUN
aji-132	502	19	in	in	ADP
aji-132	502	20	the	the	DET
aji-132	502	21	treatment	treatment	NOUN
aji-132	502	22	of	of	ADP
aji-132	502	23	rheumatoid	rheumatoid	NOUN
aji-132	502	24	arthritis	arthritis	NOUN
aji-132	502	25	,	,	PUNCT
aji-132	502	26	china	china	PROPN
aji-132	502	27	pharmacy	pharmacy	PROPN
aji-132	502	28	.	.	PUNCT
aji-132	503	1	2017;28(32):4530–4532	2017;28(32):4530–4532	X
aji-132	503	2	.	.	PUNCT
aji-132	504	1	42	42	NUM
aji-132	504	2	.	.	PUNCT
aji-132	505	1	wu	wu	PROPN
aji-132	505	2	yx	yx	PROPN
aji-132	505	3	,	,	PUNCT
aji-132	505	4	sun	sun	PROPN
aji-132	505	5	y	y	PROPN
aji-132	505	6	,	,	PUNCT
aji-132	505	7	ye	ye	PROPN
aji-132	505	8	yp	yp	PROPN
aji-132	505	9	,	,	PUNCT
aji-132	505	10	et	et	PROPN
aji-132	505	11	al	al	PROPN
aji-132	505	12	.	.	PROPN
aji-132	505	13	,	,	PUNCT
aji-132	505	14	iguratimod	iguratimod	PROPN
aji-132	505	15	prevents	prevent	VERB
aji-132	505	16	ovariectomyinduced	ovariectomyinduce	VERB
aji-132	505	17	bone	bone	NOUN
aji-132	505	18	loss	loss	NOUN
aji-132	505	19	and	and	CCONJ
aji-132	505	20	suppresses	suppress	VERB
aji-132	505	21	osteoclastogenesis	osteoclastogenesis	NOUN
aji-132	505	22	via	via	ADP
aji-132	505	23	inhibition	inhibition	NOUN
aji-132	505	24	of	of	ADP
aji-132	505	25	peroxisome	peroxisome	NOUN
aji-132	505	26	proliferator	proliferator	NOUN
aji-132	505	27	activated	activate	VERB
aji-132	505	28	receptorgamma	receptorgamma	PROPN
aji-132	505	29	,	,	PUNCT
aji-132	505	30	mol	mol	PROPN
aji-132	505	31	.	.	PROPN
aji-132	506	1	med	med	PROPN
aji-132	506	2	.	.	PROPN
aji-132	507	1	rep	rep	PROPN
aji-132	507	2	.	.	PROPN
aji-132	507	3	2017;16(6):8200–8208	2017;16(6):8200–8208	PROPN
aji-132	507	4	.	.	PUNCT
aji-132	508	1	43	43	NUM
aji-132	508	2	.	.	PUNCT
aji-132	509	1	gan	gan	PROPN
aji-132	509	2	k	k	PROPN
aji-132	509	3	,	,	PUNCT
aji-132	509	4	yang	yang	PROPN
aji-132	509	5	l	l	PROPN
aji-132	509	6	,	,	PUNCT
aji-132	509	7	xu	xu	PROPN
aji-132	510	1	l	l	PROPN
aji-132	510	2	,	,	PUNCT
aji-132	510	3	et	et	PROPN
aji-132	510	4	al	al	PROPN
aji-132	510	5	.	.	PROPN
aji-132	510	6	iguratimod	iguratimod	PROPN
aji-132	511	1	(	(	PUNCT
aji-132	511	2	t614	t614	PROPN
aji-132	511	3	)	)	PUNCT
aji-132	511	4	suppresses	suppress	VERB
aji-132	511	5	rankl	rankl	VERB
aji-132	511	6	-	-	PUNCT
aji-132	511	7	induced	induce	VERB
aji-132	511	8	osteoclast	osteoclast	ADJ
aji-132	511	9	differentiation	differentiation	NOUN
aji-132	511	10	and	and	CCONJ
aji-132	511	11	migration	migration	NOUN
aji-132	511	12	in	in	ADP
aji-132	511	13	raw264.7	raw264.7	PROPN
aji-132	511	14	cells	cell	NOUN
aji-132	511	15	via	via	ADP
aji-132	511	16	nf	nf	NOUN
aji-132	511	17	-	-	PUNCT
aji-132	511	18	kappab	kappab	NOUN
aji-132	511	19	and	and	CCONJ
aji-132	511	20	mapk	mapk	NOUN
aji-132	511	21	pathways	pathway	NOUN
aji-132	511	22	,	,	PUNCT
aji-132	511	23	int	int	NOUN
aji-132	511	24	.	.	PUNCT
aji-132	512	1	immunopharmacol	immunopharmacol	PROPN
aji-132	512	2	.	.	PROPN
aji-132	512	3	2016	2016	NUM
aji-132	512	4	;	;	PUNCT
aji-132	513	1	35:294–300	35:294–300	NUM
aji-132	513	2	.	.	NOUN
aji-132	514	1	44	44	NUM
aji-132	514	2	.	.	PUNCT
aji-132	515	1	du	du	PROPN
aji-132	515	2	f	f	PROPN
aji-132	515	3	,	,	PUNCT
aji-132	515	4	lu	lu	PROPN
aji-132	515	5	lj	lj	PROPN
aji-132	515	6	,	,	PUNCT
aji-132	515	7	teng	teng	PROPN
aji-132	515	8	jl	jl	PROPN
aji-132	515	9	,	,	PUNCT
aji-132	515	10	shen	shen	PROPN
aji-132	515	11	n	n	CCONJ
aji-132	515	12	,	,	PUNCT
aji-132	515	13	ye	ye	PROPN
aji-132	515	14	p	p	NOUN
aji-132	515	15	,	,	PUNCT
aji-132	515	16	bao	bao	PROPN
aji-132	515	17	cd	cd	PROPN
aji-132	515	18	.	.	PUNCT
aji-132	515	19	t-614	t-614	PUNCT
aji-132	515	20	alters	alter	VERB
aji-132	515	21	the	the	DET
aji-132	515	22	production	production	NOUN
aji-132	515	23	of	of	ADP
aji-132	515	24	matrix	matrix	NOUN
aji-132	515	25	metalloproteinases	metalloproteinase	NOUN
aji-132	515	26	(	(	PUNCT
aji-132	515	27	mmp-1	mmp-1	NOUN
aji-132	515	28	andmmp-3	andmmp-3	NOUN
aji-132	515	29	)	)	PUNCT
aji-132	515	30	and	and	CCONJ
aji-132	515	31	inhibits	inhibit	VERB
aji-132	515	32	the	the	DET
aji-132	515	33	migratory	migratory	ADJ
aji-132	515	34	expansion	expansion	NOUN
aji-132	515	35	of	of	ADP
aji-132	515	36	rheumatoid	rheumatoid	ADJ
aji-132	515	37	synovial	synovial	ADJ
aji-132	515	38	fibroblasts	fibroblast	NOUN
aji-132	515	39	,	,	PUNCT
aji-132	515	40	in	in	ADP
aji-132	515	41	vitro	vitro	X
aji-132	515	42	,	,	PUNCT
aji-132	515	43	int	int	NOUN
aji-132	515	44	.	.	PUNCT
aji-132	516	1	immunopharmacol	immunopharmacol	PROPN
aji-132	516	2	.	.	PUNCT
aji-132	517	1	2012;13(1):54	2012;13(1):54	NUM
aji-132	517	2	–	–	PUNCT
aji-132	517	3	60	60	NUM
aji-132	517	4	.	.	X
aji-132	518	1	45	45	NUM
aji-132	518	2	.	.	PUNCT
aji-132	519	1	nam	nam	PROPN
aji-132	519	2	jl	jl	PROPN
aji-132	519	3	,	,	PUNCT
aji-132	519	4	winthrop	winthrop	PROPN
aji-132	519	5	kl	kl	PROPN
aji-132	519	6	,	,	PUNCT
aji-132	519	7	van	van	PROPN
aji-132	519	8	vollenhoven	vollenhoven	NOUN
aji-132	519	9	rf	rf	PROPN
aji-132	519	10	,	,	PUNCT
aji-132	519	11	et	et	PROPN
aji-132	519	12	al	al	PROPN
aji-132	519	13	.	.	PUNCT
aji-132	520	1	current	current	ADJ
aji-132	520	2	evidence	evidence	NOUN
aji-132	520	3	for	for	ADP
aji-132	520	4	the	the	DET
aji-132	520	5	management	management	NOUN
aji-132	520	6	of	of	ADP
aji-132	520	7	rheumatoid	rheumatoid	VERB
aji-132	520	8	arthritis	arthritis	NOUN
aji-132	520	9	with	with	ADP
aji-132	520	10	biological	biological	ADJ
aji-132	520	11	disease	disease	NOUN
aji-132	520	12	-	-	PUNCT
aji-132	520	13	modifying	modify	VERB
aji-132	520	14	antirheumatic	antirheumatic	ADJ
aji-132	520	15	drugs	drug	NOUN
aji-132	520	16	:	:	PUNCT
aji-132	520	17	a	a	DET
aji-132	520	18	systematic	systematic	ADJ
aji-132	520	19	literature	literature	NOUN
aji-132	520	20	review	review	NOUN
aji-132	520	21	informing	inform	VERB
aji-132	520	22	the	the	DET
aji-132	520	23	eular	eular	ADJ
aji-132	520	24	recommendations	recommendation	NOUN
aji-132	520	25	for	for	ADP
aji-132	520	26	the	the	DET
aji-132	520	27	management	management	NOUN
aji-132	520	28	of	of	ADP
aji-132	520	29	ra	ra	PROPN
aji-132	520	30	,	,	PUNCT
aji-132	520	31	ann	ann	PROPN
aji-132	520	32	.	.	PUNCT
aji-132	520	33	rheum	rheum	PROPN
aji-132	520	34	.	.	PUNCT
aji-132	521	1	dis	dis	PROPN
aji-132	521	2	.	.	PUNCT
aji-132	522	1	2010;69(6):976–986	2010;69(6):976–986	NUM
aji-132	522	2	.	.	PROPN
aji-132	523	1	46	46	NUM
aji-132	523	2	.	.	PUNCT
aji-132	524	1	wei	wei	PROPN
aji-132	524	2	y	y	PROPN
aji-132	524	3	,	,	PUNCT
aji-132	524	4	sun	sun	PROPN
aji-132	524	5	x	x	SYM
aji-132	524	6	,	,	PUNCT
aji-132	524	7	hua	hua	PROPN
aji-132	524	8	m	m	PROPN
aji-132	524	9	,	,	PUNCT
aji-132	524	10	tan	tan	PROPN
aji-132	524	11	w	w	PROPN
aji-132	524	12	,	,	PUNCT
aji-132	524	13	wang	wang	PROPN
aji-132	524	14	f	f	PROPN
aji-132	524	15	,	,	PUNCT
aji-132	524	16	zhang	zhang	PROPN
aji-132	524	17	m	m	PROPN
aji-132	524	18	,	,	PUNCT
aji-132	524	19	inhibitory	inhibitory	ADJ
aji-132	524	20	effect	effect	NOUN
aji-132	524	21	of	of	ADP
aji-132	524	22	a	a	DET
aji-132	524	23	novel	novel	ADJ
aji-132	524	24	antirheumatic	antirheumatic	ADJ
aji-132	524	25	drug	drug	NOUN
aji-132	524	26	t-614	t-614	PUNCT
aji-132	524	27	on	on	ADP
aji-132	524	28	the	the	DET
aji-132	524	29	il-6induced	il-6induce	VERB
aji-132	524	30	rankl	rankl	PROPN
aji-132	524	31	/	/	SYM
aji-132	524	32	opg	opg	PROPN
aji-132	524	33	,	,	PUNCT
aji-132	524	34	il-17	il-17	X
aji-132	524	35	,	,	PUNCT
aji-132	524	36	and	and	CCONJ
aji-132	524	37	mmp-3	mmp-3	NUM
aji-132	524	38	expression	expression	NOUN
aji-132	524	39	in	in	ADP
aji-132	524	40	synovial	synovial	ADJ
aji-132	524	41	fibroblasts	fibroblast	NOUN
aji-132	524	42	from	from	ADP
aji-132	524	43	rheumatoid	rheumatoid	ADJ
aji-132	524	44	arthritis	arthritis	NOUN
aji-132	524	45	patients	patient	NOUN
aji-132	524	46	,	,	PUNCT
aji-132	524	47	biomed	biome	VERB
aji-132	524	48	res	re	NOUN
aji-132	524	49	.	.	PUNCT
aji-132	525	1	int	int	NOUN
aji-132	525	2	.	.	PUNCT
aji-132	526	1	2015;214683	2015;214683	X
aji-132	526	2	.	.	PUNCT
aji-132	527	1	_	_	PUNCT
aji-132	528	1	_	_	PUNCT
aji-132	529	1	_	_	PUNCT
aji-132	530	1	_	_	PUNCT
aji-132	531	1	_	_	PUNCT
aji-132	532	1	_	_	PUNCT
aji-132	533	1	_	_	PUNCT
aji-132	534	1	_	_	PUNCT
aji-132	535	1	_	_	PUNCT
aji-132	536	1	_	_	PUNCT
aji-132	537	1	_	_	PUNCT
aji-132	538	1	_	_	PUNCT
aji-132	539	1	_	_	PUNCT
aji-132	540	1	_	_	PUNCT
aji-132	541	1	_	_	PUNCT
aji-132	542	1	_	_	PUNCT
aji-132	543	1	_	_	PUNCT
aji-132	544	1	_	_	PUNCT
aji-132	545	1	_	_	PUNCT
aji-132	546	1	_	_	PUNCT
aji-132	547	1	_	_	PUNCT
aji-132	548	1	_	_	PUNCT
aji-132	549	1	_	_	PUNCT
aji-132	550	1	_	_	PUNCT
aji-132	551	1	_	_	PUNCT
aji-132	552	1	_	_	PUNCT
aji-132	553	1	_	_	PUNCT
aji-132	554	1	_	_	PUNCT
aji-132	555	1	_	_	PUNCT
aji-132	556	1	_	_	PUNCT
aji-132	557	1	_	_	PUNCT
aji-132	558	1	_	_	PUNCT
aji-132	559	1	_	_	PUNCT
aji-132	560	1	_	_	PUNCT
aji-132	561	1	_	_	PUNCT
aji-132	562	1	_	_	PUNCT
aji-132	563	1	_	_	PUNCT
aji-132	564	1	_	_	PUNCT
aji-132	565	1	_	_	PUNCT
aji-132	566	1	_	_	PUNCT
aji-132	567	1	_	_	PUNCT
aji-132	568	1	_	_	PUNCT
aji-132	569	1	_	_	PUNCT
aji-132	570	1	_	_	PUNCT
aji-132	571	1	_	_	PUNCT
aji-132	572	1	_	_	PUNCT
aji-132	573	1	_	_	PUNCT
aji-132	574	1	_	_	PUNCT
aji-132	575	1	_	_	PUNCT
aji-132	576	1	_	_	PUNCT
aji-132	577	1	_	_	PUNCT
aji-132	578	1	_	_	PUNCT
aji-132	579	1	_	_	PUNCT
aji-132	580	1	_	_	PUNCT
aji-132	581	1	_	_	PUNCT
aji-132	582	1	_	_	PUNCT
aji-132	583	1	_	_	PUNCT
aji-132	584	1	_	_	PUNCT
aji-132	585	1	_	_	PUNCT
aji-132	586	1	_	_	PUNCT
aji-132	587	1	_	_	PUNCT
aji-132	588	1	_	_	PUNCT
aji-132	589	1	_	_	PUNCT
aji-132	590	1	_	_	PUNCT
aji-132	591	1	_	_	PUNCT
aji-132	592	1	_	_	PUNCT
aji-132	593	1	_	_	PUNCT
aji-132	594	1	_	_	PUNCT
aji-132	595	1	_	_	PUNCT
aji-132	596	1	_	_	PUNCT
aji-132	597	1	_	_	PUNCT
aji-132	598	1	_	_	PUNCT
aji-132	599	1	_	_	PUNCT
aji-132	600	1	_	_	PUNCT
aji-132	601	1	_	_	PUNCT
aji-132	602	1	_	_	PUNCT
aji-132	603	1	_	_	PUNCT
aji-132	604	1	_	_	PUNCT
aji-132	605	1	_	_	PUNCT
aji-132	606	1	_	_	PUNCT
aji-132	607	1	_	_	PUNCT
aji-132	608	1	©	©	PRON
aji-132	608	2	copyright	copyright	NOUN
aji-132	608	3	(	(	PUNCT
aji-132	608	4	2024	2024	NUM
aji-132	608	5	):	):	PUNCT
aji-132	608	6	author(s	author(s	NOUN
aji-132	608	7	)	)	PUNCT
aji-132	608	8	.	.	PUNCT
aji-132	609	1	the	the	DET
aji-132	609	2	licensee	licensee	NOUN
aji-132	609	3	is	be	AUX
aji-132	609	4	the	the	DET
aji-132	609	5	journal	journal	PROPN
aji-132	609	6	publisher	publisher	NOUN
aji-132	609	7	.	.	PUNCT
aji-132	610	1	this	this	PRON
aji-132	610	2	is	be	AUX
aji-132	610	3	an	an	DET
aji-132	610	4	open	open	ADJ
aji-132	610	5	access	access	NOUN
aji-132	610	6	article	article	NOUN
aji-132	610	7	distributed	distribute	VERB
aji-132	610	8	under	under	ADP
aji-132	610	9	the	the	DET
aji-132	610	10	terms	term	NOUN
aji-132	610	11	of	of	ADP
aji-132	610	12	the	the	DET
aji-132	610	13	creative	creative	ADJ
aji-132	610	14	commons	common	NOUN
aji-132	610	15	attribution	attribution	NOUN
aji-132	610	16	license	license	NOUN
aji-132	610	17	(	(	PUNCT
aji-132	610	18	http://creativecommons.org/licenses/by/4.0	http://creativecommons.org/licenses/by/4.0	NOUN
aji-132	610	19	)	)	PUNCT
aji-132	610	20	,	,	PUNCT
aji-132	610	21	which	which	PRON
aji-132	610	22	permits	permit	VERB
aji-132	610	23	unrestricted	unrestricted	ADJ
aji-132	610	24	use	use	NOUN
aji-132	610	25	,	,	PUNCT
aji-132	610	26	distribution	distribution	NOUN
aji-132	610	27	,	,	PUNCT
aji-132	610	28	and	and	CCONJ
aji-132	610	29	reproduction	reproduction	NOUN
aji-132	610	30	in	in	ADP
aji-132	610	31	any	any	DET
aji-132	610	32	medium	medium	NOUN
aji-132	610	33	,	,	PUNCT
aji-132	610	34	provided	provide	VERB
aji-132	610	35	the	the	DET
aji-132	610	36	original	original	ADJ
aji-132	610	37	work	work	NOUN
aji-132	610	38	is	be	AUX
aji-132	610	39	properly	properly	ADV
aji-132	610	40	cited	cite	VERB
aji-132	610	41	.	.	PUNCT
aji-132	611	1	peer	peer	NOUN
aji-132	611	2	-	-	PUNCT
aji-132	611	3	review	review	NOUN
aji-132	611	4	history	history	NOUN
aji-132	611	5	:	:	PUNCT
aji-132	611	6	the	the	DET
aji-132	611	7	peer	peer	NOUN
aji-132	611	8	review	review	NOUN
aji-132	611	9	history	history	NOUN
aji-132	611	10	for	for	ADP
aji-132	611	11	this	this	DET
aji-132	611	12	paper	paper	NOUN
aji-132	611	13	can	can	AUX
aji-132	611	14	be	be	AUX
aji-132	611	15	accessed	access	VERB
aji-132	611	16	here	here	ADV
aji-132	611	17	:	:	PUNCT
aji-132	611	18	https://www.sdiarticle5.com/review-history/115805	https://www.sdiarticle5.com/review-history/115805	PROPN
aji-132	611	19	https://www.sdiarticle5.com/review-history/115805	https://www.sdiarticle5.com/review-history/115805	PROPN